UCB [ADDRESS_63999] Number: 2016-001102-42
IND Number: 128708
UCB BIOPHARMA SPRL
Allée de la Recherche 60
1070 Brussels
BELGIUM
Protocol/Amendment number Date Type of 
amendment
Final Protocol 29 Jul 2016 Not applicable
Protocol Amendment 1 15 Mar 2017 Nonsubstantial
Protocol Amendment 2 09 Mar 2018 Substantial
Confidential Material
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.REDACTED COPY OPHAOPHA
ée de le de 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. E E
TTISIS
-[ADDRESS_64000] INFORMATION
Sponsor
UCB BIOPHARMA SPRL
Allée de la Recherche 60
1070 BrusselsBELGIUM
Sponsor Study Physician
Name: , MD, MSc, PhD
Address: UCB Pharma Ltd.
[ADDRESS_64001]
Slough, SL1 3WE
UNITED KINGDOM
Phone:
Clinical Project Manager
Name: , PharmD, PhD
Address: UCB BIOSCIENCES GmbH
Alfred-Nobel-Str.10
[ZIP_CODE] Monheim am Rhein
GERMANY
Phone:
Clinical Trial Biostatistician
Name: , MS
Address: UCB BIOSCIENCES Inc.
[ADDRESS_64002]
Raleigh, NC [ZIP_CODE]
UNITED STATES
Phone:REDACTEDharmharm
ES GES G
Str.10Str.[ADDRESS_64003] Research Organization
Name: [CONTACT_18466]: [ADDRESS_64004]
Raleigh, NC [ZIP_CODE]
UNITED STATES
Phone:
Fax:
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or orrrvariations vthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 4 of 143SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: [PHONE_1064]
[LOCATION_003] and Canada: +[PHONE_299] or +[PHONE_300]
Email Global: [EMAIL_311]
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or orvariations vthereof. 
UCB [ADDRESS_64005] OF ABBREVIATIONS..................................................................................................11
1 SUMMARY.....................................................................................................................162 INTRODUCTION ...........................................................................................................182.1 Axial spondylo arthritis..................................................................................................... 18
2.1.1 Clinical studies.....................................................................................................192.1.2 Nonclinical studies...............................................................................................21
3 STUDY OBJECTIVES....................................................................................................213.1 Primary objective ........................................................................................................... ..21
3.2 Secondary objectives .......................................................................................................2 2
3.3 Other objectives ............................................................................................................ ...22
4 STUDY VARIABLES.....................................................................................................224.1 Primary variable(s)......................................................................................................... ..22
4.1.1 Primary efficacy  variable.....................................................................................22
4.2 Secondary variables ......................................................................................................... 22
4.2.1 Secondary eff icacy var iables ...............................................................................22
4.2.2 Secondary safety variables ..................................................................................23
4.3 Other variables ............................................................................................................. ....23
4.3.1 Other efficacy variables.......................................................................................234.3.2 Other safety variables ..........................................................................................244.3.3 Other PK and PD variables..................................................................................244.3.4 Other immunological variables............................................................................244.3.5 Other pharmacogenomic, proteomic, and metabolite variables ..........................24
5 STUDY DESIGN.............................................................................................................255.1 Study desc ription ........................................................................................................... ..25
5.1.1 Screening Period/Baseline ...................................................................................255.1.[ADDRESS_64006] ...................................................................................285.1.9 Planned number of subjects and site(s) ...............................................................285.1.10 Anticipated regions and countries .......................................................................28
5.2 Schedule of study assessments.........................................................................................285.3 Schematic diagram........................................................................................................... 34
5.4 Rationale for study design and selection of dose.............................................................35
REDACTED ........
.................
..........
blesbles
iCOPY .....
............
This document5.5.cannot 6
.1.71.7beSaSaused e-BB
Rescuescuto B
BlinBlinsupport ........
Period/eriod
Blind lindany .........
..marketing .........
riables.riable
mic, prmic, pauthorization ....
..........
..............
..........application ........
...........
..........
.....and ..........any ...........extensions ...............
..........
..........or..........variations .[ADDRESS_64007] compliance................................................................457.8 Concomitant medication(s)/treatment(s)..........................................................................45
7.8.1 Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014]) ..........................467.8.2 Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014]) .........................46
7.9 Blinding.................................................................................................................... ........47
7.9.1 Procedures for maintaining and breaking the treatment blind.............................48
[IP_ADDRESS] Maintenance of study treatment blind .......................................................[IP_ADDRESS] Breaking the treatment blind in an emergency situation...........................48
7.10 Randomization and numbering of subjects......................................................................498 STUDY PROCEDURES BY [CONTACT_16990] ...............................................................................498.1 Screening (Visit 1) ......................................................................................................... ..49
8.2 Baseline (Day 1, first dose of IMP) (Visit 2)...................................................................518.3 Double-Blind Period (Week 1 to Week 12).....................................................................52
8.3.1 Week 1 (+/-3 da ys) (Visit 3)................................................................................52
8.3.2 Week 2 (+/-3 da ys) (Visit 4)................................................................................53
8.3.3 Week 4 (+/-3 da ys) (Visit 5)................................................................................53
8.3.4 Week 8 (+/-3 da ys) (Visit 6)................................................................................54
8.3.5 Week 12 (+/-3 days) (Visit 7)..............................................................................55
8.4 Dose-Blind Period (Week 16 to Week 48) ......................................................................56
8.4.1 Week 16 (+/-4 days) (Visit 8)..............................................................................568.4.2 Week 20 (+/-4 days) (Visit 9)..............................................................................578.4.3 Week 24 (+/-4 days) (Visit 10)............................................................................578.4.4 Week 28 (+/-4 days) (Visit 11)............................................................................598.4.5 Week 32 (+/-4 days) (Visit 12)............................................................................598.4.6 Week 36 (+/-4 days) (Visit 13)............................................................................608.4.7 Week 40 (+/-4 days) (Visit 14)............................................................................60REDACTED ea
atmenatmen
nt blint blin
of subjof sub
IISISCOPY .........
akingking
This document8.48.4cannotosee-B-B
4.14.1
44beWW
BlBlused kk
Weekeek88
WeeWto4 (+4 (+support W
3 day days
+/+/-3 d3 d
/any of of
eek 1eek 1marketing bjej
IT .....T .....
.............
f IMPfI Mauthorizationg the tg the t
nt blint blin
nd in ad in a
ectsctsapplication .
d therather
s and thand 
...........and .......
.......any ........
......extensions...........
..............
...............or ......variations 4343
444thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 7 of 1438.4.8 Week 44 (+/-4 days) (Visit 15)............................................................................61
8.4.9 Week 48 (+/-4 days) (Visit 16)............................................................................61
8.5 Early Termination Visit ...................................................................................................628.6 Safety Follow-Up Visit (20 weeks [-3 days/+7 days] after the final dose)......................648.7 Unscheduled Visit........................................................................................................... .65
9 ASSESSMENT OF EFFICACY......................................................................................659.1 ASAS20, 40, ASAS 5/6 response, and ASAS partial remission .....................................659.2 Patient global assessment.................................................................................................669.3 Total and nocturnal spi[INVESTIGATOR_18172]........................................................................................669.4 Function – BASFI ............................................................................................................6 6
9.5 Inflammation – BASDAI (mean of questions 5 and 6) ...................................................669.6 CRP 669.7 ASDAS-CRP................................................................................................................... .67
9.8 BASDAI...................................................................................................................... .....67
9.9 BASMI....................................................................................................................... ......67
9.10 MASES ...................................................................................................................... ......68
9.11 PhGADA..................................................................................................................... .....68
9.12 SF-[ZIP_CODE].13 MOS-12..................................................................................................................... .......68
9.14 ASQoL ...................................................................................................................... .......69
9.15 MRI Assessment (SPARCC and ASspi[CONTACT_9268]) ..................................................................699.[ADDRESS_64008] ...................................................7412.1.11 Safety signal detection.........................................................................................74
REDACTED ............
...........
d ASspd ASsp
on Son SCOPY .........
This document 1212
1canno4
[IP_ADDRESS].5
2121beAdA
PPuseddverseverse
AdvdvtotiontionsupportSAFEAFE
............
noany MUNOMUNO
Tmarketing pi[INVESTIGATOR_58883] ..........
...........
iMRMRapplication .
............
............
...........and .......
.......any ...extensions...........
..............
................or ......variations 6565
666thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 8 of [ZIP_CODE].2 Serious adverse events ..................................................................................................... 75
12.2.1 Definition of serious adverse event .....................................................................7512.2.2 Procedures for reporting serious adverse events .................................................7512.2.3 Follow-up of serious adverse events....................................................................76
12.3 Immediate reporting of adverse events ............................................................................7612.4 Anticipated serious adverse events ..................................................................................7612.5 Laboratory measurements................................................................................................77
12.5.1 Evaluation of PDILI ............................................................................................78
[IP_ADDRESS] Consultation with Medical Monitor and local hepatologist ......................8212.5.1.2 Immediate action: determination of IMP discontinuation.........................8212.5.1.3 IMP restart/rechallenge .............................................................................8212.5.1.4 Testing: identification/exclusion of alternative etiology...........................8212.5.1.5 Follow-up evaluation.................................................................................84
12.6 Other safety measurements ..............................................................................................84
12.6.1 Vital signs ............................................................................................................8412.6.2 Body weight and height .......................................................................................85
12.6.3 Physical examination ...........................................................................................8512.6.4 12-lead electrocardiogram ...................................................................................8512.6.5 Tuberculosis and TB risk factor assessment and management ...........................85
[IP_ADDRESS] Tuberculosis assessment by [CONTACT_18406]............................................................8712.6.5.[ADDRESS_64009] Screening and Enrollment log/Subject Identification Code list..............92
14.4 Termination of the study..................................................................................................9 2
14.5 Archiving and data retention............................................................................................9214.6 Audit and inspection ....................................................................................................... .92
14.7 Good Clinical Practice ..................................................................................................... 93
15 STATISTICS ................................................................................................................... 93
15.1 Definition of analysis sets................................................................................................ 93
15.2 General statistical considerations.....................................................................................9415.3 Planned efficacy analyses ................................................................................................94
15.3.1 Analysis of the primar y efficacy variable............................................................94
[IP_ADDRESS] Supportive analyses...................................................................................95
15.3.2 Other efficacy analyses........................................................................................95
[IP_ADDRESS] Analysis of the seconda ry efficacy variables ............................................95
[IP_ADDRESS] Analysis of the other efficacy variables ....................................................[ADDRESS_64010] privacy............................................................................................................ ...101
16.5 Protocol amendments.....................................................................................................[ZIP_CODE] FINANCE, INSURANCE, AND PUBLICATION .......................................................[ZIP_CODE] REFERENCES ..............................................................................................................[ZIP_CODE] APPENDICES ...............................................................................................................[ZIP_CODE].1 Modified [LOCATION_001] (mNY) Classification Criteria for AS ..........................................[ZIP_CODE].[ADDRESS_64011] OF TABLES
Table 5‒1: Schedule of study assessments.........................................................................29
Table 7‒1: Prohibited or restricted medications and required wash-out periods prior 
to Baseline........................................................................................................46
Table 7‒2: Preparation of placebo and bimekizumab injections .......................................48
Table 12‒1: Anticipated serious adverse events for the population of subjects with 
ankylosing spondylitis .....................................................................................77
Table 12‒2: Laboratory measurements................................................................................78
Table 12‒3: Required investigations and follow-up for PDILI ...........................................80
Table 12‒4: PDILI laboratory measurements......................................................................83
Table 12‒5: PDILI information to be collected ...................................................................84
Table 19‒1: Modified [LOCATION_001] (mNY) Classification Criteria for AS ..........................106
Table 19‒2: Definitions of markedly abnormal hematology values..................................107
Table 19‒3: Definitions of markedly abnormal biochemistry values................................[ADDRESS_64012] OF FIGURES
Figure 5‒1: Schematic diagram...........................................................................................[ADDRESS_64013] OF ABBREVIATIONS
AE adverse event
AESI adverse event of special interestAESM adverse event for special monitoringALP alkaline phosphataseALT alanine aminotransferaseANCOVA analysis of covarianceAS ankylosing spondylitisASAS Assessment of SpondyloArthritis International SocietyASAS20, 40, 5/6 Assessment in SpondyloArthritis International Society 20%, 40%, [ADDRESS_64014] aspartate aminotransferaseaxSpA axial spondyloarthritisBASDAI Bath Ankylosing Spondylitis Disease Activity IndexBASFI Bath Ankylosing Spondylitis Functional IndexBASMI Bath Ankylosing Spondylitis Metrology IndexBSA body surface areaCDC Centers for Disease Control CDMS clinical data management systemCHO Chinese Hamster OvarianCL/F total body clearance
COX-[ADDRESS_64015] research organizationCRP C-reactive proteinC-SSRS/eC-SSRS Columbia-Suicide Severity Rating Scale/electronic C-SSRSCZP certolizumab pegolREDACTEDeraseerase
hritisritis
sing Spsing Sp
iiCOPY MaM
QualityQualit
This document PMPM
CRCRcannot h
MPMPbebitorbitoused to supportntersnters
clinicclini
Canyrfacrfac
fmarketing Spop
ng Spog Spo
ylosingosingauthorization yofofy
ondyondyapplication o
tyy ScorScoyy
netic Retic R
f LiffL iand orere-C-Canyietyietyextensions yy22or variations thereof. 
UCB [ADDRESS_64016] SetFAS Full Analysis SetFDA Food and Drug AdministrationGCP Good Clinical PracticeGFR glomerular filtration rateGI gastrointestinalHADS Hospi[INVESTIGATOR_58884]-A Hospi[INVESTIGATOR_5620]—Anxiety HADS-D Hospi[INVESTIGATOR_5620]—Depression HbcAg hepatitis B core antibodyHbsAg hepatitis B surface antigenHBV hepatitis B virusHCV hepatitis C virusHIV human immunodeficiency virusHLA human leukocyte antigenHRQoL health-related quality of lifehs-CRP high sensitivity C-reactive proteinIB Investigator’s BrochureIBD inflammatory bowel diseaseICH International Council for HarmonisationICF Informed Consent FormIEC Independent Ethics CommitteeIGRA Interferon-Gamma Release Assay
REDACTEDd Deprd Dep
yand Dand y
xietyxiety aayCOPY 
This document BDBD
ICICcannot be used to support epatitipatiti
humhumany tis B vis B marketingand nd
re antibre ant
B surfasurfauthorization ressioressio
DepreDepre
dDdDapplication and any extensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 13 of 143IIV interindividual variability
IL interleukinim intramuscularIMP investigational medicinal productIRB Institutional Review BoardIUD intrauterine deviceIUS intrauterine hormone-releasing systemiv intravenousIXRS interactive voice or web response system LTB latent tuberculosisLTBI latent tuberculosis infection MAR missing at randomMASES Maastricht Ankylosing Spondylitis Enthesitis IndexMCID minimal clinically important differenceMCP-Mod multiple comparison procedure – modelingMCS mental component summaryMedDRA
®Medical Dictionary for Regulatory Activities
MI multiple imputationMMR measles-mumps-rubellamNY Modified [LOCATION_001] (criteria)MOS Medical Outcomes StudyMRI magnetic resonance imagingMTB mycobacterium tuberculosis MTX methotrexatenr-axSpA nonradiographic-axial spondyloarthritisNRI nonresponder imputationNRS Numeric Rating ScaleNSAID nonsteroidal anti-inflammatory drugNTMB nontuberculous mycobacteriaNYHA [LOCATION_001] Heart AssociationOMERACT Outcome Measures in Rheumatology Clinical TrialsOPV oral polio vaccineREDACTEDummaumma
aryry forfoyy
utatioutatioCOPYdiffediff
cedureedure
This documentNSANSA
NNcannot AIAIbe used to support magnetiagnet
mymyany al al OuOumarketing onn
psps--rubrub
New YNew authorizatione ––mm
aryry
r RegRegapplication hesitishesiti
renceence
moand any extensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 14 of 143PCS physical component summary
PD pharmacodynamicsPDILI potential drug-induced liver injuryPD-PPS Pharmacodynamics Per-Protocol SetPGADA Patient’s Global Assessment of Disease ActivityPhGADA Physician’s Global Assessment of Disease ActivityPK pharmacokineticsPK-PPS Pharmacokinetic Per-Protocol SetPPS Per-Protocol SetPS Patient SafetyPsA psoriatic arthritisQ4W every 4 weeks (monthly)QTcB QT interval corrected for heart rate using Bazett’s formula QTcF QT interval corrected for heart rate using Fridericia’s formula RA rheumatoid arthritisRIF mycobacterium tuberculosis rifampi[INVESTIGATOR_58885](ly)SD standard deviationSF-[ADDRESS_64017] upper limit of normalVAS visual analog scaleV/F volume of distributionVU vertebral unit
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 16 of 1431S U M M A R Y
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 
dose-ranging study to investigate the efficacy, safety, pharmacokinetics (PK), and 
pharmacodynamics (PD) of bimekizumab (also known as UCB4940) compared with placebo in 
adult subjects with active ankylosing spondylitis (AS) in order to guide the selection of doses and clinical indices in the Phase [ADDRESS_64018] active AS, determined by [CONTACT_58943] (X-ray) 
fulfilling the Modified [LOCATION_001] criteria for AS (1984), including symptoms for ≥3 months and 
age of onset <45. Furthermore, subjects will have moderate to severe active disease (Bath 
Ankylosing Spondylitis Disease Activity Index [BASDAI] ≥4 and spi[INVESTIGATOR_18172] ≥4 [BASDAI 
Question 2]). Subjects must have at least 1 of the following: 1) inadequate response to nonsteroidal anti-inflammatory drug (NSAID) therapy, 2) intolerance to administration of at least 
1 NSAID, or 3) contraindication(s) to NSAID therapy. Inadequate response to an NSAID is 
defined as lack of response for at least [ADDRESS_64019]: 
•experienced an inadequate response to previous treatment given for at least 3 months 
•been intolerant to administration (eg, had a side effect/AE that led to discontinuation) 
•lost access to TNF inhibitor for other reasons 
The primary objective is to assess the dose-response based on the efficacy of bimekizumab
administered subcutaneously (sc) Q4W for 12 weeks in the treatment of subjects with active AS. 
The primary efficacy variable is the Assessment in Axial SpondyloArthritis International Society
40% response criteria (ASAS40) response at Week 12. An ASAS40 response is defined as an improvement of ≥40% and ≥[ADDRESS_64020] 3 out of the following 4 domains on a scale of 
0 to 10 and no worsening at all in the remaining domain and includes the following assessments:
•Patient global assessment: numeric rating scale (NRS) (global disease activity last week)
•Pain assessment: NRS (last week/spi[INVESTIGATOR_050]/at night due to AS) 
•Function: Bath Ankylosing Spondylitis Functional Index (BASFI) 
•Inflammation: mean of BASDAI Questions 5 and 6
The secondary objectives of the study are to assess the efficacy of the individual dose regimens 
of bimekizumab compared to placebo, safety and tolerability, PK, PD, immunogenicity, and the 
exposure:response relationship of bimekizumab as it relates to efficacy and safety. The secondary efficacy variables include: Change from Baseline in Ankylosing Spondylitis Disease 
Activity Score- C-reactive protein (ASDAS-CRP), Assessment in Axial SpondyloArthritis 
International Society 20% response criteria (ASAS20) response, Assessment in Axial SpondyloArthritis International Society 5 out of 6 response criteria (ASAS5/6) response, Change 
from Baseline in BASDAI, and Change from Baseline in BASFI, all at Week 12. Safety 
variables include incidence of adverse events (AEs), serious adverse events (SAEs), and withdrawal due to AEs as secondary safety variables and change from Baseline in vital signs, a sida sid
reasoneason
e dosedose
4W4WCOPY us treas tre
ded
This documentexpoxpo
secosec
Acannotcondaonda
imekimek
osuosubematiatiusedath Ath A
ionito t: Nt: Nsupport ala
sment: ment
NRSNRSanyunitsunit
ll in tl in tmarketingfor 12for 12
AssessAsses
responsespon
ts ints iauthorization atm
e effeceffec
ns ns
respoespoapplication al dudu
or. Subr. Su
ment ment andtreatmreatm
durauraanye toe to
erapyrapyextensions at
BASDASD
nse tonse to
inistranistra
to aoaor th hvariations yy) ) 
hs anhs anthereof. 
UCB [ADDRESS_64021] on patient-reported quality of life (fatigue, sleep, and 
pain), the impact of administration of bimekizumab on biological pathways relating to disease biology and response to therapy via candidate biomarker analysis, and to enable genomic and 
proteomic analysis of subject samples and evaluation of the potential for subject stratification 
approaches, and to assess the impact of bimekizumab on inflammatory changes in the spi[INVESTIGATOR_58886] (SI) joint using magnetic resonance imaging (MRI) in a subset of subjects. 
An estimated 100 sites in Europe and North America will randomize 285 subjects (57 subjects 
per treatment arm). The enrollment of TNF inhibitor-experienced subjects will be limited to 30% of the total study population.
The study consists of a Screening Period (up to 28 days), Double-Blind Period (12 weeks), 
Dose-Blind Period (36 weeks) and Safety Follow-up (SFU) Period (20 weeks; only for subjects who do not enter the extension study). Therefore, the maximum duration of the study is 
68 weeks. 
Screening Period/Baseline
The Screening Period will be up to 28 days. During the Screening Period, the Investigator will 
assess the eligibility of subjects according to the inclusion and exclusion criteria. The Screening 
Period will also enable washout of any medications not permitted for use during the study and allow initiation of latent TB treatment where necessary and appropriate. 
Double-Blind Period
At Baseline/Day 1 subjects will be randomized in a 1:1:1:1:1 ratio (stratified by [CONTACT_58944]) to receive the following blinded study treatment regimens during the 
Double-Blind Period:
•Placebo
•Bimekizumab 16mg administered sc every 4 weeks (Q4W)
•Bimekizumab 64mg administered sc Q4W
•Bimekizumab 160mg administered sc Q4W
•Bimekizumab 320mg administered sc Q4W
The investigational medicinal product (IMP) will be administered sc in the clinic at Baseline, 
Week 4, Week 8, and Week 12. Additional study visits in the Double-Blind Period (without 
dosing) will occur at Week 1 and Week 2. At Week 12, subjects will transition from the 
Double-Blind Period into the 36-week Dose-Blind Period. REDACTEDnecenece
andomandom
he fhe fCOPYhe e
clusioclusio
ons nons n
This document ouocannot, WeWe
ng) wig) wi
ubleblebeigatiigati
eeeeusedabab3232
onto160m60msupport minmi
g adminadm
0mg many nistenistmarketing miz
followfollowauthorizationot peot pe
ssarysary
zed ed application eeningening
n and n and
rmand on n any ekseks;
of thofextensionssu
imitedmited
od (12d (12
;oorubjeubjevariations nd nd thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 18 of 143Dose-Blind Period
The Dose-Blind Period lasts from Week 12 to Week 48. Subjects randomized to bimekizumab 
160mg Q4W or bimekizumab 320mg Q4W will remain on their randomized dose and subjects 
randomized to placebo, bimekizumab 16mg Q4W, and bimekizumab 64mg Q4W, will be rerandomized in a 1:1 fashion to bimekizumab 160mg Q4W or bimekizumab 320mg Q4W. The 
total duration of treatment is 48 weeks.
During the 36-week Dose-Blind Period, subjects will be evaluated for eligibility to rescue
treatment at defined time points. Subjects who do not show an improvement in both PGADA and 
spi[INVESTIGATOR_58887] 5.1.4 .
Safety Follow-Up (SFU) Visit/Extension study
At the completion of the Dose-Blind Period, subjects will be given the opportunity to enter an 
extension study at Week 48. All subjects who complete the study and do not enter the extensionstudy or who discontinue early, including those withdrawn from study treatment, will have a 
SFU Visit at [ADDRESS_64022] dose of IMP. 
2 INTRODUCTION
2.1 Axial spondyloarthritis
Spondyloarthritis (SpA) is an umbrella term applied to a family of rheumatic diseases (including axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], reactive arthritis, the arthritis of 
inflammatory bowel disease [IBD], and undifferentiated spondyloarthritis) that have features in common with each other and distinct from other inflammatory arthritides, particularly 
rheumatoid arthritis (RA). 
Axial SpA is a chronic inflammatory disease that impacts a substantial proportion of the 
population. Limited evidence exists regarding the exact prevalence of axSpA; however, recent 
data suggest that the prevalence is similar to that of RA in the US (axSpA: 0.7% to 1.4%; 
RA: 0.5% to 1.0%) (Reveille et al, 2012; Myasoedova et al, 2010; Helmick et al, 2008).  
The ASAS working group established classification criteria to distinguish [ADDRESS_64023] categories of 
SpA: peripheral SpA and axSpA (Rudwaleit et al, 2011; Rudwaleit, 2010; Rudwaleit et al, 
2009b). This division is based on the body part predominantly involved in the inflammatory process. Therefore, peripheral SpA includes diseases affecting mainly peripheral joints, such as 
reactive arthritis and PsA, whereas axSpA comprises those diseases with mainly axial 
involvement (SI joints and spi[INVESTIGATOR_050]), including AS diagnosed with radiographic involvement and nonradiographic axSpA (nr-axSpA). 
Patients with axSpA have inflammatory back pain. The disease typi[INVESTIGATOR_58888], then progresses to the spi[INVESTIGATOR_050]. In the sacroiliac joints and the spi[INVESTIGATOR_050], active inflammation results in erosions, sclerosis, and fatty lesions seen on MRI. However, the most 
characteristic feature is new bone formation leading to ankylosis of the SI joints and 
syndesmophytes attached to the vertebral bodies. As a result of extended syndesmophyte formation, over time the spi[INVESTIGATOR_58889]. Objective signs of inflammation (such as 
enthesitis, dactylitis, peripheral arthritis, or uveitis), genetic features (such as the presence of 
human leukocyte antigen [HLA] B27), and laboratory parameters (such as elevated C-reactive REDACTEDp
hritishritis
ndifferndiffer
rom otom otCOPY lied toied t
This documentsacrosacro
infinfcannotiograogra
ients ents
ibent (nt (SSusedore, pre, p
tis antis antoon ion isupport up estabp est
and axand ax
is bisany is is
et al, et al,marketing diseasedisea
ts regars rega
s simsimauthorizationto a fato a fa
[PsA][PsA]
rentiaentia
ther inher inapplication andyytretreyanynot ennot e
atmtextensions n
rtunitunior variations DA aDA athereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 19 of 143protein [CRP]) may also be present (Braun, 2012; Rudwaleit et al, 2009a; Braun and Sieper, 
2007). Disability in axSpA is related to both the degree of inflammatory activity, causing pain, 
stiffness, fatigue, and poor quality of sleep, and to the degree of bony ankylosis, causing loss of 
spi[INVESTIGATOR_18171]. Patients with AS show radiographic progression of disease with X-ray identified sacroiliitis, while "Bamboo spi[INVESTIGATOR_050]" may develop when the outer fibers of the fibrous ring of the 
intervertebral discs ossify, which results in the formation of marginal syndesmophytes between 
adjoining vertebrae.
Nonsteroidal anti-inflammatory drugs are often rapi[INVESTIGATOR_58890] (pain and 
stiffness) of axSpA (Poddubnyy, 2013; Poddubnyy et al, 2012), but many patients lose or never 
have clinically meaningful response and structural damage often progresses despi[INVESTIGATOR_18186]. Conventional disease-modifying antirheumatic drugs (DMARDs,eg, methotrexate [MTX] and 
sulfasalazine [SSZ]) have no proven efficacy in axial disease, but may benefit patients with 
peripheral joint disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2005). Therefore, DMARDs are recommended only in patients with predominantly peripheral manifestations 
(Braun et al, 2011). Patients who are intolerant of or have inadequately responded to NSAIDs, or 
those in whom NSAIDs are contraindicated, have approved treatment options such as TNF inhibitors.
Recently, the interleukin (IL)-17 cytokine family has been identified as a therapeutic target in 
axSpA and secukinumab, an IL-17A monoclonal antibody, has recently been approved as a treatment option in active AS. 
Bimekizumab (UCB4940) is an engineered, humanized full-length monoclonal antibody of IgG1 
subclass of approximately 150,000 Dalton, which is expressed in a genetically engineered Chinese Hamster Ovarian (CHO) cell line. Bimekizumab has high affinity for human IL-17A 
and human IL-17F and selectively and potently inhibits the activity of both isoforms in vitro. 
Interleukin-17A and IL-17F are key proinflammatory cytokines believed to play important roles in autoimmune and inflammatory diseases. Therefore, bimekizumab permits an evaluation of the 
potential for additional efficacy, which may be conferred by [CONTACT_58945], in 
patients suffering from diseases in which both cytokines are active. Bimekizumab is being developed for the treatment of patients with inflammatory diseases such as PsA, PsO, and 
AxSpA. 
As a consequence, a Phase 2b dose-ranging study (AS0008) was designed to investigate the 
efficacy and safety of various bimekizumab dose regimens in subjects with active AS. 
2.1.[ADDRESS_64024] been completed: UP0008 in 39 subjects with mild to 
moderate plaque psoriasis, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, and UP0031 in 12 healthy volunteers. 
UP0008 was a Phase 1, single ascending dose study in adults with mild to moderate psoriasis 
affecting ≤5% body surface area (BSA). In this blinded study, single doses of bimekizumab up to 
640mg (approximately 8mg/kg in an 80kg adult) were evaluated. There were no clinically 
relevant safety findings identified at any dose and all doses were well tolerated. The prespecified 
exploratory assessment of disease activity showed clinically relevant and statistically significant improvements at the higher doses studied.REDACTEDhumahuma
,,whicwhic
ine. Bine. B
nd potnd po
proprCOPYntibodtibo
This document UP0UP0
aacannot icac
rate pate p
UP0UP0be al sal susedty oy o
CliClito a P
of vofsupportt of pof 
Phasehasanyes in wes in 
fp afp amarketingotentent
roinflamoinflam
iseasessease
which whichauthorization nized nized
ch is ech is e
Bimekimek
ntltlyyapplication dentifieentifi
yy, has , hasandy rere
nt optt opanyral mal m
espoespextensionsheir heir
e [MT[MT
patienpatien
005). 05).orr nr n
uvariations nd d 
nevnevthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 20 of 143RA0124 was a Phase 1, open-label, parallel-group, single-dose study in healthy subjects. The 
primary objective of this study was to determine the absolute bioavailability of single sc doses of 
bimekizumab (80mg and 160mg). The secondary objectives were to evaluate the dose 
proportionality of bimekizumab 80mg and 160mg sc, and to evaluate the safety and tolerability of these sc doses and 160mg given by [CONTACT_33980] (iv) infusion. In RA0124, the absolute 
bioavailability was similar for the 2 doses tested (0.656 and 0.631 for the bimekizumab 80mg 
and 160mg sc doses, respectiv ely). The median half-life (t
½) following sc administration was 
similar to that following iv administration (27.81 days and 28.25 days for bimekizumab 160mg 
sc and bimekizumab 160mg iv, respectively).
Bimekizumab has also been investigated in a Phase 1b, proof of concept, randomized, 
placebo-controlled, multiple-dose study (PA0007). The primary objective of PA0007 was to 
assess the safety and PK of multiple dose administration of iv bimekizumab in subjects with 
PsA. Four active doses and a placebo were tested. Drug was administered as a loading dose of bimekizumab 80mg, 160mg, 240mg, or 560mg at Week 1, and 2 additional doses of 
bimekizumab 40mg, 80mg, 160mg, or 320mg at Week 4 and Week 7. In each treatment group, 
subjects received a total of 3 doses of bimekizumab, administered every 3 weeks. There were no unexpected clinically relevant safety findings and all doses were well tolerated. The PK was 
linear across the tested dose range and no change in PK was observed following multiple doses. 
Observed changes in inflammatory biomarkers were consistent with expectations based on the IL-17A and IL-17F mechanism of action. The exploratory analysis showed clinically relevant 
improvement in activity of PsA and in skin involvement in those subjects with concomitant 
active psoriatic lesions. Data from the top 3 bimekizumab dose groups pooled showed that by [CONTACT_10585] 9 80% [95% CI: 62.7, 90.5] of subjects achieved an ACR20 response (vs 16.7% [95% CI: 
4.7, 44.8] in the placebo group) and 100% [95% CI: 79.6, 100.0] of subjects with active psoriatic 
lesions had achieved a PASI75 response (vs 0% [95% CI: 0.0, 43.4] in the placebo group).
Infections (mostly nasopharyngitis) were the most commonly reported events in both the active
(36.8% of subjects) treatment and the placebo group (35.7% of subjects). None of the infections 
were considered serious or required treatment with antibiotics. Two subjects in the active treatment group experienced 1 local candida infection each (oropharyngitis and vulvovaginitis, 
respectively) that were nonserious and resolved with topi[INVESTIGATOR_8588]. There was a reduction in 
mean neutrophil count in the active treatment group, although this drop was not clinically relevant and a clear relationship with dose or time was not evident. IL-[ADDRESS_64025] commonly reported GI AEs were 
abdominal distension, abdominal pain, diarrhea, flatulence, nausea, and vomiting. All of these 
events, except 1 event of vomiting, were mild or moderate in intensity. T helper-17 and other IL-17-producing cell types are present in a high frequency in the physiologic, healthy state of the 
intestinal mucosa. Interleukin-17 is recognized as an important player in the pathophysiology of 
infectious and immune-mediated GI diseases, and has been shown to contribute to the gut barrier function (Ivanov et al, 2008). Clinical data with secukinumab suggest that the drug may worsen olv
bimekbimek
ects aects a
00% [900% [
onse (onse (COPYconcon
loratolorato
vemvem
This documentn thn th
abdabdcannotle. e. SS
ionshionsh
hehbetion tion 
SoSousedutroptrop
be asbe astor relrel
phphsupportd 11
onserionseri
t in thein th
elatiolatianyiredire
1localocamarketing (vs 0vs 0
were thwere t
the plathe p
dt rdauthorizationoryy
ment inent in
kizumkizum
achievachiev
95% C95% 
0%0%application well well
observeobserv
stent wtent w
yyanaanayyandIn en e
veryery33yyanyal doal do
eaceacextensions d, ,
007 w07 w
subjesubje
a loaa loaor variations 0mg mg thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 21 of 143symptoms of co-existing Crohn’s disease in patients with psoriasis and ankylosing spondylitis 
(Baeten et al 2015). 
UP0031 was a Phase 1, open-label, parallel-group, randomized, single-dose study to evaluate the 
BA, PK, and tolerability of 2 different formulations of bimekizumab in healthy subjects. There were no treatment-emergent adverse events (TEAEs) leading to discontinuation, and no SAEs or 
fatalities were reported. 
One additional study of bimekizumab is ongoing. RA0123 is a Phase 2a, double-blind, 
randomized, placebo-controlled, multiple dose study to evaluate the safety, PK, PD, and efficacy 
of multiple doses of bimekizumab administered as add-on therapy to stable certolizumab pegol 
(CZP; Cimzia
®) therapy in subjects with moderate to severe RA.
Additional information on the clinical data for bimekizumab is available in the current version of 
the Investigator’s Brochure (IB).
2.1.[ADDRESS_64026] level of 
200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious enteritis (observed in the single dose study) and asymptomatic mild colonic ulceration in a 
proportion of animals (in the repeat-dose study); this latter finding was not associated with 
hematology abnormalities. Data suggest that bimekizumab has induced primary lesions to the mucosa-associated lymphoid tissue via a pharmacologically-related mechanism. In a second 
repeat-dose study, none of the minor apoptosis/necrosis findings observed in gut associated 
lymph nodes were seen. In animals given the highest dose of bimekizumab in the study (20mg/kg/week), a slightly higher number of protozoa ( Balantidium coli ) was observed in the 
cecum and colon as compared to the control animals and low dose animals. Therefore, the 
gut-associated lymph node lesions observed in the first study are considered to be accidental and/or linked to exaggerated pharmacology and proliferation of Balantidium coli and are 
considered to be the result of a change in local mucosal immunity. 
Additional information on the nonclinical data for bimekizumab is available in the current 
version of the IB.
3 STUDY OBJECTIVES
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group dose-ranging study to evaluate the efficacy and safety of bimekizumab in subjects with active AS. 
3.1 Primary objective
The primary objective is to assess the dose-response based on the efficacy of bimekizumabadministered sc Q4W for 12 weeks in the treatment of subjects with active AS.REDACTEDbimebime
pharmaharma
poptosoptos
given tgiven 
umbumbCOPY ese
yymptomptoyy
this lthis 
k
This document .11
ThThcannotginginbehasease
ng sng susedSTUTU
e2 be2to UDUDsupportof af a
on theon thanyharmharm
a chac hmarketing thehe
mber of ber of 
e controcont
s obse obse
maauthorizationlatterlatter
kizumizum
acologcolog
sis/necs/nec
eh ieh iapplication bwaw
verse eerse 
re diare dia
matic matic
fandn a vara va
aany extensions ab
currenurrenorb peb pevariations fficacfficacthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 22 of 1433.2 Secondary objectives
The secondary objectives of the study are as follows:
•To assess the efficacy of the individual dose regimens of bimekizumab compared to placebo 
•To assess the safety and tolerability of bimekizumab
•To assess the PK of bimekizumab
•To assess the PD of bimekizumab
•To assess the immunogenicity of bimekizumab
•To assess the exposure:response relationship of bimekizumab as it relates to efficacy and 
safety
3.3 Other objectives
•To assess disease activity
•To assess the impact on patient-reported quality of life (function, fatigue, sleep, and pain)
•To assess the impact on enthesitis
•To assess the impact of administration of bimekizumab on biological pathways relating to 
disease biology, progression, and response to therapy via biomarker analysis, and to enable 
genomic and related approaches for analysis of subject samples and evaluation of the 
potential for subject stratification approaches
•To assess the impact of bimekizumab on inflammatory changes in the spi[INVESTIGATOR_58891] a subset of subjects
4 STUDY VARIABLES
4.1 Primary variable(s)
4.1.1 Primary efficacy variable
The primary efficacy variable for this study is as follows:
•ASAS40 response at Week 12 
4.2 Secondary variables
4.2.1 Secondary efficacy variables
The secondary efficacy variables for this study are as follows:
•Change from Baseline in ASDAS-CRP at Week 12
•ASAS20 response at Week 12
•ASAS5/6 response at Week 12
•Change from Baseline in BASDAI at Week 12 
•Change from Baseline in BASFI at Week 12REDACTEDis is oo
achesaches
ababon on 
ssCOPYzumzum
therapthera
of sof
This document ••AAcannotcondaonda
ChanChanbe usedSecoeco
SeSeto se
osupport riable fiable
e at Wat Wany cacyacyyymarketing LLESES
le(s)le(sauthorizationpy vy v
subjecubjec
inflamnflamapplication on, n,
bbon bon 
via viaand fatfatany extensions fficacyficacyor variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 23 of 1434.2.2 Secondary safety variables
Assessment time points for safety variables are specified in Table 5‒1. Variables are as follows: 
•Incidence of AEs and SAEs
•Withdrawal due to AEs
4.3 Other variables
4.3.1 Other efficacy variables
Assessment time points for the other efficacy variables are specified in Table 5‒1(analyses at all 
time points not specified in Section 4.1.1 or Section 4.2.1 are exploratory). Variables are as 
follows:
•ASAS40 response
•Time to ASAS40 response
•Change from Baseline in ASDAS-CRP
•ASDAS status (eg, inactive disease, moderate, high and very high disease activity)
•ASAS20 response 
•Time to ASAS20 response
•ASAS5/6 response
•Ankylosing Spondylitis Disease Activity Score major improvement (ASDAS-MI) 
•ASAS partial remission 
•Change from Baseline in BASDAI 
•Change from Baseline in BASFI 
•Change from Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
•Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index
•Physician’s Global Assessment of Disease Activity (PhGADA)
•Change from Baseline in Patient’s Global Assessment of Disease Activity (PGADA)
•Change from Baseline in total and nocturnal spi[INVESTIGATOR_18172] (NRS)
•Change from Baseline in the average of Questions 5 and 6 of the BASDAI  
•Change from Baseline in Physical Component Summary (PCS) and Mental Component 
Summary (MCS) of the SF-36 (Short-Form 36-Item Health Survey) 
•Change from Baseline in Sleep quality (Medical Outcomes Study [MOS]-12 item scale)
•Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL)REDACTED vityvityScSyy
AIAICOPY 
This documentCCcanChChonge ge 
annobe fro
frfrusedm BaBa
om Bom to aseasesupport e in th in th
al Assl AssanyBath ABath marketing I 
SFI FI authorization core mcore mapplicationyy highhighyyand any extensionsy
s are areoryssesesvariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 24 of 143•Change from Baseline in:
−Spondyloarthritis Research Consortium of Canada (SPARCC) MRI index for Assessment 
of Spi[INVESTIGATOR_58892], and
−Ankylosing Spondylitis spi[INVESTIGATOR_25342]- activity (ASspi[CONTACT_9268]-a) in the Berlin modification 
score 
•Change from Baseline in Hospi[INVESTIGATOR_5620] - Anxiety (HADS-A) and 
Hospi[INVESTIGATOR_5620] - Depression (HADS-D) scores 
•Percentage of subjects with scores below 8 in HADS-A and HADS-D (subjects with normal 
scores)
4.3.2 Other safety variables
Assessment time points for other safety variables are specified in Table 5‒1. Variables are as 
follows: 
•Change from Baseline in vital signs (blood pressure, pulse rate) and body weight 
•Standard 12-lead electrocardiogram (ECG) intervals (RR, PR, QRS, QT, and QT intervals 
corrected for heart rate using Bazett’s and Fridericia’s formulas [QTcB and QTcF]), 
including changes from Baseline Electrocardiogram (ECG) variables 
•Change from Baseline in clinical laboratory variables (hematology, biochemistry, and 
urinalysis)
4.3.3 Other PK and PD variables
•The PK variables are plasma concentrations of bimekizumab.
•The PD variables are concentrations of cytokines of relevance to the IL-17A/F signaling 
pathway and AS biology, and include but are not limited to IL-17A, IL-17F, IL-23, IL-6, and 
TNFα. 
4.3.4 Other immunological variables
Immunological variables allow evaluation of immunogenicity as well as immunological 
biomarkers. 
•Anti-bimekizumab antibody detection prior to and following study treatment
•Serum complement concentrations.
•Flow cytometry analysis of key immune cell populations, including but not limited to CD3, 
CD19, CD4, CD8, and CD69 (using fluorescence activated cell sorting). 
•Cytokines and other exploratory markers  
4.3.5 Other pharmacogenomic, proteomic, and metabolite variables
Where local regulations permit, additional blood samples will be collected from consenting 
subjects at specific time points and stored at -80°C for up to 20 years to allow for potential, 
exploratory analyses of genomic, genetic, proteomic, and metabolomic biomarkers relevant to disease biology and progression, response to therapy, and the inflammatory and immune 
response processes. REDACTED ablesables
ncentrancentraCOPYram (ram 
variabvaria
This documentCC
4.4cannotw cycy
CD19,D19
CyCbe om
totousedzumum
mplempleto mabmasupport unun
es allows alloany nolonolmarketing atiotio
ns of cs of 
ncludecludauthorizationbles (bles (
ionsonsapplication R, QRR, QR
rmulasrmula
ECG) vECG)
hand and band bany   extensions ith 
VarVarornornovariations d thereof. 
UCB [ADDRESS_64027] meet the following key inclusion criteria: 
•Subject has active AS, determined by [CONTACT_58943] (X-ray) fulfilling the 
Modified [LOCATION_001] criteria for AS (1984) (see Table 19‒1), including symptoms for 
≥3 months and age of onset <45 years. 
•Subject has moderate to severe active disease as defined by [CONTACT_58946]:
−BASDAI score ≥4
−Spi[INVESTIGATOR_18172] ≥4 on a 0 to 10 NRS (from BASDAI item 2)
•Subjects must have at least 1 of the following: 
−inadequate response to NSAID therapy
−intolerance to administration of at least 1 NSAID 
−contraindication(s) to NSAID therapy
Inadequate response to an NSAID is defined as lack of response for at least [ADDRESS_64028] 4 weeks total duration.
•Subjects may be TNF inhibitor-naïve or may have received [ADDRESS_64029]:
−experienced an inadequate response to previous treatment given for at least 3 months 
−been intolerant to administration (eg, had a side effect/AE that led to discontinuation)
−lost access to TNF inhibitor for other reasons
Approximately 285 eligible subjects will be randomized to 1 of 5 treatment arms to receive 
treatment according to their randomized placebo or bimekizumab dose regimen ( Section 5.1.2 ) 
until Week 12. Thereafter, subjects randomized to bimekizumab 160mg Q4W or bimekizumab
320mg Q4W will remain on their randomized dose and subjects randomized to placebo, bimekizumab 16mg Q4W, and bimekizumab 64mg Q4W, will be rerandomized in a 1:1 fashion 
to bimekizumab 160mg Q4W or bimekizumab 320mg Q4W. The total duration of treatment is 
48 weeks.
5.1.1 Screening Period/Baseline
Assessments of eligibility as described in Section 6 will be initiated during the 28-day Screening 
Period. The Screening Period will also enable the washout of medications not permitted for use 
during the study and allow initiation of latent TB treatment where necessary. 
The assessments at the Screening Period Visit are presented in Table 5‒1.REDACTEDned aned a
hest toest to
at leasat leasCOPY AIDID
This document4848ww
55cannotQ4WQ4W
kizumizum
bimekimekbe12. 2.
WwWused [ADDRESS_64030] 2 Napplication and any extensions wing:wingor r r variations ng the g thethereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 26 of 1435.1.2 Double-Blind Period
At Baseline/Day 1, subjects will be randomized 1:1:1:1:1 (stratified by [CONTACT_58944]) to receive the following blinded IMP treatment regimens at the clinical 
site. The enrollment of TNF inhibitor-experienced subjects will be limited to approximately 30% 
of the total study population.
•Placebo
•Bimekizumab 16mg administered sc Q4W
•Bimekizumab 64mg administered sc Q4W
•Bimekizumab 160mg administered sc Q4W
•Bimekizumab 320mg administered sc Q4W
The IMP will be administered sc in the clinic at Baseline and Q4W thereafter up to Week 12. 
Additional study visits (without dosing) are scheduled at Week 1 and Week 2. At 12 weeks, subjects will transition from the Double-Blind Period into the 36-week Dose-Blind Period, as 
discussed in Section 5.1.3
Subjects withdrawing early from the study will undergo the Early Termination Visit assessments 
and will enter the SFU Period.
The assessments during the Treatment Period are presented in Table 5‒1.
5.1.3 Dose-Blind Period
After the 12-week Double-Blind Period, subjects will enter the 36-week Dose-Blind Period. At 
the Week 12 Visit, subjects will be allocated to bimekizumab treatment regimens as follows:
•Subjects in the placebo group, bimekizumab 16mg Q4W, or bimekizumab 64mg Q4W will 
be rerandomized in a 1:1 fashion to bimekizumab 160mg or bimekizumab 320mg Q4W.
•Subjects in the bimekizumab 160mg dose group will continue to receive bimekizumab 
160mg Q4W.
•Subjects in the bimekizumab 320mg dose group will continue to receive bimekizumab 
320mg Q4W.
At the completion of the Dose-Blind Period, Investigators should discuss treatment options with 
the subject. Subjects will be given the opportunity to enter an extension study at Week 48.
The assessments during the Dose-Blind Period are presented in Table 5‒1.REDACTED , subje subj
llocatelocateCOPY e prespres
This document cannot sbemenmenusedon ofo
ubjectbjecto of thof thsupport kizumkizumanyb 16b 1marketing ed
mekizumekizum
n to bin to b
60m60authorizationsentesente
ects wcts w
d to bto bapplication Early TEarly 
ddand WeWe
ekekDoDoanyfter ufter 
eekek2extensions upor variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 27 of 1435.1.4 Rescue therapy
At Weeks 16, 24, and 36 of the Dose-Blind Period, subjects will be evaluated for their response 
to treatment to determine eligibility for rescue therapy. 
Subjects with <10% improvement from Baseline in both PGADA and total and nocturnal spi[INVESTIGATOR_18173] (ASAS domain response criteria) are eligible for rescue treatment. Rescue therapy will be at the Investigator’s discretion, with the following options:
•NSAIDS and/or joint injections as outlined below. Subjects may receive these add-on rescue 
therapi[INVESTIGATOR_58893].
For subjects taking NSAID/COX-2 inhibitors at Baseline or at Weeks 16, 24, or 36, a change 
can be made to a different NSAID/COX-2 inhibitor. Changes from an NSAID to a COX-2 
inhibitor or from a COX-2 inhibitor to an NSAID are permitted up to the maximum approved 
or tolerated dose, whichever is lower. Only 1 NSAID/COX-2 inhibitor may be taken at a given time.
−For subjects not taking NSAID/COX-2 inhibitors at Baseline, Weeks 16, 24, or 36, either 
NSAIDs, or COX-2 inhibitors can be initiated, up to the maximum approved or tolerated 
dose, whichever is lower. Only 1 NSAID/COX-2 inhibitor may be taken at a given time.
−After the NSAID/COX-2 regimen has been optimized, SI joint injection is permitted, 
either unilaterally or bilaterally, performed by a qualified physician. 
•If the subject does not achieve sufficient response to the above options and/or the 
Investigator feels that a biologic other than bimekizumab is warranted, the subject must 
discontinue from study treatment (bimekizumab) and follow the withdrawal criteria and 
follow up as outlined in Section 6.3 .
A decrease in dose or dosing frequency of any agent for the treatment of AS is permitted for 
reasons of intolerance/AEs/side effects at any time. 
Rescue therapy will be determined by [CONTACT_58947]-life of 
bimekizumab (27.8 days).
Subjects may be withdrawn from the study or from study medication at any time and continue 
treatment per the Investigator’s discretion, as described in the Withdrawal Section ( Section 6.3) .
5.1.[ADDRESS_64031] a SFU Visit at 
20 weeks after their final dose of IMP. 
The assessments at the SFU Visit are presented in Table 5‒1.
5.1.6 Safety monitoring strategy
An independent Data Monitoring Committee (DMC) will review study safety data on an ongoing 
basis. Details will be available in the DMC charter. A cardiovascular adjudication committee 
will review cardiovascular events. Further details are provided in Section 12.1.11.REDACTEDresporespo
than bthan b
bimekibimeki
6.36.3..COPYoptimoptim
d bd by y a
This document he
5.15.1cannotstust
eksksafaf
e asseassebe w
udyudysedSafeafe
who cho to etyetysupport rawn frawn f
estigatstigaanyned nedmarketing cycy of anof yy
fects atcts a
bbauthorizationa ququ
nse tonse to
bimekimek
izumazumaapplicationmaximmaxi
bitor mitor m
ized, Szed, S
ualifualiand e, Wee, Weany maextensions36, a36, a
D to a D to a
maximaxim
mayaybby[CONTACT_58948]. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 28 of 1435.1.7 Imaging evaluation
In a subpopulation of AS0008, MRIs of the spi[INVESTIGATOR_58894] 20 subjects per treatment arm at Baseline. Magnetic resonance imaging at
Week 12 and Week 48 will be performed only for subjects who are MRI-positive at Baseline
based on an ASAS-Outcome Measures in Rheumatology Clinical Trials (OMERACT) assessment. The Baseline MRI should be performed after confirmation of eligibility for the study 
based on screening assessments and before the first bimekizumab injection. Magnetic resonance 
imaging at Week 12 and Week 48 should be performed  as close to the Week 12/Week [ADDRESS_64032] a maximum of up to 68 weeks, as follows:
•Screening Period: up to 28 days
•Double-Blind Period: 12 weeks
•Dose-Blind Period: 36 weeks
•A SFU Visit: [ADDRESS_64033] in the study.5.1.9 Planned number of subjects and site(s)
The planned number of randomized subjects is 285; there will be 57 subjects per treatment arm. 
The planned number of study sites is approximately 100. The enrollment of 
TNF inhibitor-experienced subjects will be limited to 30% of the total study population. 
5.1.10 Anticipated regions and countries
The study sites will be located in Europe and North America.
5.2 Schedule of study assessments
The schedule of study assessments is presented in Table 5‒1.REDACTED he lhe 
jectsjects
ubjectsubjects
s apprs appr
iiCOPY fof
cludingcludin
lastlas
This document cannot be used to supporte of e of 
yassesassesyanyin Euin Emarketing roximroxi
ill be lill be 
ons aons aauthorization g
t visit visit
s andand
s is 28is [ADDRESS_64034]
g thosethosand any extensions s:s:or tureurvariations y
nce nce 
Visit aisit a
re arethereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 29 of 143Table 5‒1: Schedule of study assessments
Screening 
(Visit 1) (up to 
28 days)
Baseline 
(Day 1, Visit 2) 
(first dose)Double-Blind Period 
(weeks after first dose)Dose-Blind Period
(weeks after first dose)ET SFUb
Visita3456789 [ADDRESS_64035] medical history and 
concomitant diseasesXXc
Inclusion/exclusion criteria X X
Prior medication X
Concomitant medication X X XXXXXXXXXXXXXX X X
A d v e r s e  e v e n t s X XXXXXXXXXXXXXX X X
e C - S S R S X X XXXXXXXXXXXXXX X X
HADS X X XXXXXXXXXXXXX X X
AsQoL X XXXX X X X X X
BASDAI X XXXXXX X X X X X
BASFI X XXXXXX X X X X X
SF-36 X X X X X X X X X
MOS Short Sleep Scale (12 items) X X X X X X X X X
PGADA X XXXXXX X X X X X
T o t a l a n d  n o c t u r n a l  s p i n a l  p a i n  ( N R S ) X XXXXXX X X X X X
T u b e r c u l o s i s  q u e s t i o n n a i r e X X XXXX X X
REDACTED 
DDEDCTAC
XXDAAARE
ARRRR
COPY 
YYYYCO
YCThis 
document naireairee
cannot pain (Nain (N
noca
be be
used edse
to tosupport 
oroooposup
any XX
Xan
marketing 
ngXX
ngngngk
ng
Xkkkearkm
authorization 
ontiorizoririiuth
ri
XX
utututut
application 
natiatatatpp
atpppppppp
and d a
any 2828nyan
extensionst dosdo
1212
ssisix
ns
8
xxxtex
or ose)se
variations 
onva
thereof. 090
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 30 of 143Table 5‒1: Schedule of study assessments
Screening 
(Visit 1) (up to 
28 days)
Baseline 
(Day 1, Visit 2) 
(first dose)Double-Blind Period 
(weeks after first dose)Dose-Blind Period
(weeks after first dose)ET SFUb
Visita3456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6
Weeka1248 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8
Height X
Vital signs (BP, pulse, temperature)dX X XXXXXXXXXXXXXX X X
Body weight X X XXXX X X
Physical examinationeXX X X X X
MASES XX X X X
BASMI X XXXX X X X X X
P h G A D A X XXXX X X X X X
ECGfXX X X X
Hematology/biochemistry/urinalysis X X XXXXXXXXXXXXXX X X
Blood sample for CRPgXX X X X X X
Blood sample for hs-CRPgX XXXXXX X X X X X
Pregnancy testinghXX X X X
Hepatitis B and C testing X
HIV testing X
Collect blood sample for determination of 
HLA-B27 statusX
Blood sample for bimekizumab plasma 
concentrationsgX XXXXXXXX X X X X
Bimekizumab antibody detectiongX XXXXXX X X X X
REDACTED XXEDEDEDEDAC
EDACACACE
AC
XXEEEDRE
COPY 
YYYYCO
Y
XXCOCOCOCOThis 
document 
cannotctionion
ot ggotan
be ma ma 
used edus
to support 
tpor
XX
ppppps
any XXya
marketing XX Xngtinnnark
n
X
ararrar
authorization 
nXXonononz
on
XX
zzzahrizhhhoutha
application 
natiatatatpp
at
XXpppppppp
and XXd a
any 2828nyan
extensionst dosdo
1212
ssisix
ns
8
xxxtex
or ose)se
variations 
onva
thereof. 090
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 31 of 143Table 5‒1: Schedule of study assessments
Screening 
(Visit 1) (up to 
28 days)
Baseline 
(Day 1, Visit 2) 
(first dose)Double-Blind Period 
(weeks after first dose)Dose-Blind Period
(weeks after first dose)ET SFUb
Visita3456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6
Weeka1248 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8
Blood samples for cytokines, complement, 
and biomarker analysisgX XXX X X X
Blood sample for genomic, 
proteomic/metabolomic analysesg, iX XXX X X X
Blood samples for genetic/epi[INVESTIGATOR_58895]
g,iXX X X
For participating centers: 
Blood samples for flow cytometryg,X XXX X X X
IGRA tuberculosis testjX XX X
Evaluation for rescue therapykXX X
Chest x-raylX
Sacroiliac joint x-ray Xm
Spi[INVESTIGATOR_58896] X
Enter IXRSoX X XXXXXXXXXXXXXX X X
Bimekizumab or placebo administrationp, qX XXXXXXXXXXX
AS=ankylosing spondylitis; ASAS=Assessment of SpondyloArthritis International Society; AsQoL=Ankylosing Spondylitis Quality of Life; BASDAI=Bath 
Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing Spondylitis Functional Index; BASMI=Bath Ankylosing Spondy litis Metrology 
Index;BP=blood pressure; CRP=C-reactive protein; eC-SSRS=electronic Columbia Suicide Severity Rating Scale; ECG=electrocardiogr am; ET=Early 
Termination; HADS=Hospi[INVESTIGATOR_5620]; HIV=human immunodeficiency virus; hs-CRP=high sensitivity C-reactive p rotein; 
IGRA=interferon gamma release assay; IMP=investigational medicinal product; IMS=International Menopause Society; IXRS= interacti ve voice or web 
response system; MASES=Maastricht Ankylosing Spondylitis Enthesitis Index; MOS=Medical outcomes study; MRI=magnetic resonance im aging; 
NRS=numeric rating scale; PGADA=Patient’s Global Assessment of Disease Activity; PhGADA=Physician’s Global Assessment of Disease , Activity; SF-
36=Short Form-36; SFU=Safety Follow-Up; TB=tuberculosis
REDACTED 
EDCTACDAAARE
ARRRR
COPY O
Y
XXCOCOCOCOThis 
document 
cannotastrichtrich
PGADAGADA
Safetyafety
be ty 
say; say; 
htht
used ndexde
ive prove pro
and and 
to nt ont o
ex; Bex; B
suof Spof Ssupport 
orpopopoposup
any XX
Xan
marketing 
ngngngngk
ngkkkearkm
authorization 
nnnnriz
onoririiuth
rutututu
application 
ati
X
icaaapp
a
and XXaaaaa
any 2828nyan
extensionst dosdo
1212
ssisix
ns
8
xxxtex
or ose)se
variations 
onva
thereof. 090
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 32 of 143Table 5‒1: Schedule of study assessments
Screening 
(Visit 1) (up to 
28 days)
Baseline 
(Day 1, Visit 2) 
(first dose)Double-Blind Period 
(weeks after first dose)Dose-Blind Period
(weeks after first dose)ET SFUb
Visita3456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6
Weeka1248 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8
aVisit windows of +/-[ADDRESS_64036] dose at all visits through Week 12 and +/- 4 days for all visits after Week 12 except SFU. The SFU Visit window 
is -3 and +[ADDRESS_64037] based on the exclusion criteria.
dAt Baseline/Day [ADDRESS_64038] occ urred after 12 consecutive 
months of amenorrhea, for which there is no other obvious pathological or physiological cause (International Menopause Society [ IMS], 2015). A urine 
pregnancy test is also required at the Baseline, Week 48, ET, and at SFU visits. A urine pregnancy test will also be performed at any study visit where there 
has been a delay in menses. This recommendation also applies to women of childbearing potential with infrequent or irregular me nstrual cycles. Pregnancy 
test results must be negative prior to administering IMP. 
iA separate Informed Consent Form will be required for subjects who provide samples for genetic testing. The Informed Consent Fo rm must be signed prior to 
collecting samples.
jIt is recommended that Quantiferon TB GOLD test be performed.
kAt Weeks 16, 24, and 36 of the Dose-Blind Period, subjects will be evaluated for their response to treatment to determine eligi bility for rescue therapy. 
Subjects with <10% improvement from Baseline in both PGADA and total and nocturnal spi[INVESTIGATOR_18172] (ASAS domain response criteria) are eligible for rescue 
treatment. Rescue therapy will be at the Investigator’s discretion as outlined in Section 5.1.[ADDRESS_64039] dosdo
1212
ssisix
ns
8
xxxtex
or ose)se
variations 
onva
thereof. 090
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 33 of 143Table 5‒1: Schedule of study assessments
Screening 
(Visit 1) (up to 
28 days)
Baseline 
(Day 1, Visit 2) 
(first dose)Double-Blind Period 
(weeks after first dose)Dose-Blind Period
(weeks after first dose)ET SFUb
Visita3456789 1 0 1 1 1 2 1 3 1 4 1 5 1 6
Weeka1248 1 2 1 6 2 0 2 4 2 8 3 2 3 6 4 0 4 4 4 8
nAn MRI of the spi[INVESTIGATOR_58897] a substudy with approximately 20 subjects per treatment arm at Ba seline. A central reader will 
assess Baseline MRIs to identify MRI-positive subjects as per the ASAS-Outcome Measures in Rheumatology Clinical Trials (OMERAC T) criteria. An MRI 
at Week [ADDRESS_64040] bimekizumab injection. Magnetic resonance imagin g at Week 12 and Week 48 
should be performed as close to the Week12/Week [ADDRESS_64041] at Baseline/Day 1, rerandomize the Subject at Week 12 (Subject in the placebo, 
bimekizumab 16mg, and bimekizumab 64mg treatment groups), and to register all visits. 
pThe minimum time between doses during the Double-Blind Period should be no less than 25 days and no more than 31 days and durin g the Dose-Blind Period 
should be no less than 24 days and no more than 32 days.
qAt Week 12, the Dose-Blind Period dosing will start, as detailed in Section 5.1.3 .REDACTED no
ionion5.5.
COPYe/Daye/Day
all visiall vis
o leso leThis 
document 
cannot 
be 
used 
to support 
any 
marketing 
authorization its. s. 
s than than
.33..
applicationhe
tion. ion. MM
it may nt may
1, reran, rera
andpp
atologtolo
e Ba Ba
any [ADDRESS_64042] dosdo
1212
ssisix
ns
8
xxxtex
or ose)se
variations 
onva
thereof. 090
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 34 of 1435.3 Schematic diagram
The study schematic diagram for AS0008 is presented in Figure 5‒1.
Figure 5 ‒1: Schematic diagram
ASAS=Assessment of SpondyloArthritis International Society; DMARD=disease-modifying antirheumatic drug; 
NSAID=nonsteroidal anti-inflammatory drug; PGADA=Patient’s Global Assessment of Disease Activity; Q4W=every 4 weeks; SFU=Safety Follow-Up
aAfter 12 weeks of double-blind treatment, subjects randomized to placebo, bimekizumab 16mg Q4W, or 
bimekizumab 64mg Q4W doses will be rerandomized 1:1 to receive either bimekizumab 160mg Q4W or 
bimekizumab 320mg Q4W. Subjects rando mized to bimekizu mab 160mg Q4W or 320mg Q4W will continue to 
receive their originally randomized dose ( Section 5.1.3 ).
bAt Weeks 16, 24, and 36 of the Dose-Blind Period, subjects will be evaluated for their response to treatment to 
determine eligibility for rescue therapy. Subjects with <10% improvement from Baseline in both PGADA and total and nocturnal spi[INVESTIGATOR_18172] (ASAS domain response criteria) are eligible for rescue treatment. Rescue therapy will be at the Investigator’s discretion as outlined 
in Section 5.1.4 .
REDAnternatnternat
g;g;
DAAACCCCCCCCCCCCTTTTTTTTTTTTEEEEEEEEEEEEEDDDDDDDDDDDD 
CCOPY 
This document cannot be usedare elige elitomprovprosupportct
ized dozed d
of the Df the 
escue tscue tany e e rer
s srandrandmarketing tional onal
PGADAPGAD
UpUp
ent, ent, subsu
eraaulSlS
auttthhhhhooooooooooooorrrrrrrrrrrriiiiiiiiiiiizzzzzzzzzzzzaaaaaaaaaaaaattttttttttttiiiiiiiiiiiooonnnnnnnnnnnn 
aappllliiicccatiooooonnnnn 
aaaaaaannnnnnnnnd 
aaanyyyy 
extensssiiioonnnnnnnnnnnnssssssssssss 
oooooooooooorrrrrrrrrrrr   ions 
vvvvvvvvvvvvaaaaaaaaaaaariiiiiiaaaaaaattiothereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 35 of 1435.4 Rationale for study design and selection of dose
The following doses of bimekizumab are proposed in the Phase 2b study: 16mg, 64mg, 160mg, 
and 320mg administered sc Q4W. The proposed dose range has been selected based on a dose 
response model developed using literature data of other biologics, such as secukinumab, in this 
disease and bimekizumab data in PsA (Diderichsen and Cox, 2016). 
Doses greater than 320mg have been previously studied in the development of bimekizumab. In 
the single ascending dose study UP0008, a single dose of bimekizumab 640mg was tested. In the 
multiple dose study PA0007, a bimekizumab 560mg loading dose followed by [ADDRESS_64043] be met:
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent Form is signed and dated by [CONTACT_29254]. 
2. Subject or legal representative is considered reliable and capable of adhering to the protocol 
(eg, able to understand and complete diaries), visit schedule, or medication intake according 
to the judgment of the Investigator.
3. Subject is male or female and at least [ADDRESS_64044] be postmenopausal (at least 1 year; to be confirmed hormonally as part 
of the screening process, if less than [ADDRESS_64045] menstrual period), permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpi[INVESTIGATOR_1656]) or, if of childbearing 
potential (and engaged in sexual activity that could result in procreation), must be willing to 
use a highly effective method of contraception up till [ADDRESS_64046] at Visit 1 (Screening) and immediately prior to first 
dose. The following methods are considered highly effective when used consistently and 
correctly.
−combined (estrogen and progestogen) hormonal contraception associated with inhibition 
of ovulation (oral, intravaginal or transdermal) 
−progestogen-only hormonal contraception associated with inhibition of ovulation (oral, 
injectable, implantable)
−intrauterine device (IUD)
−intrauterine hormone-releasing system (IUS)
−bilateral tubal occlusion
−vasectomized partner
−sexual abstinence if it is in accordance with a subject’s preferred and common lifestyle. 
Subjects who use abstinence as a form of birth control must agree to abstain from 
heterosexual intercourse until [ADDRESS_64047]’s lifestyle 
at regular intervals during the study.
Male subjects with a partner of childbearing potential must be willing to use a condom when 
sexually active, up till [ADDRESS_64048] administration of IMP (anticipated 5 half-lives).
5. Subject has active AS, determined by [CONTACT_58943] (X-ray) fulfilling the 
Modified [LOCATION_001] criteria for AS (1984) (see Table 19‒1), including symptoms for 
≥3 months and age of onset <[ADDRESS_64049] has moderate to severe active disease as defined by [CONTACT_58946]:
−BASDAI score ≥4
−Spi[INVESTIGATOR_18172] ≥4 on a 0 to 10 NRS (from BASDAI item 2)
7. Subjects must have at least 1 of the following: 
−inadequate response to NSAID therapy
−intolerance to administration of at least 1 NSAID 
−contraindication(s) to NSAID therapy
Inadequate response to an NSAID is defined as lack of response for at least [ADDRESS_64050] 4 weeks total duration.REDACTEDks aftks af
nence nence 
tudtudy.y.
childchildCOPY h a subh a sub
f birthbirth
This document cannot inadinad
−−bets muts mused pain ≥ain ≥to oreoresupport nsense
te to see to s
≥4≥anya fora fo
et <4et <marketingdbearidbear
fter theter th
ined bined 
rAauthorizationj
h conh con
er ther the
is stilis stil
iiapplication ject’s ect’s
tand any extensions vulatiovulatiorhibhibvariations bitibitithereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 37 of 1438. Subjects who are regularly taking NSAIDs/COX-[ADDRESS_64051] be on an average daily dose of ≤10mg/day prednisone or 
equivalent for at least 14 days before Baseline and should remain on a stable dose up to Week 16.
10. Subjects taking MTX ( ≤25mg/week) are allowed to continue their medication if started at 
least [ADDRESS_64052] 8 weeks before randomization. Dose, dosing schedule, and route of administration (oral or subcutaneous) should remain 
stable up to Week 16. It is strongly recommended that subjects taking MTX are also taking 
folic acid supplementation.
11. Subjects taking sulfasalazine (up to 3g/day) or hydroxychloroquine (up to 400mg per day 
total) are allowed to continue their medication if started at least [ADDRESS_64053]: 
−experienced an inadequate response to previous treatment given for at least 12 weeks 
−been intolerant to administration (eg, had a side effect/AE that led to discontinuation) 
−lost access to TNF inhibitor for other reasons
6.2 Exclusion criteria
Subjects are not permitted to enroll in the study if any of the following criteria are met:
1. Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the 
study or within [ADDRESS_64054] 5 half-lives whichever is greater. 
4. Subjects with a known hypersensitivity to any excipi[INVESTIGATOR_58898].
5. Subjects with a total ankylosis of the spi[INVESTIGATOR_050], or a diagnosis of any other inflammatory arthritis 
eg, RA, sarcoidosis, systemic lupus erythematosus, or reactive arthritis. 
6. Subjects with use of any medication listed in Table 7‒1meeting the exclusionary criteria for 
the specific medication(s) including wash-out described in the table. 
7. Subject has any current sign or symptom that may indicate an active infection (except for the 
common cold) or has had an infection requiring systemic antibiotics within 2 weeks of 
Baseline.REDACTED ad ad 
er reaer rea
in thin thCOPYious trious t
a sias i
This document6.SScannotbjectsjects
eg, RAg, RAbets wis wusedon witn wit
withwithtopatipatsupportarticiparticip
inganythe stuhe stmarketing he studhe stu
feedingeedin
owingwinauthorization ide efde ef
sonsonsapplication1 prior1 prio
reatmeeatmand ananany ksksp
d dod doextensionsalso talso 
o 400m400m
prprormainmaivariations at 
izatiozatiothereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 38 of 1438. Subjects with a history of chronic or recurrent infections, or a serious or life-threatening 
infection within the 6 months prior to the Baseline Visit (including herpes zoster). Subjects with a high risk of infection in the Investigator’s opi[INVESTIGATOR_1649] (eg, subjects with leg ulcers, 
indwelling urinary catheter, persistent or recurrent chest infections, subjects who are 
permanently bedridden or wheelchair assisted, prior prosthetic joint infection at any time, etc).
9. Subjects with concurrent acute or chronic viral hepatitis B or C or human immunodeficiency 
virus (HIV) infection. Subjects who have evidence of, or tested positive for hepatitis B or hepatitis C are excluded. 
A positive test for the hepatitis B virus (HBV) is defined as: 
•positive for hepatitis B surface antigen (HbsAg+); or, 
•positive for anti-hepatitis B core antibody (HbcAb+) 
A positive test for the hepatitis C virus (HCV) is defined as: 
•positive for hepatitis C antibody (anti-HCV Ab), and 
•positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction)
10. Subjects with known history of or current clinically active infection with Histoplasma, 
Coccidioides, Paracoccidioides, Pneumocystis, nontuberculous mycobacteria (NTMB), Blastomyces, or Aspergillus or current active Candidiasis (local or systemic).
11. Subjects receiving any live (includes attenuated) vaccination within the 8 weeks prior to 
Baseline (eg, inactivated influenza and pneumococcal vaccines are allowed but nasal influenza vaccination is not permitted). Live vaccines are not allowed during the study or for 
[ADDRESS_64055] dose of IMP.
Live vaccines include, but are not limited to the following: 
−Anthrax vaccine
−Intranasal influenza vaccine
−Measles-mumps-rubella (MMR) vaccine
−Polio live oral vaccine (OPV)
−Smallpox vaccine
−Tuberculosis BCG vaccine
−Typhoid live oral vaccine
−Varicella vaccine
−Yellow fever vaccine
12. Subjects receiving Bacillus Calmette-Guerin (BCG) vaccinations within 1 year prior to IMP
administration.
13. Subjects with a history of a lymphoproliferative disorder including lymphoma or current 
signs and symptoms suggestive of lymphoproliferative disease.ve 
ttenuatttenuat
nd pnnd pn
itted).itted)
MPMPCOPYllyllyayy
, nontnon
e CanCan
This document −cannot ub
TyTybebercubercused pox vaox vtoral vral supppsportvacvac
--ruberub
vaany cciccmarketing . L
not limiot limauthorization tub
ndidiandidia
ated) ved) v
neumoeumo
LLiveiveapplication HCV pHCV
tive infive in
bercubercand any extensions or variations ncy cy 
or or thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 39 of [ZIP_CODE]. Subjects with primary immunosuppressive conditions, including subjects who are taking 
immunosuppressive therapy following organ transplants.
15. Subjects with known TB infection, at high risk of acquiring TB infection, with latent TB 
infection (LTBI)* or current or history of NTMB infection (refer to Section 12.6.5 for details 
on determining full TB exclusion criteria).*Subjects with LTBI may enter the study only after they have completed at least [ADDRESS_64056] had a splenectomy.
17. Subjects with concurrent malignancy or a history of malignancy (including surgically 
resected uterine/cervical carcinoma-in-situ) during the past 5 years will be excluded, with the following exceptions that may be included: 
a)≤3 excised or ablated basal cell carcinomas of the skin
b) One squamous cell carcinoma of the skin (stage T1 maximum) successfully excised, or 
ablated only (other treatments, ie, chemotherapy, do not apply), with no signs of 
recurrence or metastases for more than 2 years prior to Screening 
c) Actinic keratosis (-es)d) Squamous cell carcinoma-in-situ of the skin successfully excised, or ablated, more than 
6 months prior to Screening
18. Subjects having had major surgery (including joint surgery) within the 6 months prior to 
Screening, or planned surgery within 6 months after entering the study.
19. Subjects with a current or recent history, as determined by [CONTACT_737], of severe, 
progressive, and/or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac (eg, congestive heart failure [LOCATION_001] Heart Association [NYHA] Grade 3 and 4), 
gastrointestinal (GI) (note: subjects with active peptic ulcer disease are excluded; subjects 
with a history of peptic ulcer disease are allowed), or neurological disease.
20. Subjects with a history of uncompensated heart failure, fluid overload, or myocardial 
infarction, or evidence of new-onset ischemic heart disease or in the opi[INVESTIGATOR_58899], within 12 weeks prior to Baseline.
21. Subjects with clinically significant laboratory abnormalities (eg, glomerular filtration rate 
[GFR] <60 mL/min/1.73m
2, neutropenia <1.5x109/L, hemoglobin <8.5g/dL, lymphocytes 
<1.0 x109/L, platelets <100x109/L). Individual screening tests, for which the results are in 
error, borderline, or indeterminate for inclusion in the study, can be repeated once for 
confirmation during the Screening Period if they are within 25% of the exclusion limit. Upon 
retesting, subjects whose results remain outside this threshold should not be randomized.REDACTED cludincludin
in 6 min 6 m
histhistCOPY kin sukin su
This documentrrcannot x1x1
rror, bror, b
confconfbe<60 60
0099/used with clith cl
0m0mtoher ser ssupporyryort of uof yy
ence oence o
seranyubjub
cer dicer dmarketingtorytory, a, 
renal, henal,
ew Yow Y
bjectbjeauthorizationuccescces
ng joinng joi
monthmonthapplicationpplypply
ScreenScree
ssfussfuandm) sucm) suc
yy))any extensions gicallygicall
xcludxcludor variations thereof. 
UCB [ADDRESS_64057] has >2x upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase* (ALP), or >ULN total bilirubin ( ≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
*An isolated elevation between 2xULN and <3xULN of ALP is acceptable in the absence of 
an identified exclusionary medical condition.
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation during the Screening Period. Upon retesting, subjects whose ALT, 
AST, or ALP remain above the thresholds defined above, should not be randomized.
For randomized subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, 
a baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the electronic Case Report Form (eCRF).
If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at screening, 
repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically 
relevant increase. In case of a clinically relevant increase, inclusion of the subject must be 
discussed with the Medical Monitor.
23. Subjects with any other condition which, in the Investigator's judgment, would make the 
subject unsuitable for inclusion in the study.
24. Subjects with erythrodermic, guttate, pustular form of PSO or drug-induced PSO.25. Subjects with a diagnosis of inflammatory conditions other than AS, including but not 
limited to rheumatoid arthritis or systemic lupus erythematosus. Subjects with a diagnosis of 
Crohn’s disease or ulcerative colitis (whether primary or as an extra-articular manifestation of AS) are allowed provided they have no active and/or symptomatic disease at Screening 
and Baseline.
26. Subjects with fibromyalgia or osteoarthritis symptoms that in the Investigator’s judgement 
would have potential to interfere with efficacy assessments
27. Subject has a history of chronic alcohol or drug abuse within the previous year.
28. Subject has 12-lead ECG with changes considered to be clinically significant upon medical 
review by [CONTACT_18370]. 
29. Subject has presence of significant uncontrolled neuropsychiatric disorder, active suicidal 
ideation, or positive suicide behavior using the “Baseline” version of the electronic Columbia-Suicide Severity Rating Scale (eC-SSRS) and the Hospi[INVESTIGATOR_58900] (HADS) with either of the following criteria: 
−Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by 
a positive response (“Yes”) to either Question 4 or Question 5 of the “Screening/Baseline” version of the eC-SSRS at screening. 
−Any subject who develops a HADS-D Depression Score >10 or Anxiety (HADS-A)
score≥15.REDACTEDstular stular
matorymatory
sysystemstem
litis litis COPYIInvesnve
This document cannottionon
olumblumb
DeprDepbehashas
nonousedhe e InvIn
spsptoleadleadsupporo inteint
ryyof cof yy
dEdanya or oa or o
terftermarketingm
(whet(whe
yhave nhaveauthorization form form 
ycondcondy
mic luc luapplicationo fu
nclusioclusio
tigatorigatoandcluslus
furthurthany sionsioextensions ized.zed.
or totor tot
on muon muorALTALTvariations peatedeate
Tthereof. 
UCB [ADDRESS_64058] is Investigator site personnel directly affiliated with this study and/or immediate 
families of Investigator site personnel. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
31. Subject is a UCB employee or is an employee of a third-party organization involved in the 
study.
6.3 Withdrawal criteria
Subjects are free to withdraw from the study at any time, without prejudice to their continued care. 
Subjects should be withdrawn from the study if any of the following events occur:
1. Subject withdraws his/her consent.
2. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test.
3. The Sponsor or a regulatory agency requests withdrawal of the subject.
Subjects withdrawn from study treatment : 
Subjects should be withdrawn from all study treatment if any of the following events occur: 
4. Subject develops an illness that would interfere with his/her continued participation. 
5. Subject considered as having either a suspected new LTBI or who develops active TB or 
NTMB infection during the study (including but not limited to, conversion demonstrated by 
[CONTACT_14234]-gamma release assay [IGRA] or other diagnostic means) must be immediately 
discontinued from IMP, and an unscheduled visit must be conducted as soon as possible, but not later than the next regular visit.
The subject must be permanently withdrawn if further examinations result in a diagnosis of 
active TB, or if the subject is diagnosed with LTBI with no initiation of prophylactic treatment, prematurely discontinues prophylactic treatment, or, in the opi[INVESTIGATOR_58901], is noncompliant with prophylactic TB therapy. 
Confirmed active TB is a serious adverse event (SAE) and must be captured on an SAE 
Report Form and provided to the Sponsor in accordance with SAE reporting requirements. 
As with all SAEs, periodic follow-up reports should be completed as per protocol 
requirements until such time as the TB infection resolves. Additional information on TB policies are provided in Section 12.6.5.
6. Subject is noncompliant with the study procedures or medications which may present a risk 
to the safety of the subject in the opi[INVESTIGATOR_689].
7. Subject uses prohibited concomitant medications as defined in this protocol ( Section 7.8.2 ), 
that may present a risk to the safety of the subject in the opi[INVESTIGATOR_58902]. This includes subjects who start a biologic other than bimekizumab as described in Section 5.1.4.REDACTED ecteecte
uding bding b
AA]]oror
nschednsche
sit.sit.COPY e with e with
ted ned
This document .SS
tcannot ect ct 
the sahe s
SubSubbe ti sti susedts untunt
re proe protoEs, pEs, 
tiisupport is ais ase
providprovid
pepeany ntint
s noncnonmarketing withdrwithd
diagnosagno
tinuetinuauthorization new new LL
but nout no
r otherothe
uled vuled application yyof theof thyy
his/hehis/heandubjecbjecany extensions posiposior variations ed d thereof. 
UCB [ADDRESS_64059] develops laboratory abnormalities (with or without clinical symptoms) of ALT or 
AST as defined in Section 6.3.1 ; neutropenia <0.5x109/L; lymphopenia <0.5x109/L. Any 
laboratory value or change judged to be clinically significant by [CONTACT_58949]. For clarification, 
laboratory values that are markedly abnormal as per Table 19‒2and Table 19‒3will be 
flagged to the Investigator and to the medical monitor but do not trigger mandatory 
withdrawal unless listed above (Refer to Section 6.3.1 for withdrawal criteria in relation to 
potential drug-induced liver injury [PDILI].)
9. Subject has active suicidal ideation as indicated by a positive response (“Yes”) to 
Questions 4 or 5 or to the suicidal behavior questions of the “Since Last Visit” version of the 
self-rated eC-SSRS. The subject should be referred immediately to a Mental Healthcare Professional and must be withdrawn from the study.
10. Subjects with a HADS-D score ≥[ADDRESS_64060] who develops a 
HADS-D score of >[ADDRESS_64061]:
−Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist
−Discontinue IMP and be followed-up until resolution of active IBD symptoms
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgment in deciding whether the subject should continue in the study and contact [CONTACT_58950]'s suitability for continued 
participation in the study.
In an attempt to prevent missing data during the study, efforts will be made to collect data from 
subjects that withdraw early from the study (NRC, 2010). If a subject withdraws from study 
treatment for any of the above criteria (#4 through #10) prior to Week 12, they will be asked to return for the study assessments [ADDRESS_64062] dose (ie, Week 12 Visit) and for the 
SFU Visit ([ADDRESS_64063] dose administration). These data will be used in a sensitivity 
analysis which is described in Section 15.7 . If any of these criteria occur after Week 12, subjects 
will complete an Early Termination (ET) Visit and the SFU Visit. All subjects who withdraw 
from the study due to an AE must be followed until resolution of the event or until the event is 
considered stable. All subjects who withdraw from the study due to development of a laboratory abnormality specified in Criterion #[ADDRESS_64064] an ALT and/or AST >5X but <8X ULN.
Investigators should attempt to obtain information on subjects in the case of withdrawal or 
discontinuation. For subjects considered as lost to follow-up, the Investigator should make an effort (at least [ADDRESS_64065]), and document his/her effort 
(date and summary of the phone call and copy of the written message in the source documents), 
to complete the final evaluation. All results of these evaluations and observations, together with a narrative description of the reason(s) for removing the subject, must be recorded in the source 
documents. The eCRF must document the primary reason for withdrawal or discontinuation.REDACTED cy durcy dur
e subjee subj
sician ician COPY il resol res
This document n AA
InvInvcannotmarmar
sidereddered
ALTALTbeyyspspyy
kkusedue te t
able. Able. toarlarlyy
tosupport enen
rlastlastd
ribedibed i
yT eyTanycritecrite
nts 12ts marketing a durindurin
the stuthe s
eriaerauthorizationolutiooluti
riing thng t
ect shect sh
to cono conapplicationg the the
nal treanal tre
onanddrawarawa
esany hoo
lly to y to
allextensionsersiorsio
ealthcealthc
odevdevor ononvariations thereof. 
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRREEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOPY 
This 
docummeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeennnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnntttttttttttttttt 
cccccccccccccccccccccccccccccccccccccccccccccccccccaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnot 
bbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee 
uuuuuuuuuuuuuuusssssssssssssssssssssssssssssssssssssssssssssseeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeed 
tttttttttttttttttttttttttttttttooooooooooooooooooooooooooooooo 
ssssssssssssssssuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrttttttttttttttttttttttttttttttt 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy 
mmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaarrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeettttttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiinggggggggggggggggggggggggggggggggggggggggggggggggggggggggggggggggggg 
aaaaaaaaaaaaaaaaaaaaaaaaauuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuttttttttttttttttttttttttttttttttttttttttttttttthhhhhhhhhhhhhhhhhhhhhhhhhhhhhoooooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrriiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiizzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaatttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiioooooooooooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn 
aaaaaaaaaaaaaaaaaaaaaaaaaaapplicccccccccccccccccccccccccccccccccccccccccccccaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaattttttttttttttttttttttttttttttttttttttiiiiiiiiiiiion 
aaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnndddddddddddddddddddddddddddddddddddddddddddddd 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy 
eeeeeeeeeeeeeeeeeeeeeeeeeeeextensions 
or 
variations 
thereof. 
UCB [ADDRESS_64066]. 
The IMP (bimekizumab and placebo) will be administered at the times indicated in Table 5‒1. 
The minimum time between doses during the Double-Blind Period should be no less than 
25 days and no more than 31 days and during the Dose-Blind Period should be no less than 24 days and no more than 32 days. 
An IMP Handling Manual will be provided to each site containing instructions regarding drug 
preparation and dosing.
7.3 Packaging
Bimekizumab and placebo will be manufactured, packaged and labeled according to Good Manufacturing Practice (GMP) guidelines and applicable laws or regulations. They will be suitably packaged in such a way as to protect the product from deterioration during transport and 
storage. Further information regarding storage and transport conditions are provided in the IMP 
Handling Manual.
7.4 Labeling
Clinical drug supplies will be labeled in accordance with the current International Council forHarmonisation (ICH) guidelines on Good Clinical Practice (GCP) and Good Manufacturing Practice and will include any locally required statements. If necessary, labels will be translated 
into the local language.
7.[ADDRESS_64067] be stored under refrigerated conditions (2ºC to 8ºC) 
protected from light. The IMP must not be frozen. 
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by [CONTACT_58951] a secured area with 
limited access.
Appropriate storage conditions must be ensured either by [CONTACT_58952] a temperature log in accordance with local requirements on a regular basis 
(eg, once a week), showing minimum and maximum temperatures reached over the time interval.
In case an out-of-range temperature is noted, it must be immediately communicated to the 
Clinical Project Manager (CPM) (or designee) before further use of the IMP.
Investigational Medicinal Product will be shipped to the study sites in temperature controlled 
containers. Out-of-range shippi[INVESTIGATOR_58903], immediately. Authorization to use any out-of-range IMP must be 
documented and received prior to dispensing or administering the IMP at the study site. REDACTED andan
d in ad in a
GGCOPYcablecabl
producprodu
nd trdt
This document(eg,eg,oo
InIncannotpriateriate
mpletiopletio
onbe ess.ess.usedr (or (or 
al medl meto rdrdsupport anan
nal Proal Pro
The The IMIany nd sdsmarketing accorcco
Good ClGood C
y requy reqauthorization uct fct 
ranspoansp
ddapplication nd labend lab
laws oaws o
fromfromand anyctionsctionextensions ableble
ss thass tha
no leso lesor ee55variations thereof. 
UCB [ADDRESS_64068] (due to breakage or wastage), not used, disposed of at the study site, or returned to 
the Sponsor or designee must also be recorded on the appropriate forms. All supplies and pharmacy documentation must be made available throughout the study for UCB (or designee) to 
review.
In order to maintain the blind, all IMP documentation (eg, shippi[INVESTIGATOR_18220], drug accountability 
logs, and interactive voice or web response system [IXRS] randomization materials) must be 
maintained and accessed by [CONTACT_58953], trained site personnel only. Designated, unblinded site 
personnel must be appropriately trained and licensed (per country guidelines) to administer injections. 
The packaging identifies each kit by a unique number that does not correlate to the contents and 
therefore, does not unblind study site staff. Unblinded study staff will be responsible for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial material, including 
recording the administration information on source document.
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.
The Investigator must ensure that the IMP is used only in accordance with the protocol.
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers) and unused IMP containers must be reconciled and returned to UCB (or designee), preferably in their original package. Onsite destruction of used kits only may be allowed with 
prior approval from the Sponsor or designee after reconciliation. Investigational medicinal 
product intended for the study cannot be used for any other purpose than that described in this protocol.
7.[ADDRESS_64069] be 
recorded on the Drug Accountability Form.
7.8 Concomitant medication(s)/treatment(s)
All concomitant medications, including over-the-counter products, herbal, traditional remedies, vitamin/mineral supplements, other dietary supplements, “nutraceuticals,” and hormones must be 
recorded in the subject’s source documentation (eg, clinical chart) and on the eCRF. This record should include the name [CONTACT_18467], the dose, the route and date(s) of administration, and the 
indication for use.REDACTED P is usP is u
of theof the
ers mers COPY gator’ator
This document tama
recorrecor
shshannot oncomoncom
aminminbe usedbe dbe d
he Druhe Drto BliBli
dedesupport dures ures
lind indanycanncannmarketing e c
must bmust 
OnsiteOnsit
or desigr des
notnoauthorization’s duts du
sed onsed on
clinicliniapplication used, used,
tieiand be e 
trial trial anyate toate t
respresextensionsmu
linindedde
admindmin
totorst bst bvariations abilitabilitthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 46 of 1437.8.1 Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])
The following AS medications/treatments are allowed during this study from Baseline onward, 
with the following restrictions (if any):
Nonsteroidal anti-inflammatory drugs and/or joint injections as outlined below. For subjects 
taking NSAID/COX-2 inhibitors at Baseline or at Weeks 16, 24, or 36, a change can be made to 
a different NSAID/COX-2 inhibitor. Changes from an NSAID to a COX-2 inhibitor or from a COX-2 inhibitor to an NSAID are permitted up to the maximum approved or tolerated dose 
whichever is lower. Only 1 NSAID/COX-2 inhibitor may be taken at a given time.
•For subjects not taking NSAID/COX-2 inhibitors at Baseline, Weeks 16, 24, or 36, either can 
be initiated, up to the maximum approved or tolerated dose, whichever is lower. Only 
1 NSAID/COX-2 inhibitor may be taken at a given time.
•After the NSAID/COX-2 regimen has been optimized, SI joint injection is permitted, either 
unilaterally or bilaterally, performed by a qualified physician. 
•If the subject does not achieve sufficient response to the above options and/or the 
Investigator feels that a biologic other than bimekizumab is warranted, the subject must 
discontinue from study treatment (bimekizumab) and follow the withdrawal criteria and 
follow up as outlined in Section 6.3 .
A decrease in dose or dosing frequency of any agent is permitted for reasons of 
intolerance/AEs/side effects at any time. 
Subjects may be withdrawn from the study or from study medication at any time and continue 
treatment per the Investigator’s discretion, as described in the Withdrawal Section 6.3 .
7.8.2 Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])
Medications listed in Table 7‒1are prohibited or restricted as follows:
Table 7‒1: Prohibited or restricted medications and required wash-out periods 
prior to Baseline
Drug class Dose Exclusion criteria
Analgesics, including opi[INVESTIGATOR_2467]
(acetaminophen/paracetamol, etc)Any dose Any ad hoc use in the 24 hours prior to any
study visit. 
Stable doses of analgesics permitted.
NSAIDs/COX-2 inhibitors Any dose regimen Any change in dose/dose regimen in the 
14 days prior to the Baseline Visit
Oral corticosteroids Any dose regimen Any change in dose/dose regimen in the 
14 days prior to the Baseline Visit
Intramuscular (im)/intravenous (iv)/intra-articular (ia) corticosteroids/bursal corticosteroidsAny dose Use in the [ADDRESS_64070]
 descrdescr
rereapplicationwarranarra
ow the ww the
ermitrmiand ptionsption
anany extensions6, eie
r. Onl. On
is pes peor eithithvariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 47 of 143Table 7‒1: Prohibited or restricted medications and required wash-out periods 
prior to Baseline
Drug class Dose Exclusion criteria
DMARDs:
-azathioprine
-cyclosporine,-cyclophosphamide,-mycophenolic acid,-mycophenylate mofetil-any other small molecule DMARDs 
(eg tofacitinib, apremilast)Any dose Use within 12 weeks prior to the Baseline 
Visit.
MTX Any dose regimen Use within 12 weeks prior to the Baseline 
Visit unless Inclusion Criterion # 10is met
SSZ Any dose Use within 12 weeks prior to the Baseline 
Visit unless Inclusion Criterion # 11is met
HCQ Any dose Use within 12 weeks prior to the Baseline 
Visit unless Inclusion Criterion # 11is met
DMARDs:
-leflunomide Any dose Use in the 6 months prior to the Baseline 
Visit unless a cholestyramine washout has been performed; in which case, use up to 
28 days prior to the Baseline Visit is 
acceptable. 
TNF inhibitors-infliximab (IFX)-adalimumab (ADA)-etanercept (ETN)-golimumab (GOL)
-certolizumab pegol (CZP)Any dose For IFX, ADA, GOL, and CZP, any use 
within the 12 weeks prior to the Baseline Visit
For ETN, use within the 28 days prior to 
the Baseline Visit.
This applies to biosimilar versions of any 
TNF inhibitors.
Any non-TNF biologic medications Any dose Any exposure history.
ADA=adalimumab; COX-2=cyclooxygenase 2; CZP=certolizumab pegol; DMARD=disease modifying antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; ia=intra-articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
anti-inflammatory drug; sc=subcutaneous; SSZ=sulfasalazine; TNF=tumor necrosis factor 
Subjects who are receiving an established anti-depressant regimen should be on a stable dose of 
anti-depressant for 12 weeks prior to Baseline.
7.9 Blinding
Due to differences in presentation of the IMPs (bimekizumab and placebo), special precautions will be taken to ensure study blinding and study sites will have blinded and unblinded personnel.
Bimekizumab and placebo injections will be prepared and administered at the investigational 
sites by [CONTACT_58953], dedicated study personnel according to Table 7‒2. The unblinded personnel 
will not be involved in the study in any way other than assuring the medication is taken from the correct kit and prepared according to the pharmacy manual instructions, and administering the REDACTED oseoseTECOPY 
This document 7.97.9
Dcannot cts whts wh
-depr-deprbe usedETNT
im=inm=in
ry druy drutoX
TN=eN=esupport cationscationort
2=cy2=cupany ymarketing mauthorization n
rizapplication in 1
nless Inless 
Use in the in t
Visit uVisit
beebeat
aand cluclu
12 w12 wndanyeks preks p
usionsioextensions orto thto th
CriterCritersio
eor variations atithereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 48 of 143drug to the subjects. Preparation will be made from either vials (bimekizumab) or Ampoule 
(placebo) and will be in identical syringe and needle for all arms of the study. Provisions will be made to ensure that volume of injection is not revealed to the subject. The number of injections 
will be kept identical for all patients by [CONTACT_58954] 1 injection. 
Table 7‒2: Preparation of placebo and bimekizumab injections
Treatment Arm Number/volume Placebo injections Number/volume bimekizumab
injections
Placebo [ADDRESS_64071], signed by [CONTACT_9532], which will detail the site’s steps for ensuring that the double-blind nature of the 
study is maintained. 
During the study the Sponsor will provide blinded and unblinded site monitors for the purposes 
of verifying safety, efficacy, and drug administration and documentation records. Blinded study 
monitors and study site personnel, blinded to treatment assignment, will not discuss or have 
access to any drug-related information.
Bioanalytical staff analyzing blood samples for bimekizumab and anti-bimekizumab antibody 
detection will be unblinded. 
Further details are provided in the study manuals and site blinding plan.7.9.1 Procedures for maintaining and breaking the treatment blind
[IP_ADDRESS] Maintenance of study treatment blindAll subject treatment details (bimekizumab or placebo) will be allocated and maintained by [CONTACT_58955].
[IP_ADDRESS] Breaking the treatment blind in an emergency situation
The integrity of this clinical study must be maintained by [CONTACT_58956]. In the 
event of an emergency for which the appropriate treatment for a subject cannot be made without 
knowing the treatment assignment, it will be possible to determine to which treatment arm and 
dose the subject has been allocated by [CONTACT_58957]. All sites will be provided with details of how to contact [CONTACT_58958]. The Medical 
Monitor or equivalent should be consulted prior to unblinding, whenever possible.
The CPM will be informed immediately via the IXRS when a code is broken, but will remain 
blinded to specific treatment information. Any unblinding of the IMP performed by [CONTACT_58959].REDACTEDstratistrat
to treato trea
samplsamplCOPY d and d and
tiotio
This document oses
detaidetai
MMcannotf an an 
wing thing th
e thee thebeityity o oyy
ememusedBreaBrea
ffto supportnce once 
details detailsanyor mor m
ofmarketingles foes f
studystudy my
maauthorizationd unbunb
on andn and
atmentmen
forforapplicationace, siace, s
at the dat the 
blinblinand anany 1 x 11 x 
22anextensions mLLns
0.4mL.4mns
1exor rvariations abbtioothereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 49 of 1437.10 Randomization and numbering of subjects
An IXRS will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by [CONTACT_1034]. 
The randomization schedule will be produced by [CONTACT_58960] (CRO) who is otherwise not involved in this study. Subject treatment assignment will be stratified by [CONTACT_58961] (yes/no). The IXRS will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Enrollment of TNF inhibitor experienced subjects will be limited to 30% of the total study population.
At Screening, each subject will be assigned a 5-digit number that serves as the subject identifier 
throughout the study. The subject number will be required in all communication between the Investigator or designee and the IXRS regarding a particular subject. 
At the Baseline Visit (Day 1), a subject will be randomized into the study. The Investigator or 
designee will use the IXRS for randomization. The IXRS will automatically inform the Investigator or designee of the subject’s ID number. The IXRS will allocate kit numbers to the 
subject based on the subject number during the course of the study.
Subject numbers and kit numbers will be tracked via the IXRS.
8 STUDY PROCEDURES BY [CONTACT_58962] ( Table 5‒1) provides a general overview of study 
assessments. A list of procedures to be completed at each visit is described below.
Visit windows are +/-3 days from Baseline (Day1, first dose of IMP) at all visits through the 
Week 12 Visit and +/-4 days for all visits after Week 12 except the SFU Visit. For the SFU Visit ([ADDRESS_64072] dose), the visit should occur no more than 3 days prior to the scheduled 
visit date and within 7 days after the scheduled visit date (-3 days/+7 days). The minimum of 
time between doses should be no less than [ADDRESS_64073] withdrawal.
8.1 Screening (Visit 1)
The Screening Period will last up to 28 days. 
Prior to any study specific activities, subjects will be asked to read, sign, and date an Informed 
Consent Form (ICF) that has been approved by [CONTACT_58963]/IRB, and that complies 
with regulatory requirements. Subjects will be given adequate time to consider any information 
concerning the study given to them by [CONTACT_18370]. As part of the informed consent procedure, subjects will be given the opportunity to ask the Investigator any questions 
regarding potential risks and benefits of participation in the study.
Subjects will also be given the option to participate in the genomic, genetic/epi[INVESTIGATOR_18193], and 
proteomic substudy. Subjects who decide to participate in the substudy will need to complete a 
separate ICF following the same procedure and given the same considerations as the main ICF. 
Their willingness to participate in the substudy will be independent from their consent to participate in the main study.REDACTED 11) ) pp
pletedpleted
line (Dline (D
visits avisits 
sit ssitCOPYVISVIS
propro
This documentregaregar
SuScannot ulatla
rning ning
sent psent p
ddbe rm m 
atoryatoryused udydy spspyy
m((ICICtood wod support ithdthd
ninging(
wilwany allowallo
drawdramarketing afteaft
shouldhould
e schedsche
less thess t
weauthorization ovidesvides
d at eaat ea
DayDay1,1,
fter Wer Wapplication dydy..
RS.RS.
IT T and icaca
allocaallocaanyTheTh
allyallyiyextensionsect idect id
betwebetwe
eor variations l 
otal otal thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 50 of 143Subjects who initially fail to meet selected eligibility criteria (including but not limited to 
documented completion of LTBI prophylactic therapy) or for whom eligibility assessments could not be completed as planned may be rescreened once after discussion with the Medical Monitor.
The following procedures or assessments will be performed at the Screening Visit: 
•Obtain written informed consent for main study. 
•Collect demographic data.
•Collect AS history. 
•Collect significant past medical history and concomitant diseases.
•Assess inclusion and no exclusion criteria. 
•Record prior medications. 
•Record concomitant medications.
•eC-SSRS
•HADS
•Administer the tuberculosis questionnaire.
•Measure height. 
•Measure temperature, pulse, and blood pressure. 
•Measure weight. 
•Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB. 
•Perform an ECG. 
•Collect samples for hematology/biochemistry/urinalysis. 
•Perform a serum pregnancy test if the subject is a woman of childbearing potential. This 
requirement also applies to women of childbearing potential with infrequent or irregular 
menstrual cycles and women during menopause. Natural menopause is recognized to have 
occurred after 12 consecutive months of amenorrhea, for which there is no other obvious pathological or physiological cause (International Menopause Society, 2015). 
•Collect samples for Hepatitis B and C tests. 
•Collect samples for an HIV test.
•Perform an IGRA tuberculosis test.
•Obtain a chest radiograph, unless one has been obtained 3 months prior to the Screening 
Visit.REDACTEDessuressu
includincludCOPY r
This document ••cannot ollect llect 
PerfPerfbet samt samused1
al or pl or pto12 c2 csupport nancyancy
plies toplies t
and wnd wanylogylog
yteymarketing din
yy/b/yyauthorization e. 
ng ang aapplication and any extensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 51 of 143•Obtain a radiograph of the SI joint. Note: If subject has a previous x-ray documenting AS 
meeting eligibility criteria, he/she is eligible for study entry after reconfirming his/her 
eligibility by [CONTACT_18014]. If no x-ray is available one must be performed at Screening. If 
the previous x-ray is more than 1 year old, and central read criteria for randomization are not met, another x-ray may be performed if permitted by [CONTACT_13144].
•Register the subject using the interactive voice or web response system (IXRS). 
The MRI (done at selected sites) can be performed prior to the Baseline (Day 1, first dose of 
IMP, Visit 2) if eligibility is confirmed based on screening assessments, and before the first dose of IMP. 
8.2 Baseline (Day 1, first dose of IMP) (Visit 2)
The following procedures of assessments will be completed prior to administration of IMP:
•Review significant past medical history and concomitant diseases to ensure there are no 
significant changes in medical history that would exclude the subject based on the exclusion 
criteria. 
•Confirm that the subject meets all inclusion and no exclusion criteria. 
•Record concomitant medications.
•Record AEs.
•eC-SSRS
•HADS
•Administer the AsQoL.
•Determine the BASDAI. 
•Determine the BASFI.
•Administer the SF-36.
•Administer the MOS Short Sleep Scale.
•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].
•Administer the tuberculosis questionnaire.
•Measure temperature, pulse, and BP. 
•Measure weight.
•Determine the MASES.
•Determine the BASMI.
•Administer the PhGADA. 
•Collect samples for hematology/biochemistry/urinalysis. 
•Collect blood sample for CRP. REDACTED COPY 
This document ••cannot easureasure
MeaMeabeisteristerusedthe tohe t
ttto ADADsupport S ShorS Sho
DA.DAany marketing authorization application onncritcriandject bect banynsurensur
basbextensions trationrationorrstrsvariations of f 
st dotd othereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 52 of 143•Collect blood sample for hs-CRP. 
•Perform a urine pregnancy test if the subject is a woman of childbearing. This requirement 
also applies to women of childbearing potential with infrequent or irregular menstrual cycles and women during menopause. Natural menopause is recognized to have occurred after 12 
consecutive months of amenorrhea, for which there is no other obvious pathological or physiological cause (International Menopause Society [IMS], 2015).  
•Collect blood sample for determination of HLA-B27 status.
•Collect blood sample for bimekizumab plasma concentrations and anti-bimekizumab
antibody detection.
•Collect blood samples for cytokines, complement, and biomarker analyses.
•If subject provides consent (separate from the consent for the main study): 
−Collect blood samples for genomic and proteomic/metabolomic analyses
−Collect blood samples for genetic/epi[INVESTIGATOR_58895]
•For participating centers, collect blood sample for flow cytometry.
•Obtain MRI of spi[INVESTIGATOR_58904]. The 
Baseline MRI should be performed after confirmation of eligibility based on screening 
assessments for the study and before the first bimekizumab injection. 
•Randomize the subject using the IXRS.
•Administer IMP (bimekizumab or placebo). 
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP 30 minutes and 1 hour after dosing.
8.3 Double-Blind Period (Week 1 to Week 12)
8.3.1 Week 1 (+/-3 days) (Visit 3)
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•Determine the BASDAI. 
•Determine the BASFI.
•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].
•Measure temperature, pulse, and BP.
•Collect samples for hematology/biochemistry/urinalysis.
•Collect blood sample for hs-CRP. 
•If there has been a delay in menses, perform a urine pregnancy test.REDACTED placebplaceb
mentsmentsCOPY t isi
matiomatio
bimebim
This documentPP
••cannot mm
etermeterm
PePbe mine mine used eetoeveevsupport/t-3 3 dd
nt medmeanyPeP
dadmarketings wills wil
andand1
erierauthorizationekizuekizu
bo). o). 
llapplication ometrymetr
articipaticip
n of elof eand any nalynalyssextensions ): : or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 53 of 143•Collect blood sample for bimekizumab plasma concentrations.
•Collect blood samples for cytokines, complement, and biomarker analyses.
•For consenting subjects:
−Collect blood samples for genomic, proteomic/metabolomic analyses.
−Collect blood sample for genetic/epi[INVESTIGATOR_58895].
•For participating centers, collect blood sample for flow cytometry.
•Record visit in the IXRS.
8.3.2 Week 2 (+/-3 days) (Visit 4)
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Determine the BASDAI. 
•Determine the BASFI.
•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].
•Measure temperature, pulse, and BP. 
•Collect samples for hematology/biochemistry/urinalysis.
•Collect blood sample for hs-CRP. 
•If there has been a delay in menses, perform a urine pregnancy test.
•Collect blood sample for bimekizumab plasma concentrations.
•Record visit in the IXRS.
8.3.3 Week 4 (+/-3 days) (Visit 5)
The following procedures of assessments will be completed prior to administration of IMP:
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Administer the AsQoL.
•Determine the BASDAI. 
•Determine the BASFI.
•Administer the SF-36.REDACTED nal al paipai
BP. P. 
/bioc/biocCOPY 
This document•ee
•cannot rd d 
Recorecorbe g
cocoused Weeee
g proproto ekek4support for or bibi
IXRSXRSanymenme
imimarketing chemichem
P. P. 
nsensauthorization in NRn NRapplication and any extensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 54 of 143•Administer the MOS Short Sleep Scale.
•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].
•Measure temperature, pulse, and BP. 
•Determine the MASES.
•Determine the BASMI.
•Administer the PhGADA. 
•Collect samples for hematology/biochemistry/urinalysis.
•Collect a blood sample for CRP.
•Collect blood sample for hs-CRP. 
•If there has been a delay in menses, perform a urine pregnancy test.
•Collect blood sample for bimekizumab plasma concentrations and anti-bimekizumab
antibody detection.
•Collect blood samples for cytokines, complement, and biomarker analyses.
•For consenting subjects, collect blood samples for genomic, and proteomic/metabolomic 
analyses.
•For participating centers, collect blood sample for flow cytometry.
•Record visit in the IXRS.
•Administer IMP (bimekizumab or placebo). 
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing.
8.3.4 Week 8 (+/-3 days) (Visit 6)
The following procedures of assessments will be completed prior to administration of IMP:
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Administer the AsQoL.
•Determine the BASDAI. 
•Determine the BASFI.
•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].REDACTED od samd samCOPYnt, ant, an
es for s for
This document ••cannotSSRSSR
HADHADbeadvdvusedcomiomi
ververto edusupport (+/(+/--[ADDRESS_64074]
ssmentsmenauthorizationr genor gen
mple fomple fapplications andand
d bibiomaom
omand t..
ddany extensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 55 of 143•Measure temperature, pulse, and BP. 
•Determine the BASMI.
•Administer the PhGADA. 
•Collect samples for hematology/biochemistry/urinalysis.
•Collect blood sample for hs-CRP. 
•If there has been a delay in menses, perform a urine pregnancy test.
•Collect a blood sample for bimekizumab plasma concentrations and anti-bimekizumab
antibody detection.
•Record visit in the IXRS.
•Administer IMP (bimekizumab or placebo). 
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing.
8.3.5 Week 12 (+/-3 days) (Visit 7)
The following procedures of assessments will be completed prior to administration of IMP:
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Administer the AsQoL.
•Determine the BASDAI. 
•Determine the BASFI.
•Administer the SF-36.
•Administer the MOS Short Sleep Scale.
•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].
•Administer the tuberculosis questionnaire.
•Measure temperature, pulse, and BP. 
•Measure weight.
•Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB.
•Determine the MASES.
•Determine the BASMI.REDACTED COPYmplemple
This documentMM
••cannot Adminidmin
MeMebeisteristerused e PGAPGAtoMOMOsupport 36.6.
OSOSany marketing authorization application ted prioed prand adadany dminiminiextensions mor ababvariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 56 of 143•Administer the PhGADA. 
•Perform an ECG. 
•Collect samples for hematology/biochemistry/urinalysis.
•Collect a blood sample for CRP. 
•Collect blood sample for hs-CRP. 
•If there has been a delay in menses, perform a urine pregnancy test.
•Collect a blood sample for bimekizumab plasma concentrations and anti-bimekizumab
antibody detection.
•Collect blood samples for cytokines, complement, and biomarker analyses.
•For consenting subjects: 
−Collect blood samples for genomic and proteomic/metabolomics analyses.
−Collect blood sample for genetic/epi[INVESTIGATOR_58895].
•For participating centers, collect blood sample for flow cytometry.
•Obtain MRI of spi[INVESTIGATOR_58905]-positive at Baseline. Magnetic resonance imaging at Week 12 should be 
performed as close to the Week 12 Visit as possible.
•Record visit in the IXRS.
•Administer IMP (bimekizumab). 
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing (pulse and BP to be collected 30 minutes and 1 hour 
after dosing).
8.4 Dose-Blind Period (Week 16 to Week 48)
8.4.1 Week 16 (+/-4 days) (Visit 8)
The following procedures of assessments will be completed prior to administration of IMP:
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Administer the AsQoL.
•Determine the BASDAI. 
•Determine the BASFI.
•Administer the SF-36.
•Administer the MOS Short Sleep Scale.REDACTED popo
menmenCOPYhe sube su
gneticgneti
ossioss
This document ••cannotSSRSSR
HADHAbeadvdvusedcomiomi
vetoeduedusupport d Pd 
66(+/(+/-[ADDRESS_64075] is
esonesonand cs as any analyanaextensions mor ababvariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 57 of 143•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].
•Measure temperature, pulse, and BP. 
•Determine the BASMI.
•Administer the PhGADA. 
•Collect samples for hematology/biochemistry/urinalysis.
•Collect blood sample for hs-CRP. 
•If there has been a delay in menses, perform a urine pregnancy test.
•Collect a blood sample for bimekizumab plasma concentrations and anti-bimekizumab
antibody detection.
•Evaluation for rescue treatment eligibility ( Section 5.1.4).
•Record visit in the IXRS.
•Administer IMP (bimekizumab).
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing.
8.4.2 Week 20 (+/-4 days) (Visit 9)
The following procedures of assessments will be completed prior to administration of IMP:
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Measure temperature, pulse, and BP. 
•Collect samples for hematology/biochemistry/urinalysis.
•If there has been a delay in menses, perform a urine pregnancy test.
•Collect a blood sample for bimekizumab plasma concentrations and anti-bimekizumab
antibody detection.
•Record visit in the IXRS.
•Administer IMP (bimekizumab).
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing.
8.4.3 Week 24 (+/-4 days) (Visit 10)
The following procedures of assessments will be completed prior to administration of IMP:REDACTED sit 9)sit 9)
nts wints wi
ssCOPYmplemple
This document ••cannotibodybody
RecoRecobet a bt a blused as beenbeentos fors fosupport ure, pule, pu
rhany marketing authorization ill be cll be capplication ed follod foland any extensions imekimekior variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 58 of 143•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Administer the AsQoL.
•Determine the BASDAI. 
•Determine the BASFI.
•Administer the SF-36.
•Administer the MOS Short Sleep Scale.
•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].
•Administer the tuberculosis questionnaire.
•Measure temperature, pulse, and BP. 
•Measure weight.
•Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB.
•Determine the BASMI.
•Administer the PhGADA. 
•Collect samples for hematology/biochemistry/urinalysis.
•Collect a blood sample for CRP. 
•Collect blood sample for hs-CRP. 
•If there has been a delay in menses, perform a urine pregnancy test.
•Collect a blood sample for bimekizumab plasma concentrations and anti-bimekizumab
antibody detection.
•Collect blood samples for cytokines, complement, and biomarker analyses.
•For consenting subjects: 
−Collect blood samples for genomic and proteomic/metabolomic analyses.
−Collect blood sample for genetic/epi[INVESTIGATOR_58895].
•For participating centers, collect blood sample for flow cytometry.
•Evaluation for rescue treatment eligibility ( Section 5.1.4).
•Record visit in the IXRS.
•Administer IMP (bimekizumab).REDACTED an anCOPY n evaev
This document cannotconsons
−CCbe bloousedectioctio
ood oodtosamsam
ononsupport r hh
delayelay iny
mplmpany RR
hshs--CRCmarketing biochebioch
RP. P. authorization valuatialuatiapplication and any extensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 59 of 143The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing.
8.4.4 Week 28 (+/-4 days) (Visit 11)
The following procedures of assessments will be completed prior to administration of IMP:
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Measure temperature, pulse, and BP. 
•Collect samples for hematology/biochemistry/urinalysis.
•If there has been a delay in menses, perform a urine pregnancy test.
•Record visit in the IXRS.
•Administer IMP (bimekizumab).
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing.
8.4.5 Week 32 (+/-4 days) (Visit 12)
The following procedures of assessments will be completed prior to administration of IMP:
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Measure temperature, pulse, and BP. 
•Collect samples for hematology/biochemistry/urinalysis.
•If there has been a delay in menses, perform a urine pregnancy test.
•Record visit in the IXRS.
•Administer IMP (bimekizumab).
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing.REDACTED Visit 1Visit [ADDRESS_64076] v
AdmAdmbe hashas
iiusedples les 
as besb eto at
fofsupport ure, pure, pany marketing wilwiauthorization et
12)2)
ill bll bapplication ted ed fofoand st.t.any extensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 60 of 1438.4.6 Week 36 (+/-4 days) (Visit 13)
The following procedures of assessments will be completed prior to administration of IMP:
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Administer the AsQoL.
•Determine the BASDAI. 
•Determine the BASFI.
•Administer the SF-36.
•Administer the MOS Short Sleep Scale.
•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].
•Administer the tuberculosis questionnaire.
•Measure temperature, pulse, and BP. 
•Measure weight.
•Determine the BASMI.
•Administer the PhGADA. 
•Collect samples for hematology/biochemistry/urinalysis.
•Collect blood sample for hs-CRP. 
•If there has been a delay in menses, perform a urine pregnancy test.
•Collect a blood sample for bimekizumab plasma concentrations and anti-bimekizumab
antibody detection.
•Evaluation for rescue treatment eligibility ( Section 5.1.4).
•Record visit in the IXRS.
•Administer IMP (bimekizumab).
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing.
8.4.7 Week 40 (+/-4 days) (Visit 14)
The following procedures of assessments will be completed prior to administration of IMP:
•Record concomitant medications.
•Record adverse events.REDACTED COPY 
This document he
••cannotminisminis
e follfollbevisivisusedfor refor re
ititto ononsupporayyin inyy
mple fomple f
nanyCRCR
nmnmmarketing y/biochbiochy
RPRPauthorization application and any extensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 61 of 143•eC-SSRS
•HADS
•Measure temperature, pulse, and BP. 
•Collect samples for hematology/biochemistry/urinalysis.
•If there has been a delay in menses, perform a urine pregnancy test.
•Record visit in the IXRS.
•Administer IMP (bimekizumab).
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing.
8.4.8 Week 44 (+/-4 days) (Visit 15)
The following procedures of assessments will be completed prior to administration of IMP:
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Measure temperature, pulse, and BP. 
•Collect samples for hematology/biochemistry/urinalysis.
•If there has been a delay in menses, perform a urine pregnancy test.
•Perform the IGRA tuberculosis test. 
•Record visit in the IXRS.
•Administer IMP (bimekizumab). This is the last dose of IMP. 
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing.
8.4.9 Week 48 (+/-4 days) (Visit 16)
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Administer the AsQoL.
•Determine the BASDAI. 
•Determine the BASFI.
•Administer the SF-36.REDACTED iochemioche
esesCOPY 
This document ••cannotord crd c
RecoRecobe used andan
WWto nd Bnd Bsupportekizumkizu
ures oures oany marketing m
s, perfoperfo
s test. test.authorization mimistrstrapplication andadminadmiany iextensions ion ofon ofor variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 62 of 143•Administer the MOS Short Sleep Scale.
•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].
•Administer the tuberculosis questionnaire.
•Measure temperature, pulse, and BP. 
•Measure weight. 
•Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB.
•Determine the MASES.
•Determine the BASMI.
•Administer the PhGADA. 
•Perform an ECG.
•Collect samples for hematology/biochemistry/urinalysis.
•Collect a blood sample for CRP. 
•Collect blood sample for hs-CRP. 
•Perform a urine pregnancy test if the subject is a woman of childbearing potential. This 
requirement also applies to women of childbearing potential with infrequent or irregular 
menstrual cycles and women during menopause. Natural menopause is recognized to have 
occurred after 12 consecutive months of amenorrhea, for which there is no other obvious pathological or physiological cause (International Menopause Society, 2015).  
•Collect a blood sample for bimekizumab plasma concentrations and anti-bimekizumab
antibody detection.
•Collect blood samples for cytokines, complement, and biomarker analyses.
•For consenting subjects, collect blood samples for genomic and proteomic/metabolomic 
analyses.
•For participating centers, collect blood sample for flow cytometry.
•Obtain MRI of spi[INVESTIGATOR_58905]-positive at Baseline. Magnetic resonance imaging at Week 48 should be 
performed as close to the Week 48 Visit as possible.
•Record visit in the IXRS.
8.5 Early Termination Visit
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADSREDACTED bject ibject i
f childf child
ng menng men
onthsonthsCOPY 
This documentRR
8cannotstudytudy
performerfor
RbeMRMRused patingating
Ito supportfor cfor c
bjects, bjects,any cymarketings of as of a
se (Intese (Int
mekizumekizauthorization is a wos a w
dbearidbear
nopaunopauapplication and any extensions f oractiactvariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 63 of 143•Administer the AsQoL.
•Determine the BASDAI. 
•Determine the BASFI.
•Administer the SF-36.
•Administer the MOS Short Sleep Scale.
•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].
•Administer the tuberculosis questionnaire.
•Measure temperature, pulse, and BP. 
•Measure weight.
•Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB.
•Determine the MASES.
•Determine the BASMI.
•Administer the PhGADA
•Perform an ECG.
•Collect samples for hematology/biochemistry/urinalysis.
•Collect a blood sample for CRP. 
•Collect blood sample for hs-CRP. 
•Perform a urine pregnancy test if the subject is a woman of childbearing potential. This 
requirement also applies to women of childbearing potential with infrequent or irregular 
menstrual cycles and women during menopause. Natural menopause is recognized to have occurred after 12 consecutive months of amenorrhea, for which there is no other obvious 
pathological or physiological cause (International Menopause Society, 2015).  
•Collect a blood sample for bimekizumab plasma concentrations and anti-bimekizumab
antibody detection.
•Collect blood samples for cytokines, complement, and biomarker analyses.
•For consenting subjects, collect blood samples for genomic and proteomic/metabolomic 
analyses.
•For participating centers, collect blood sample for flow cytometry.
•Perform an IGRA tuberculosis test.
•Record visit in the IXRS. 
•If subject is a PDILI case that results in immediate, permanent IMP discontinuation, conduct 
a thorough evaluation as described in Section 12.5.1 .REDACTED chemichemCOPY 
This document ••cannot ect ct 
For coor co
anaanabe t blot blousedood sod s
detectetectto ph
sasupportwomeome
onsecutnsecu
hysysioliolany sts
o womo wo
enmarketing P. 
t if tht if tauthorization istrystry/u/uyyapplication ands andandany dsdextensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 64 of 1438.6 Safety Follow-Up Visit (20 weeks [-3 days/+7 days] after the final 
dose)
•Record concomitant medications.
•Record adverse events.
•eC-SSRS
•HADS
•Administer the AsQoL.
•Determine the BASDAI. 
•Determine the BASFI.
•Administer the SF-36.
•Administer the MOS Short Sleep Scale.
•Perform the PGADA.
•Administer the total and nocturnal spi[INVESTIGATOR_18303].
•Administer the tuberculosis questionnaire.
•Measure temperature, pulse, and BP. 
•Measure weight.
•Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB. 
•Determine the BASMI.
•Administer the PhGADA. 
•Perform an ECG.
•Collect samples for hematology/biochemistry/urinalysis.
•Collect a blood sample for CRP. 
•Collect blood sample for hs-CRP. 
•Perform a urine pregnancy test if the subject is a woman of childbearing potential. This 
requirement also applies to women of childbearing potential with infrequent or irregular 
menstrual cycles and women during menopause. Natural menopause is recognized to have 
occurred after 12 consecutive months of amenorrhea, for which there is no other obvious 
pathological or physiological cause (International Menopause Society, 2015).  
•Collect a blood sample for bimekizumab plasma concentrations and anti-bimekizumab
antibody detection.
•Perform an IGRA tuberculosis test.
•Record visit in the IXRS.REDACTED cludincludinCOPY 
This documentpp
••cannot remrem
enstrunstru
occuoccube m a ua u
menmenusedd samd sa
urinurinto sam
msupport hematoemat
mplempleany marketing authorization ng an eg an application and any extensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 65 of 1438.7 Unscheduled Visit
At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the 
study but prior to the SFU Visit, if deemed necessary for the subject’s safety and well-being. 
If an Unscheduled Visit is conducted due to safety or efficacy reasons, an eC-SSRS assessment 
will be performed with the subject during the visit. If an Unscheduled Visit is conducted for reasons other than safety or efficacy concerns (eg, replacement of lost medication, repeated 
collection of a laboratory specimen due to collection or analysis issues) an eC-SSRS will not be 
required at these visits.
At this visit, any of the following assessments may be performed, depending on the reason for 
the visit:
•Record concomitant medication
•Record AEs
•eC-SSRS
•Vital signs 
•Physical examination
•Record 12-lead ECG 
•If medically indicated, obtain blood sample(s) for:
−Standard safety laboratory tests (hematology, serum chemistry) 
−The blood sample may also be used for PK/PD assessments, if needed.
•Obtain urine sample for standard safety laboratory tests (including urine pregnancy test)
9 ASSESSMENT OF EFFICACY
The timing for all assessments described below is specified in the Schedule of Assessments, 
Table 5‒1. 
9.1 ASAS20, 40, ASAS 5/[ADDRESS_64077] 20% and absolute improvement of at least 
[ADDRESS_64078] 3 of the 4 following domains:
•PGADA (see Section 9.2 )
•Pain assessment (the total spi[INVESTIGATOR_18233]; Section 9.3 )
•Function (represented by [CONTACT_18379], Section 9.4 )
•Inflammation (the mean of the BASDAI questions 5 and 6, [see Section 9.5 ]  
) 
and absence of deterioration in the potential remaining domain [deterioration is defined as a 
relative worsening of at least 20% and an absolute worsening of at least 1 unit].
The ASAS criteria for 40% improvement are defined as relative improvements of at least 40%, 
and absolute improvement of at least [ADDRESS_64079] 3 of the 4 domains and 
no worsening at all in the remaining domain.REDACTED e(s)e(s)
ematolmatol
used used 
ds a fds a fCOPY s) fo)f o
This document ••IIcannotn assass
FunctFuncbe (s(sused10 N0 N
see seeto finene
NRNRsupport 20, 400, 40
ededaanydedescsmarketing fetfety lay la
OF EOF 
criauthorization or:r:
logyogy
for PKfor PKapplication and any extensionseasoasoor ononvariations be be thereof. 
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRREEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOPY 
This 
docummmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeennnnnnnnnnnnttttttttttttttttttttttttttttttttttttt 
cccccccccccccccccccccccccccccccccaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnooooooooooottttttttttttt 
bbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee 
uuuuuuuuuuuuuuuuuuuuuuuuuuuusssssssssssssssssssssssssssssssssssseeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeedddddddddddddddddddddddddddddddddddddddddddddddddddddddddddddddddd 
ttoo 
ssuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuupppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppppoooooooooooooooooooooooooooooooooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrttttttttttttttt 
aaaaaaaaaaannnnnnnnnnnnnyyyyyyyy 
marrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeetttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiinnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnngggggggggggggggggggggggggggggggggggggggggggggggggggggggggg 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaauuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuuttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttthhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhoooooooooooooooooooooooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrriiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiizzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaattttttttttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn 
applicatiooooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnndddddddddddddddddddddddddddddddddddddddddddddd 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy 
eeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeexxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxtttttttttttttttttttttttttttttttttttttttttttttttttttttttttttteeeeeeeeeeeeeeeeeeeeeeeeeeensions 
orrrrrrrrrrrrrrrrrrrrrrr 
vvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvvaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaarrrrrrrrrrrrrrrrrrrrrrrriiiiiiiiiations 
thereof. 
RRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRREEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDACTEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD 
CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOPPYYYYYYYYYYY 
This 
docummmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeennnnnnnnnnnnnnnnnnnnnnnnnntttttttttttttttt 
cccccccccccccccccccccccccccccccccccccccccccccccccccccccccaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaannnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnoooooooooooooooooooooooooooooooooooooooottttttttttttttttttttttttttttttttttttttttttttttttttt 
bbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbbeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee 
uuuuuuuuuuuuseeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeddddddddddddddddddddddddddddddddddddddddddddddddddddddddd 
to 
suuuuuuuuuuuuuuuuuuuuuuuuuppppppppppppppoooooooooooooooooooooooooooooooooooooooorrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrtttttttttttttttttttttttttttttttttttttttttttttttt 
aaaaaaaaaaaaanny 
maarrrrrrrrrrrrrrrrrrrrrrrrrrkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkkeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeetttttttttttttinggggggggggggggggggg 
aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaauuthorizzzzzzzzzzaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaatttttttttttttttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiioooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn 
aaapppliccaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaatttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiioooooooooooooooooooooooooooooooooooooooooooooonnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn 
aaaaaaaaaaand 
any 
eeeeeeeeeeeeeeeeexxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxtttttttttttttttttttttttttttttttttttttteeeeeeeeeeeeeeeeeeeeeeeeeeeenssiioons 
or 
variations 
thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 68 of 1439.10 MASES
Enthesitis is assessed with MASES. The MASES is an index that measures the severity (ie, 
intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral 
costochondral 1, costochondral 7, anterior superior iliac spi[INVESTIGATOR_050], posterior iliac spi[INVESTIGATOR_050], iliac crest 
and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spi[INVESTIGATOR_18239]) (Heuft-Dorenbosch et al, 2003) each scored as [ADDRESS_64080] to their AS signs and symptoms and functional capacity (considering both joint and skin components) using an NRS in 
which 0=very good, asymptomatic and no limitations of normal activities and 10=very poor, very severe symptoms which are intolerable and inability to carry out normal activities. 
This assessment by [CONTACT_58964].
The subject should be asked to consider both joint and skin components in their response to this 
question.
9.12 SF-36
The SF-36 (Version 2, standard recall) is a 36-item generic health-related quality of life (HRQoL) instrument that uses a recall period of 4 weeks. Items are grouped into 8 domains as 
follows: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General 
Health (5 items),Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items), and 1 item for perceived stability or change in health (Health 
Transition) during the last year. The concepts represented by [CONTACT_58965], mental, and social aspects of HRQoL.
In addition to domain scores, the Physical Component Summary and Mental Component 
Summary scores are calculated from the 8 domains (excluding the Health Transition item). 
Component scores appreciate the impact of each domain on physical and mental health status (Maruish, 2011). Each of the [ADDRESS_64081] deviation (SD) of 10 in the general US population. 
9.13 MOS-12
The MOS Sleep Scale is a validated generic self-administered scale measuring specific aspects 
of sleep. The frequency with which each problem has been experienced during the previous 
4 weeks is rated on a 6-point scale ranging from “none of the time” to “all of the time,” except sleep quantity, which is reported in hours. All scores are transformed linearly to range from 0 to 
100, again with the exception of the sleep quantity subscale, which is scored in hours. Higher 
scores indicate more of the attribute implied by [CONTACT_18381] (eg, more sleep disturbance, more adequate sleep, and greater sleep quantity). The psychometric properties of the MOS Sleep Scale 
have been found to be satisfactory by [CONTACT_58966] (Hays et al, 2005). The domains of 
interest for this study are the Sleep Disturbance and the Sleep Problems Index II domains. REDACTEDle Phle Ph
FunctiFuncti
perceperce
conceconce
of Hof HCOPYgenergene
4 wee4 we
h
This documentsleepleep
10010cannot S S S
ep.p.ThTh
eeks eeks be SleeSleeused MOMOto h supportthe 8 he 8
core indore in
a mea meany roo
the imthe i
ddmarketing eptspt
HRQoHRQo
hyysicalsica
om thom tauthorizationeks. Ieks. 
ysical sical 
tioningoning
eived ived 
ts resr eapplication ic c heahe
IteIand ents innts inany A..extensionssignsign
sing aing a
10=ver0=ve
l activactivor ns asavariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 69 of 1439.14 ASQoL
The ASQoL, a validated disease-specific 18-item questionnaire, has been developed specifically 
for measuring HRQoL in subjects with AS (Doward et al, 2003). The ASQoL has been used and 
has shown to be responsive in axSpA (Barkham et al, 2009; Haibel et al, 2008). The ASQoL 
score ranges from 0 to 18 with higher score indicating worse HRQoL. 
9.15 MRI Assessment (SPARCC and ASspi[CONTACT_9268])
While radiography can detect chronic bony changes (eg, sclerosis, erosions, bridging, and ankyloses), structural changes generally occur slowly and x-rays are insensitive; therefore, changes are difficult to detect in the relatively short duration of a randomized clinical trial. 
Unlike radiography, MRI can be used to visualize inflammation in the SI joints and spi[INVESTIGATOR_58906]. Inflammation of the SI joints and spi[INVESTIGATOR_53553] a key feature of AS that is potentially amenable to treatment with bimekizumab. If bimekizumab is effective, it is 
expected that reduction in inflammation in the SI joints and spi[INVESTIGATOR_58907] 48-week Treatment Period of this study. Recently a Danish study demonstrated significant changes in in ASspi[CONTACT_9268]-a (Berlin modification) and SPARCC MRI-assessed 
inflammation scores and in SPARCC MRI-assessed erosion scores within 12 weeks after 
initiation of adalimumab (see below for further description of these MRI scoring methods). The researchers concluded that MRI-assessed structural lesions change rapi[INVESTIGATOR_58908]-modifying treatment in clinical trials (Pedersen SJ et al, 
2016). 
An MRI of the spi[INVESTIGATOR_58897] a substudy with approximately 
20 subjects per treatment arm at Baseline. A central reader will assess Baseline MRIs to identify 
MRI-positive subjects as per the ASAS-Outcome Measures in Rheumatology Clinical Trials (OMERACT) criteria. An MRI at Week [ADDRESS_64082] bimekizumab injection. Magnetic resonance imaging at Week 12 and Week 48 should be performed as close to 
the Week 12/Week 48 Visit as possible. Additional details for standardized performance and 
processing of MRIs will be provided in an MRI manual. The MRIs will be read centrally by [CONTACT_58967] a charter for independent imaging assessment.  
The following 2 different scoring systems will be utilized to determine changes from Screening 
(Lukas et al, 2007): 
ASspi[CONTACT_9268]-a (Berlin modification) score 
This method is a scoring system with a concentration on short-tau-inversion recovery (STIR)
sequences which quantifies changes in 23 disco-vertebral units (DVU) of the spi[INVESTIGATOR_050]. A DVU is
defined as the region between [ADDRESS_64083] level of inflammation in a particular 
VU. There is no grading for erosion in the Berlin modification. The total spi[INVESTIGATOR_18241]-a 
score in the Berlin modification can range from 0 to 69. REDACTED will be ill be 
e. A ce. A c
AS-AS-OuOu
WeekWeekCOPY esioesi
tment ment 
This documenteququ
defindefi
inicannot otRIRIotmethmeth
uenuenbe 2
a(aused2 diffdiff
2007)007to penpensupportbe proe pro
d to tred to t
endenndeanymagma
s posss posmarketing12 an12 an
The BaThe B
ssessmsessm
agingagiauthorization in
perfoperfo
entralentral
comecomeapplication es s wiw
f these Mthese
changchan
n clinn clinand stutu
ARCCARCC
iianydetecdetec
udyudydyextensions triaria
d spi[INVESTIGATOR_58909] e, e, 
alalvariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 70 of 143SPARCC SI Joint score
This method is a scoring system for assessing the SI joint based on STIR sequences. An 
abnormal increased signal on the STIR sequence represents bone marrow edema. The SI joint is 
divided into 4 quadrants (upper iliac, lower iliac, upper sacral, and lower sacral). The presence of 
increased signal on STIR in each of these 4 quadrants is scored as either 0=normal signal or 1=increased signal. The maximum score for abnormal signal in the 2 SI joints of 1 coronal slice 
is therefore 8. Joints that include a lesion exhibiting intense signal are each given an additional 
score of 1 per slice (that demonstrate this feature). Each SI joint that includes a lesion demonstrating continuous increase signal of depth ≥1cm from the articular surface is also given 
an additional score of 1. The maximum score for a single coronal slice is 12. Scoring is repeated 
in each of 6 consecutive coronal slices, so that the total SI joint SPARCC MRI score can range from 0 to 72. 
9.16 Hospi[INVESTIGATOR_58910]-established psychometric properties and its use in clinical research on biological therapy in subjects with chronic plaque psoriasis (Langley et al, 2010; 
Dauden et al, 2009). The HADS scores for anxiety and for depression range from 0 to 21 with 
higher scores indicating worse state. A score below 8 is considered to be normal whereas a score of 15 and above is considered severe (Snaith and Zigmond, 1994).
10 ASSESSMENT OF PHARMACOKINETIC, 
PHARMACODYNAMIC, PHARMACOGENOMIC, AND 
PROTEOMIC VARIABLES
Plasma concentrations of bimekizumab, population PK variables (CL/F, V/F) and dose-exposure 
responses (for ASAS40 response) are the PK variables. 
The PD variables are the concentrations of cytokines of relevance to IL-17A/F signaling pathway 
and AS biology. Where local regulations permit, additional blood samples will be collected from consenting subjects at specific time points and stored at -80°C for up to 20 years to allow for 
potential exploratory analyses of genomic, genetic/epi[INVESTIGATOR_18193], proteomic, and metabolite
biomarkers relevant to the disease biology, disease progression, response to therapy, and inflammatory and immune response processes
The Investigator or designee will obtain blood samples for these measurements at the time points 
specified in Table 5‒1. When these samples are required at a visit during which the subject is 
dosed with IMP, the blood samples will be drawn prior to dosing. Samples should be drawn at 
the same time of the sampling for clinical laboratory tests. The time and date of collection will be 
recorded in the eCRF. Instructions pertaining to sample collection, processing, storage, labeling, and shippi[INVESTIGATOR_58911]. Detailed information on 
sample analysis will be provided in a bioanalytical report.
11 ASSESSMENT OF IMMUNOLOGICAL VARIABLES
The immunological variables comprise detection of anti-bimekizumab antibodies related to 
immunogenicity, serum complement concentrations, mononuclear cell subtypes (analyzed by 
[CONTACT_4133]/fluorescence-activated cell sorting), and other exploratory biomarkers.
The Investigator or designee will obtain blood samples for these measurements at the time points 
specified in Table 5‒1. When these samples are required at a visit during which the subject is REDACTED, , PHP
BLEBLE
bb, pop, pop
re there theCOPY monmo
MMAACC
HAH
This documentsampamp
11cannot timtim
ded in ed in 
shippshipp
llbe M
me me used or r
blele55
MP, MP,toddesessupport es es
e  diseadise
mune remune r
ianytimetime
of gof marketing  PK PK 
ons of ons of
ulationlation
epeauthorizationCOO
AARMRM
SS
pulatioulatioapplicationssionssion
dered tered 
, 1994)1994
OKINKIand s aa
asis (sis (LLany and itndextensionsis reis r
ore care caoro gio g
reprepvariations al 
givegivethereof. 
UCB [ADDRESS_64084] a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
In order to ensure complete safety data collection, all AEs occurring during the study (ie, after 
the signing of the Informed Consent Form), including any pretreatment and posttreatment periods required by [CONTACT_760], must be reported in the eCRF even if no IMP was taken but 
specific study procedures were conducted. This includes all AEs not present prior to the initial 
visit and all AEs that recurred or worsened after the initial visit.
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profile known to the Investigator from the subject’s history or the Baseline Period.
12.1.[ADDRESS_64085] (AESI) is any AE that a regulatory authority has mandated be reported 
on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the administration of a UCB product/compound.
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin in 
the absence of ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, 
must ALWAYS be reported to UCB as an AESI (ie, without waiting for any additional etiologic 
investigations to have been concluded). Follow-up information should then be reported if an 
alternative etiology is identified during investigation and monitoring of the subject.
12.1.3 Adverse events for special monitoring
UCB has identified AEs for special monitoring (AESM). An AESM is an AE or safety topic for 
which special monitoring, additional data collection activities, and/or enhanced signal detection 
activities (within UCB), are considered appropriate. Identified AESM can be of particular concern based on findings from the IMP clinical program to date, potential risks generally 
associated with biologic immunomodulators, or comorbidities and risk factors prevalent in the 
study population.
Adverse events for special monitoring for this study include: serious infections (including 
opportunistic infections and TB, see Section 12.6.5 ), cytopenias, hypersensitivities, suicide fter thfter t
ase forase fo
hangehange
mannmannCOPY ana
in thein the
ncludnclu
h
This documentUCBUCB
wwcannotive eve e
1.3.3beons tons 
ttused2xUxU
YS beYS betow, de, de
ULULsupportardlerdle
B prodB prod
efinefiany SI) SI) isi
essmarketingner asner as
yyor theor thy
of spof sauthorizationdes ades a
e initi init
r whicr whi
s consconapplication curring urring
pretrearetre
eeCRFCRF
landdicinaicinany n (
d withwith
allextensions subjecubjec
l relatirelat
(i(incncor variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 72 of 143ideation or behavior (assessed using the eC-SSRS), depression and anxiety (assessed using the 
HADS, see Section 9.16 ), major cardiovascular events and liver function test changes/enzyme 
elevations (ALT, AST, and bilirubin; see Section 12.5.1 ), malignancies, and inflammatory bowel 
diseases.
12.1.[ADDRESS_64086] AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator should review any self-assessment procedures (eg, diary cards) 
employed in the study.
12.1.[ADDRESS_64087]’s own words 
on his/her own records (eg, diary card) and the corresponding medical terminology should be 
clarified in the source documentation.
When recording the intensity of an AE in the eCRF (ie, mild, moderate, or severe), the 
Investigator should use the following criteria:
•Mild: the subject is aware of the sign or symptom (syndrome), but it does not interfere with 
his/her usual activities and/or is of no clinical consequence
•Moderate: the AE interferes with the usual activities of the subject or it is of some clinical 
consequence
•Severe: the subject is unable to work normally or to carry out his/her usual activities, or the 
AE is of definite clinical consequency
Details for completion of the Adverse Event eCRF (including judgment of intensity and 
relationship to IMP) are described in the eCRF Completion Guidelines.
12.1.[ADDRESS_64088] to follow-up. This 
follow-up requirement applies to AEs, SAEs, AESIs, and AESMs; further details regarding 
follow-up of PDILI events are provided in Section [IP_ADDRESS]. Information on SAEs obtained after 
clinical database lock will be captured through the Patient Safety (PS) database without 
limitation of time.
If an AE is ongoing at the end of the study for a subject, follow-up should be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow-up. If no follow-up is provided, the 
Investigator must provide a justification. The follow-up will usually be continued for [ADDRESS_64089] has discontinued his/her IMP.REDACTEDymymptp
clinicclinic
the usthe usCOPY(ie, m(ie, 
This document If anIf an
rercannotp op o
al datal dat
itatiotatiobeeququ
of Pof Pused fofo
at it is t it is 
uireuiretoolloollosupportdescribescrib
ww--upupany AdveAdve
bmarketing su
work nwork 
equenequeauthorization tom (som (s
cal concal con
ual acal aapplicationedicaledica
mild, mild, mandomsms
een teen tanyor syor syy
s or so rextensionsycardcardyor ddvariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 73 of [ZIP_CODE].1.7 Rule for repetition of an adverse event
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:
•The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening”
•The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one
12.1.[ADDRESS_64090] immediately notify UCB’s PS department by [CONTACT_58968] (for contact [CONTACT_58969]). The subject should be withdrawn from the study as soon as 
pregnancy is known (by [CONTACT_18463]), and the following should be completed:
•The subject should return for the ET Visit.
•The subject should immediately stop the intake of the IMP.
•An SFU Visit should be scheduled [ADDRESS_64091] of information currently known about potential risks 
and about available treatment alternatives.
The pregnancy will be documented on the Pregnancy Report and Outcome Form provided to the
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome Form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to follow the health of the child for [ADDRESS_64092] to follow-up and/or refuses to give information, written documentation of attempts to contact [CONTACT_58970]. 
UCB’s Drug Safety department is the primary contact [CONTACT_58971], eventual birth, and follow-up.
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investigator or designee is asked to contact [CONTACT_58972]/IEC and should be available in the Investigator site file. In case of questions about the consent process, the 
Investigator may contact [CONTACT_58973]/ CRO contract monitor for the study. The Investigator will 
complete the Pregnancy Report and Outcome Form and send it to UCB’s PS department (for contact [CONTACT_58969]) only after the 
partner has agreed that additional information can be captured and has provided the signed 
Partner Pregnancy Consent Form. UCB’s PS department is also the primary contact [CONTACT_58974], eventual birth, and follow-up.
A pregnancy becomes an SAE in the following circumstances: miscarriage, elective abortion 
when medically indicated (eg, when pregnancy is endangering life or health of woman or when fetus will be born with severe abnormalities), unintended pregnancy after hormonal 
contraceptive failure (if the hormonal contraceptive was correctly used), ectopic pregnancy, fetal REDACTEDregnanregna
nancyancy
rt andrt and
nd of tnd of t
ddCOPYation ction 
This document nn
partnpartn
PaPcannotgatorator
plete lete t
tact act bee in in
mmusedesigsig
ancyancyyy
ththto partpar
gnegnesupport mentmen
ancyncy, e
rtnertneanyneednee
nt intmarketingthe che c
ayys aftes afte
hat at follfol
d/or rd/or authorization ncyncyRRyy
and thand th
d OutcOutc
chchapplication bjeject hact h
currenturrenand anybe beextensions f anan
ompleomple
formatormat
as s soso
ec oecor nynyvariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 74 of 143demise, or any congenital anomaly/birth defect of the baby. Those SAEs must be additionally 
reported using the Investigator SAE Report form.
12.1.[ADDRESS_64093] should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and followed as any other SAE. Any organism, virus, or infectious particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.
12.1.[ADDRESS_64094]
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself is an AE or SAE (eg, suicide attempt).
12.1.[ADDRESS_64095] as early as possible any 
safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory authorities, and IRBs/IECs will be informed appropriately and as early as possible.
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed during the course of the study.
In addition, an independent DMC will periodically review and monitor the safety data from this 
study and advise UCB. The DMC membership includes clinicians knowledgeable about the disease or the treatment. All members have experience and expertise in clinical trials. Board 
members may not participate in the study as principal or co-Investigators, or as study subject 
care physicians. The duration of membership for the DMC will be inclusive of planned analyses for AS0008. The DMC may also be asked to provide a review of final study results, as deemed 
appropriate. The DMC procedures will ensure that data remain blind to the study team and 
Investigators at all times throughout the conduct of the study. The detailed role, scope, responsibilities, and complete procedures, as well as the identity of the DMC members, will be 
described in a separate charter document. A cardiovascular adjudication committee will be in 
place for this study. Specific procedures will be outlined in the charter, which will be developed by [CONTACT_58975].REDACTED prp
d desigdesig
nciliancili
lopmelopme
BmBCOPYdicalica
igatorsgators
ropriopri
This documentsc
placeplace
by[CONTACT_58976]. The. Th
rs arsusedThehe
The DMhe DM
heheto art
he duedsupporthe DMe DM
nt. All m. All
ticipticipany MC wMC w
Mmarketingent ant a
maymay ididyy
r whichr whicauthorizationrs, 
iatelyately
gnee/enee/e
ations tions
ananapplication yto deto de
 clinicliniandg thetheanyidereidere
ee xeeextensions se) shse) sh
dosidosior variations ous ous 
enic onic othereof. 
UCB [ADDRESS_64096] meet 1 or more of the following criteria:
•Death
•Life-threatening
(Life-threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)
•Significant or persistent disability/incapacity
•Congenital anomaly/birth defect (including that occurring in a fetus)
•Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious.
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section 12.1.2 ], allergic bronchospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias that do not result in inpatient hospi[INVESTIGATOR_059], or the 
development of drug dependency or drug abuse.)
•Initial inpatient hospi[INVESTIGATOR_318]
A patient admitted to a hospi[INVESTIGATOR_307], even if he/she is released on the same day, meets the criteria 
for the initial inpatient hospi[INVESTIGATOR_059]. An emergency room visit that results in admission to 
the hospi[INVESTIGATOR_58912]. However, emergency room visits that do not result in admission to the hospi[INVESTIGATOR_18254], instead, should be evaluated for 1 of the other criteria in the definition of 
serious (eg, life-threatening adverse experience, important medical event).
Hospi[INVESTIGATOR_58913] [eg, preplanned 
surgery or elective surgery for a pre-existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify for reporting. For example, if a subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospi[INVESTIGATOR_18256], 
since there is no AE upon which to assess the serious criteria. Please note that, if the pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to 
be determined.
Note: Confirmed active TB is always to be considered as an SAE and must be captured on an 
SAE Report Form and provided to the Sponsor in accordance with SAE reporting requirements.
12.2.[ADDRESS_64097] be informed within 24 hours of receipt of this information by 
[CONTACT_779] (see contact [CONTACT_58977]). The Investigator must forward to UCB (or its representative) a duly 
completed “Investigator SAE Report Form for Development Drug” (SAE report Form) provided REDACTED ngationngatio
n if hen if h
ation. ation. 
for thor thCOPYntn
n inpan inp
use.)use.)
This document NoteNote
SAScannot xisxi
is wous wou
be debe debe ere
stingstinusedcoo
nditiondition
e is nei stoondindisupport asonsson
surgeryurger
ncharncha
tianyadvadv
ns nsmarketingA
he inithe ini
ot result resu
ld be ed be 
verveauthorization n of hn of h
e/she /she 
An emn emapplication to, poto, p
ive treave tre
atient htient andn to pto anyent, ment, m
preprextensions or urrrrvariations red redthereof. 
UCB [ADDRESS_64098] be completed in English. 
It is important for the Investigator, when completing the SAE report Form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the Investigator is very important for UCB to consider in assessing the safety of the IMP and in determining whether the SAE requires reporting to the regulatory authorities in an 
expedited manner.
Additional information (eg, autopsy or laboratory reports) received by [CONTACT_18399] [ADDRESS_64099] and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
[ADDRESS_64100] to follow-up. This 
follow-up requirement applies to AEs, SAEs, AESIs, and AESMs; further details regarding 
follow-up of PDILI events are provided in Section [IP_ADDRESS]. Information on SAEs obtained after 
clinical database lock will be captured through the PS database without limitation of time.
12.[ADDRESS_64101] be reported immediately:
•SAE: AE that the Investigator classifies as serious by [CONTACT_58978]
•Suspected transmission of an infectious agent via a medicinal product
•AEs of special interest as defined in Section 12.1.[ADDRESS_64102] of Anticipated SAEs ( Table 12‒1) has been identified, as these events are 
anticipated to occur in the population studied in this protocol at some frequency that is independent of drug exposure. This original list will remain in effect for the duration of the 
protocol. Note that listed events will not be regarded as anticipated SAEs if they are life 
threatening or if they result in the death of the study subject.REDACTED y.y.
B willB will
xpectedxpecte
ous aous aCOPYn thin th
MP musMP mu
This documentAA
1212cannot i
uspecuspec
AEAEbe E 
ttyyusedAEs mEs m
that thatto mumusupportrer
ll be cabe c
ediatediatanyo Ao A
eprovprovmarketingadvedve
has resoas res
nically ically
AEsAEauthorization ust bst b
l perfoperfo
ednessness
ererapplicationUCB
associassoc
o inforo info
s periodperio
be rebe rand CB (oB (oanycumcumextensions stigatotigato
mpanimpani
menmeor n n variations sight ght 
MP MP thereof. 
UCB [ADDRESS_64103] does not change the Investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section 12.2.2.
Table 12 ‒1: Anticipated serious adverse events for the population of subjects 
with ankylosing spondylitis
MedDRA system organ class MedDRA preferred term
Skin and subcutaneous tissue disorders Psoriasis
Eye disorders Uveitis
Musculoskeletal and connective tissue disorders Dactylitis
Tendonitis
Atlantoaxial instability
Gastrointestinal disorders Colitis ulcerative
Crohn's disease
Cardiac disorders Aortic valve incompetence
Atrial tachycardia
Atrioventricular block
Bundle branch block
Cardiomyopathy
Vascular disorders Aortitis
Respi[INVESTIGATOR_696], thoracic and mediastinal disorders Pulmonary fibrosis
Nervous system disorders Cauda equina syndrome
Injury, poisoning and procedural complications Spi[INVESTIGATOR_58914]=Medical Dictionary for Regulatory Activities
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they result 
in the death of the study subject. 
12.[ADDRESS_64104] of serum chemistry, hematology, and urinalysis, and 
pregnancy tests (serum or urine) ( Table 12‒2). A centralized laboratory will be used to supply all 
laboratory test supplies and analyze all blood and urine samples for hematology, biochemistry 
and urinalysis measurements. Any unscheduled laboratory testing should also be collected using 
the central laboratory. Testing to rule out hepatitis B, hepatitis C, and HIV (see Exclusion Criterion #9, Section 6.2 ) will be performed at Screening in addition to those measurements 
listed in Table 12‒2. 
Specific details regarding the handling and processing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals.REDACTED D
ersersCT
DA
RCOPY C
This document linin
pregpreg
lalaannot nicalicalbeh of thh of tusedl DictDictd
: ListList
hto tsupport sor
supany marketing cationscationingauthorization ntio
ori
utapplicationc valvec valv
rial tachrial tac
AtriovAtriov
BunBun
Caand easeease
aany veveyextensions ilitylityonor variations ontiooo
vthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 78 of 143Table 12 ‒2: Laboratory measurements
Hematology Chemistry Urinalysis
Basophils Calcium Albumin
Eosinophils Chloride Bacteria
Lymphocytes Magnesium Crystals
Atypi[INVESTIGATOR_58915]-CRPb
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; CRP=C-reactive protein; GGT=gamma glutamyltransferase; hs-CRP=high sensitivity C-reactive protein; 
LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular hemoglobin 
concentration; MCV=mean corpuscular volume; RBC=red blood cell; SFU=Safety Follow-up; WBC=white blood cell
aA serum pregnancy test will be performed at Screening for all women of childbearing potential. This 
recommendation also applies to women of childbearing potential with infrequent or irregular menstrual cycles and 
women during menopause. Natural menopause is recognized to have occurred after 12 consecutive months of amenorrhea, for which there is no other obvious pathological or physiological cause (International Menopause Society [IMS], 2015). A urine pregnancy test is also required at the Baseline, Week 48, ET, and at SFU visits. A urine pregnancy test will also be performed at any study visit where there has been a delay in menses. This 
recommendation also applies to women of childbearing potential with infrequent or irregular menstrual cycles. 
Pregnancy test results must be negative prior to administering IMP. 
bBoth CRP and hs-CRP will be tested at specified visits per Table 5‒1.
12.5.[ADDRESS_64105] be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be REDACTED sterolsterolED
pregnpregnCT
PPbbDA
RCOPY Y
CO
This document cannotmendaenda
nancy tancy 
oth Cth Cbe]
nancynancy
atiatiusedopop
whichwhich
2015201toapp
pausepaussupport puspus
will be ill be p
pplies pliesanyH=meaH=me
sculasculmarketing RPPbbing
aminotamin
T=gamT=garkeauthorization n
at
nancy tancy thor
auapplication n
at
ppppppand ndany nyextensions ns
pregnregnns
exor or variations ontiooo
arthereof. 
UCB [ADDRESS_64106] (see Section 12.1.2 ), and, if applicable, also reported as an 
SAE (see Section 12.2.1 ). 
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table 12‒3(specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section [IP_ADDRESS] ). The local 
hepatologist is the expert usually consulted by [CONTACT_58979]. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section [IP_ADDRESS] ). 
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapi[INVESTIGATOR_58916] a conservative approach must be taken if the results from the [ADDRESS_64107] not occur.
Table 12‒3summarizes the approach to investigate PDILI.REDACTEDmedicmedic
tinuedtinued
ecessaecess
medicmedicCOPYom thm t
ca
This document cannot be used to support apapany pproapproamarketing catat
ntialltially authorization ations tions 
d. In th In th
ary cory co
tionionapplicatione sh
e to bee to b
ust be ust be
e local locaand eses
shouhouanyreperepe
ult.ultextensions ld be md be 
eaeaor variations ased ased thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 80 of 143Table 12 ‒3: Required investigations and follow-up for PDILI
Laboratory value Immediate Follow-up
ALT or AST Total 
bilirubinSymptomsaof 
hepatitis of 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
≥3xULN ≥2xULNbNA Hepatology consultc
Medical Monitor must 
be notified within 
24 hours (eg, by [CONTACT_58980]) and subject discussed with Medical Monitor ASAP.Immediate, permanent 
IMP discontinuationEssential: Must have 
repeat liver chemistry 
values and additional 
testing completed ASAP (see Section [IP_ADDRESS] ); 
recommended to occur 
at the site with HCP.Monitoring of liver 
chemistry values at least 
twice per week until values 
normalize, stabilize, or return to within baseline values
d≥3xULN NA Yes
≥5xULN NA NA Need for hepatology 
consult to be discussed.( 
required if ALT or AST 
≥8xULN)
Medical Monitor must 
be notified within 24 hours (eg, by [CONTACT_58980]) and 
subject discussed with 
Medical Monitor ASAP.Immediate, permanent 
IMP discontinuation
≥3xULN (and 
≥2x baseline) 
and <5xULN (and ≥2x 
baseline)<2xULN No Discussion with Medical 
Monitor required.
Consider need for 
hepatology consult if there is no evidence of 
resolution (see Follow-
up requirements).
cFurther investigation –immediate IMP discontinuation not required (see Section [IP_ADDRESS] ).
IMP discontinuation 
required if any of the following occur:
•Subject cannot comply with 
monitoring schedule. Essential: Every 
attempt must be made to have repeat liver chemistry values and additional testing 
completed within 
48 hours at the site with HCP (see Section [IP_ADDRESS] ).Monitoring of liver 
chemistry values at least twice per week for 2 weeks.
d
•Immediate IMP 
discontinuation required 
if liver chemistry values continue to increase.REDACTED st t 
byy
rt) anrt) an
ED
COPYediateediat
MP disP dis
YThis 
document 
me
cannot ca
be 
used 
to supportonsidensid
hepatohepat
thethesusu
any on won 
or requor req
marketing nd nd 
d with d with
nitor AStor A
withwima
authorization contonut
application , permanperm
tinutinu
plic
and vala
testtest
AAa
anyeat livat liv
ues aues
extensions al: Ml: Mxte
or FolFoo
variations 
on
llollva
thereof. 090
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 81 of 143Table 12 ‒3: Required investigations and follow-up for PDILI
Laboratory value Immediate Follow-up
ALT or AST Total 
bilirubinSymptomsaof 
hepatitis of 
hypersensitivityConsultation 
requirementsActions Testing Evaluation
•Liver chemistry 
values continue to 
increase 
•Liver chemistry 
values remain ≥3xULN (and 
≥2x baseline) after 2 
weeks of monitoring without evidence of resolutionAfter 2 weeks of monitoring 
liver chemistry values:
•Discontinue IMP if levels remain ≥3xULN 
(and ≥2x baseline) 
without evidence of 
resolution
d
Continue to monitor until 
values normalize, stabilize, or return to within baseline values.
d
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcar e practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug induced liver injury; ULN=upper limit of normal 
aHepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms in clude eosinophilia (>5%), 
rash, and fever (without clear alternative cause).
bIf the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor.
cDetails provided in Section [IP_ADDRESS] . The local hepatologist is the expert usually consulted by [CONTACT_58981]. This would usually be a hepatologist, but may be a gastroenterologist.
dUnless an alternative monitoring schedule is agreed by [CONTACT_58982]. Determination of stabili zation is at the discretion of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
REDACTED 
EDoon as on as 
=poten=poten
upper qupper 
TEEE
COPYeks ofeks o
withouwitho
resoresoThis 
document 
cannot 
be 
used 
to support pppp
anye invee inv
licablica
marketing quau
on of bon of 
the expehe exp
st, but t, bu
authorizpossibpossib
ntial druial dr
adraadra
rization t e
lutionutionriz
application ) after 2after 
monitormonito
evidenvide
and a
any 
extensions xte
or FolFoo
variations 
on
llollva
thereof. [ADDRESS_64108]
Potential drug-induced liver injury events require notification of the Medical Monitor within 
24 hours (eg, by [CONTACT_58980]), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The 
local hepatologist is the expert usually consulted by [CONTACT_58983]. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full 
hepatology assessment (see Section [IP_ADDRESS] ) and SAE report (if applicable).
[IP_ADDRESS] Immediate action: determination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) to immediate and permanent discontinuation (see Section 6.3.1 andTable 12‒3for details).
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider dose reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.
[IP_ADDRESS] IMP restart/rechallenge
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, maybe 
fatal, and must not occur.
[IP_ADDRESS] Testing: identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may ha ve been caused by [CONTACT_58985] 12‒4(laboratory measurements) and Table 12‒5(additional 
information). Results of the laboratory measurements and information collected are to be 
submitted to the sponsor on the corresponding eCRF. If the medical history of the subject indicates a requirement for other assessments not included below, these additional assessments 
should be completed and submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed ( Table 12‒4):ing ing 
on/exon/ex
formformCOPY oxo
drd
This document cannot being ng usedple mple m
mmtoshoushosupportth
or other oth
nd subnd su
uldlanyoratora
he core cormarketingmationmation
theyhey mmyy
44(lab(lab
atoryatoauthorization rugug--inin
xclusiclusapplication or shor sh
d consicons
to a suio a suandsuppleuppl
ououany22‒3‒3ffextensions hepatihepat
te ine inor variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 83 of 143Table 12 ‒4: PDILI laboratory measurements
Virology-
relatedHepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain heterophil 
antibody or monospot testing)
Immunology Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology Eosinophil count
Urinalysis Toxicology screena
Chemistry Amylase
ALT, AST
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Additional Prothrombin time/INRb
Serum pregnancy test
PK sample
ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; HBcAb-
IgM=hepatitis B core antibody-IgM; HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential drug-induced liver injury; PK=pharmacokinetic; RNA=ribonucleic acid; ULN=upper limit of normal
aFor detecting substances (ie, amphetamines, benzodiazepi[INVESTIGATOR_1651], opi[INVESTIGATOR_2438], marijuana, cocaine, phencyclidine, and tricyclic antidepressants), additional tests may be performed based on the Investigator’s medical judgment and patient’s history.
bMeasured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).REDACTED obtainobtainED
o evaluo evalAC
RRbbRRRECOPY PY
CO
This document cannotnsitivsitiv
rness; ness;
use).se).beonly fonly 
ivitivitusedan
essantssan
y.y.
fftoR
ncesces(support ASTAST
dyy--IgMIgM
lized razed r
NA=rNA=r
iany anyT=asT=amarketing g
stke
maauthorization on
n fractn fractiza
uate pate pthapplication n
at
ppand ive anve andany yextensions eteropteropns
teor variations nnnon
iat
vthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 84 of 143The following additional information is to be collected ( Table 12‒5):
Table 12 ‒5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:
•History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)
•Adverse reactions to drugs
•Allergies
•Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha-1 antitrypsin 
deficiency)
•Recent travel 
•Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by [CONTACT_5071], 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug-induced liver injury
[IP_ADDRESS] Follow-up evaluation
Potential drug-induced liver injury events require follow-up monitoring as described in 
Table 12‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to baseline. Determination of stabilization is at the discretion of the Investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
12.6 Other safety measurements
12.6.1 Vital signs
The Investigator or designee should measure all vital signs (systolic and diastolic BP, 
temperature [oral, axillary, or otic], pulse rate) after the subject has been sitting for at least 
[ADDRESS_64109] should remain seated during the measurements. Body temperature should be obtained prior to dosing with IMP at study visits when IMP is administered. At 
Baseline/Day [ADDRESS_64110] pulse and BP prior to drug administration and then at REDACTED oxemioxemiD
CTE
, if don, if donDA
RCOPY atitiati
eased aeased 
C
This document2.62.6
ThThcannot iono
6161be el
n wn wuseddu
onitoronitor
line.inetoucedcedsupport w-up eup 
liany=aspa=aspmarketing nee
onsult, onsult,ng
rk
mauthorization a witha withtio
ori
utapplicationc disedis
d/or AL/or AL
or hyper hyp
ppetiteppetitcaand seaseaany ppextensions phahaorfatfavariations on
attyattytiothereof. 
UCB [ADDRESS_64111] in kilograms. The same scale should be utilized throughout the study where possible. 
12.6.3 Physical examination
The physical examination should be conducted by [CONTACT_58986] 5‒1and will include general appearance; ear, nose, and throat; eyes, hair, and 
skin; respi[INVESTIGATOR_696]; cardiovascular; GI; musculoskeletal; hepatic; neurological (including limb 
reflexes); and mental status. Findings considered clinically significant changes since the physical 
examination at the Screening Visit will be recorded as AEs.  
12.6.4 12-lead electrocardiogram
The Investigator or designee will perform the ECG. The ECGs will be read locally.
12.6.5 Tuberculosis and TB risk factor assessment and management
All subjects will be assessed for TB at Screening and at the time points specified in the Schedule 
of Assessments ( Table 5‒1)through physical examination for signs and symptoms of TB, chest 
x-ray ( Section [IP_ADDRESS] ), laboratory testing ( Section [IP_ADDRESS] ), and subject questionnaire 
(Section [IP_ADDRESS] ). 
At Screening, all subjects will have an IGRA test (QuantiFERON TB GOLD is recommended), a 
chest x-ray (unless already performed within 3 months of screening) and examination for signs 
and symptoms of TB. In addition, each subject will complete a TB questionnaire with questions 
directed at symptoms of TB and potential exposure to TB. 
Exclusion Criteria at Screening
Subjects with known TB infection, at high risk of acquiring TB infection, with LTBI*, or current 
or history of NTMB infection.
*Subjects with LTBI may enter the study only after they have completed at least [ADDRESS_64112] is defined as:
−Active TB infection or clinical signs and symptoms suspi[INVESTIGATOR_58917] (pulmonary or 
extra-pulmonary)
−History of active TB infection involving any organ system or findings in other organ 
systems consistent with TB infection, unless adequately treated and proven to be fully 
recovered upon consult with a TB specialist.
−Any evidence by [CONTACT_58987]’s medical historyt
GRA tGRA t
d withiwith
ach sach sCOPY at tat
minatiominatio
ion on [ADDRESS_64113]
isupport tion.on.
maymay eneyy
ticticany ction, ctionmarketingsubjecsubjec
ntial exntial eauthorizationon
[IP_ADDRESS].[ADDRESS_64114] (Qest (Q
n 3n 3mmapplication l b
ment aent a
e time ptime
n for n for and be rebe reany extensionshair, hair, 
udinguding
s sincesinceorme pe pvariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 86 of 143b. High risk of acquiring TB infection is defined as:
−Known exposure to another person with active TB infection within the 3 months prior to 
Screening
−Time spent in a healthcare delivery setting or institution where individuals infected with 
TB are housed and where the risk of transmission of infection is high
c. Latent TB infection (unless appropriate prophylaxis is initiated at least 8 weeks prior to study 
treatment and continued to completion of prophylaxis) is defined as:
−The absence of signs, symptoms (ie, evidence of organ-specific involvement), or physical 
findings suggestive of TB infection with a positive IGRA test (or [ADDRESS_64115] results) and a chest x-ray (or other imaging) without evidence of TB infection. If the 
result of the IGRA test is indeterminate, the particular IGRA test previously performed may be repeated once; if positive or indeterminate on retest, the subject may not be 
randomized to IMP without further evaluation, treatment and discussion with Study 
Physician, if Latent TB infection is identified. The retest must be done during the protocol-defined Screening window.
Note: If available, respi[INVESTIGATOR_58918] (Centers for Disease Control [CDC] diagnosis of LTB infection) http://www.cdc.gov/TB/topic /testing/default.htm)
d. Current or history of NTMB infection despi[INVESTIGATOR_58919].
Signs and Symptoms
The Investigator should consider all potential sites of infection when assessing for TB during the 
physical examination, and other evaluations, and based on the subject’s medical or social history. 
The most common primary focus of TB is the lung. Other sites may include gastrointestinal 
system, bone/joints, lymph glands and meninges, etc. However, in immune compromised patients and/or patients treated with TNF inhibitors, extra-pulmonary manifestations of TB are
common compared to normal population.
Some common symptoms that the subject may present are dependent on the primary focus of 
infection and may include cough, blood in sputum, night sweats, lymphadenitis, joint 
pain/swelling, spi[INVESTIGATOR_18262], headache/confusion, abdominal pain (mimicking inflammatory 
bowel disease), etc. Unusual presentations should always be considered.
Latent tuberculosis infection is defined in the “Exclusion Criteria” above. If the result of the
IGRA is indeterminate, the particular IGRA previously performed may be repeated once; if 
positive or indeterminate on retest, the subject may not be randomized to IMP without further evaluation by a TB specialist. If LTBI or active TB is identified, subject must undergo 
appropriate study specified withdrawal procedures. The retest must be done during the protocol-
defined Screening window. Laboratory diagnosis should be undertaken via mycobacteria culture media (or if available by [CONTACT_58988] [MTB] rifampin [RIF] test) and result must be negative for TB 
inducing pathogens.REDACTED pi[INVESTIGATOR_58920]
e priep r
This documentaa
approappro
dedcannos indind
ive orve or
luatiuatiberculcu
detdeusednan
, etc. etc. 
loltoal dal dsupport al al 
ms thatms tha
lude clude 
fanywithwit
popupopumarketingons, ans, 
TB is tTB is
s and mand 
hhTauthorization rior oror or
al sitel site
aapplication must almust a
CDC] dDC] 
htm)htm)andt be dbe dany jece
cussioussio
dodextensionsor
minateinate
infectinfect
iouslyously
ect mct morphphvariations udyudythereof. 
UCB [ADDRESS_64116] (eg, pulmonologist, infectious disease specialist) for further evaluation. If 
test conversion indicates LTBI, active TB, or NTMB then, per UCB TB working instructions, TB test conversion (confirmed) should be classified adequately, either as due to LTBI, active TB 
infection, or NTMB, respectively. Additional assessments (eg, blood tests or IGRA, chest x-rays, 
or other imaging) should be performed where medically relevant and documented. Such conversions should be reported to the UCB PS function.
Latent TB
In case the evaluation by [CONTACT_18405] a new LTBI during the study, a 
prophylactic TB treatment should be initiated and the IMP can be continued no sooner than 
[ADDRESS_64117] be withdrawn.
Every related action should be discussed in advance with the Medical Monitor. 
Once withdrawn from study treatment, subjects should return for the ET Visit, complete all 
ET Visit assessments, and complete a SFU Visit ([ADDRESS_64118] dose of IMP).
Active TB or NTMB infection 
Subjects who develop active TB or NTMB infection during the study must be withdrawn from 
the study. The subject must be immediately discontinued from IMP and an ET Visit must be 
scheduled as soon as possible, but no later than the next scheduled visit. The subject should be 
encouraged to keep the SFU Visit as specified by [CONTACT_760]. Treatment should be started immediately.
Note that subjects with history of NTMB or active NTMB infection are excluded from the study 
regardless of prior or current therapy for this condition. 
[IP_ADDRESS] Tuberculosis assessment by [CONTACT_58989], the TB assessment by [CONTACT_18406] (QuantiFERON TB GOLD is 
recommended) will be performed at Screening and should be repeated at Week 44, ET, and 
SFU Visits for all subjects. The test results will be reported as positive, negative, or indeterminate. UCB also recommends that a TB specialist be consulted where TB (latent or 
active) is suspected or if there are doubts regarding test results. If latent or active TB is 
identified, subject must undergo appropriate study-specified withdrawal procedures. The retest during Screening must be done during the protocol-defined Screening window.
[IP_ADDRESS] Chest x-ray for tuberculosis
A plain posteroanterior chest x-ray must be performed in the Screening Period unless one has 
been performed within [ADDRESS_64119] x-ray (or, if done, Computed Axial Tomography of the Chest) must be clear of signs of TB infection (previous or REDACTED s shs s
Visit (Visit (
NTMNTM
didCOPYe withwith
shouho
This documentti
identdent
duducannot itsts
erminrmin
ve) ive) ibeded)ded)
fofoused ct of tt of t
)w)wtobercercsupportistorystoryy
currenturren
cuany marketing MB inB in
iatelyately dy
no latero late
as spas sauthorization uld retld re
([ADDRESS_64120] should be encouraged to complete a SFU Visit ([ADDRESS_64121] dose of IMP).
If infection with NTMB is identified during the study, the same procedure as for active TB 
acquired during the study must be followed.
12.6.[ADDRESS_64122] occurred after 12 consecutive months of amenorrhea, for which there is no other obvious 
pathological or physiological cause (International Menopause Society, 2015). 
A urine pregnancy test is also required at the Baseline, Week 48, ET, and at SFU visits. 
A urine pregnancy test will also be performed at any study visit where there has been a 
delay in menses . This recommendation also applies to women of childbearing potential with 
infrequent or irregular menstrual cycles. 
Pregnancy test results (serum and urine) must be negative prior to administering IMP.
12.6.7 Assessment of suicidal ideation and behavior
Suicidal ideation and behavior will be assessed by [CONTACT_58990]-SSRS.  
This scale will be used to assess suicidal ideation and behavior that may occur during the study. 
The visits at which the eC-SSRS assessments will be performed are specified in the schedule of 
study assessments ( Section 5.2 ). 
The eC-SSRS is a standardized and validated instrument developed for the assessment of the 
severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
Subjects respond to standardized clinical questions that are presented in a uniform fashion. The eC-SSRS defines [ADDRESS_64123] to their health and safety. In this case, this action should be taken immediately, without prior notification of the regulatory authority, IRB/IEC, or 
Sponsor.
After implementation of such measure, the Investigator must notify the CPM of the Sponsor
within 24 hours and follow any local regulatory requirements.
14.2 Monitoring
UCB (or designee) will monitor the study to meet the CRO’s monitoring Standard Operating 
Procedures (SOPs), ICH-GCP guideline, and applicable regulatory requirements, and to ensure 
that study initiation, conduct, and closure are adequate. Monitoring of the study may be delegated by [CONTACT_18410] a CRO or a contract monitor.
The Investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any missing information. The Investigator(s)/institution(s) will permit direct access to source 
data/documents for study-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).
The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg, hospi[INVESTIGATOR_58921]). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities regulations, and Investigator’s obligations are being 
fulfilled, and resolve any inconsistencies in the study records.
14.2.[ADDRESS_64124] be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], printing, 
optical disc). They should not be obscured by [CONTACT_18411] (such as removable self-stick notes). Photocopi[INVESTIGATOR_58922]. Source documents are original records in which raw data are first recorded. These 
may include hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries, x-rays, laboratory results, printouts, pharmacy records, care records, ECG or other printouts, completed scales, or quality of REDACTEDd appld app
are adare ad
act moact mo
e expe expCOPY et thet the
This document All sl 
audiaudi
oocannot 1
sousoube,
nd rend reusedrifyfyttyy
applappltowill pwill 
hsupport ow UCw U
documdocum
proanyd md mmarketingpectedpecte
s to ansto an
atortor(s)/(s
monmonauthorizationCROCRO
icableicable
dequatdequat
onitornitor
dapplicationtifyifyththyyand yy
hany cac
authoauthextensions shoushou
o proteprot
caseaseor variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 91 of 143life questionnaires, for example. Source documents should be kept in a secure, limited access 
area.
Sponsor or designee will review to ensure that computerized source documents produced by [CONTACT_58991] (FDA) Part [ADDRESS_64125] be printed for review by [CONTACT_2037] (eg, ECG reports). Once printed, these copi[INVESTIGATOR_58923] a permanent part of the subject’s source documents. The Investigator will facilitate the process for enabling the monitor to compare the 
content of the printout and the data stored in the computer to ensure all data are consistent.
Electronic data records must be saved and stored as instructed by [CONTACT_18338] (or designee).14.2.[ADDRESS_64126] to being accurate, complete, and verifiable from 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], x-ray films, laboratory notes). All data reported on the eCRF should be supported by [CONTACT_58992], unless otherwise specified in Section 14.2.1 .
14.3 Data handling
14.3.1 Case Report Form completion
This study will use electronic data capture (EDC); the Investigator is responsible for prompt 
reporting of accurate, complete, and legible data in the eCRF and in all required reports.
This study will also use an electronic device (Site Tablet) to capture patient reported outcomes.Serious AE reporting will be done using the SAE Report Form (see Section 12.2.2 ) while also 
entering the event in the appropriate eCRF section. The safety database and the clinical database 
will be reconciled during the study and discrepancies will be corrected as needed.
The Investigator should maintain a list of personnel authorized to enter data into the eCRF. 
Access to the EDC will be given after training has been received. A training certificate will be 
provided and filed.
Detailed instructions on the use of the EDC will be provided in the eCRF Completion 
Guidelines.
Corrections made after the Investigator’s review and approval (by [CONTACT_3553] a 
password/electronic signature) will be re-approved by [CONTACT_737]. Any change or correction 
to the eCRF after saving must be accompanied by a reason for the change.
14.3.2 Database entry and reconciliation
Case Report Forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data. This study is performed using EDC. The data are entered into the eCRFs once and are subsequently verified.REDACTEDDCDC);)
e datae data
eviceevice
singsingCOPY n
;t
This document CaseCas
ddcannoteCRFCRF
3.23.2bem
electelectused made adeto s oosupporgivegive
on thon tanyain a ain a
enenmarketingg the Sg the S
eCRF eCRF
yyand dand yy
lauthorization the Ihe Inn
a in thin th
(Site(Siteapplication ld bandumenmen
be sbe anye, and, and
ntstextensions e).).
d. Du. Duor nt.nt.variations e ththe ethereof. 
UCB [ADDRESS_64127] Screening and Enrollment log/Subject Identification Code list
The subject’s screening and enrollment will be recorded in a Subject Screening and Enrollment 
Log.
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.
14.[ADDRESS_64128] to quality or quantity.
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the termination or suspension by [CONTACT_12942]/institution, as specified by [CONTACT_12926](s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.
14.[ADDRESS_64129] elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained for a longer period, however, if required by [CONTACT_8146](s) or by [CONTACT_58993] (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The Investigator will contact 
[CONTACT_58994]. The Investigator will also notify UCB should he/she 
relocate or move the study-related files to a location other than that specified in the Sponsor’s 
study master file.
14.6 Audit and inspection
The Investigator will permit study-related audits mandated by [CONTACT_18338], after reasonable notice, and inspections by [CONTACT_58995].REDACTEDn, in n, in
be infobe info
ororor bor b
. In ad. In ad
corcorCOPYd, UCBd, UC
orityority (i(i
a
This documentoss oss 
relorelcannot gerer
ment wment w
B forB forbe ont
r per peusedkeke
markemarke
tinutinutoetinetinsupport d CC
rding prding 
nts arets aranyadeqade
Conseonmarketing ddidi
rdancedance
data reata 
quaqauthorization(ies) (ies) 
accordccord
ormedrmed
by [CONTACT_58996]
, noncnonc
B (or it(or 
ofandtinuenue
dingingany et hetextensionsmedimedi
ct’s t’s or variations thereof. 
UCB [ADDRESS_64130] been protected, that enrolled subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.
The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
inform UCB (or designee).
14.7 Good Clinical Practice
Noncompliance with the protocol, ICH-GCP, or local regulatory requirements by [CONTACT_737], institution, institution staff, or designees of the Sponsor will lead to prompt action 
by [CONTACT_18418]. Continued noncompliance may result in the termination of the site’s involvement in the study.
15 STATISTICS
A description of statistical methods follows and will be described in more detail in the Statistical Analysis Plan (SAP).
15.1 Definition of analysis sets
The following analysis sets were defined:
The Enrolled Set (ES) will consist of all subjects who have given informed consent.The Randomized Set (RS) will consist of all randomized subjects.
The Safety Set (SS) will consist of all randomized subjects who received at least 1 dose of IMP.
The Full Analysis Set (FAS) will consist of all randomized subjects who received at least [ADDRESS_64131] a valid measurement of the primary efficacy variable at Baseline.
The Per-Protocol Set (PPS) will consist of all subjects in the FAS who had no important protocol 
deviation affecting the primary efficacy variable. The subjects with important protocol deviations will be predefined and evaluated during a data evaluation meeting prior to unblinding of the data.
The Pharmacokinetic Per Protocol Set (PK-PPS) is a subset of the FAS, consisting of those 
subjects who had no important protocol deviations affecting the pharmacokinetic variables, as confirmed during ongoing data cleaning meetings prior to database lock.
The Pharmacodynamic Per Protocol Set (PD-PPS) will consist of all randomized subjects who 
took at least [ADDRESS_64132] 1 PD measurement postdose that is without important protocol deviation affecting that time point.
The Dose-Blind Set (DBS) consists of all subjects starting the Dose-Blind Period and who 
received at least [ADDRESS_64133] Set (ESS) consists of all subjects starting the Dose-Blind Period and who 
received at least [ADDRESS_64134] 10% reduction from Baseline in PGADA and total and nocturnal spi[INVESTIGATOR_58924] 16, Week 24, or Week 36.REDACTED subjecsubjec
ist of aist of COPY 
This documentimpompo
ThThcannotharmaarma
k at leat le
ortbeduriduriusednetineti
had nhad nto icicsupport) wil) wi
primaryrima
d evald evaanyremerem
ll cllmarketing all ll 
 random rand
consisconsi
menmeauthorization cts whcts wh
lr a nranapplication ibed inbed iand any e e terteextensions by[CONTACT_58997]
d to pd to por variations atelyelythereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 94 of 143The Dose-Blind Responder Set (DBRS) consists of all subjects starting the Dose-Blind Period 
and who received at least [ADDRESS_64135] 10% reduction from Baseline in PGADA and total and nocturnal spi[INVESTIGATOR_58925] 16, Week 24, and Week 36.
15.[ADDRESS_64136] of number of available observations, arithmetic mean, SD, median, minimum, and maximum unless stated otherwise.
All statistical tests will be performed 2-sided at a 5% level of significance unless stated 
otherwise.
15.3 Planned efficacy analyses
15.3.1 Analysis of the primary efficacy variable
The primary efficacy variable will be analyzed for all subjects in the FAS.
The dose-response relationship between treatment and ASAS40 response will be assessed with 
an ordered categorical analysis using a non-parametric correlation statistic of Mantel and 
Haenszel (Mantel and Haenszel, 1959) and modified ridit scores with the corresponding p-value. The analysis will include region and prior TNF inhibitor exposure as stratification factors. Prior 
TNF inhibitor exposure will be used as stratification factor as it may have an impact on efficacy. 
The use of region as stratification factor is intended to combine study centers in similar geographic regions. The geographic regions to be used will be defined in the IXRS and in the 
SAP. The correlation between dose and ASAS40 response will be evaluated at a significance 
level of α=0.05. This evaluation of dose-response will constitute the primary efficacy analysis.
As a supportive analysis for the primary efficacy variable, a logistic regression model will be 
used to assess the effect of each individual dose versus placebo on ASAS40 response. The model
will include fixed effects for treatment, region, and prior TNF inhibitor exposure (yes/no). If the logistic regression model is unable to converge, then region may be dropped from the model to 
facilitate convergence. Comparisons will be made for each dose vs placebo at a 2-sided 
significance level of α=0.05. For each dose, the odds ratio vs placebo, the 95% confidence 
interval, and the corresponding p-value will be calculated. 
The pairwise comparisons of bimekizumab versus placebo will be formally evaluated for 
statistical significance only if the primary dose response efficacy analysis is statistically significant. Once the dose response has been established, pairwise testing of each bimekizumab 
dose versus placebo will account for multiplicity by [CONTACT_2329] a fixed sequence testing procedure 
with each bimekizumab dose being tested sequentially from the highest dose to the lowest dose. Each test will only be conducted if the previous test reaches significance at a 2-sided significance 
level of α=0.05. This procedure will control the overall Type I error rate. If the dose response 
relationship fails to reach significance at a significance level of α=0.05, then no further testing 
will be conducted and the pairwise comparisons are seen as nonsignificant.
Nonresponder imputation will be used to account for missing data in the primary analysis. That 
is, subjects with a missing ASAS40 score at Week 12 or who discontinued study treatment prior to the Week 12 visit will be considered nonresponders for the primary analysis.REDACTEDendeende
ns to bns to b
d ASAASA
oseose-rereCOPYridid
ibitor ibitor
tion fion f
d
This document achach
leveleve
rercannotersus rsus 
each each 
ht eht ebe. On. Onusedmpampa
nificaificato re
ariisupportmparmpar
=0.05. F0.05. 
esponsponany atmtm
nable nable
risimarketing espsp
aryary effieffyy
dividuavidu
mentmenauthorizationfactorfactor
d to coto co
be usee use
AS40 rS40 r
ponponapplication respoespo
tion staon st
cores wores 
exposexpo
raandFASAS
ononany extensions ed ed or variations ean, an, thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 95 of [ZIP_CODE].3.1.1 Supportive analyses
The following supportive analyses for the primary endpoint are planned: 
1. The primary dose-response analysis and pairwise comparisons will be repeated for all 
subjects in the PPS to evaluate the effect of important protocol deviations on the analysis. 
2. The primary dose response analysis and pairwise comparisons will be repeated for all 
subjects in the RS to evaluate the consistency of the FAS with the intent-to-treat (ITT) 
principle. Subjects with no valid measurement of the primary efficacy variable at Baseline 
will be included as nonresponders.
3. The primary dose response analysis and pairwise comparisons will also be repeated for all 
individual components of the ASAS40 response to explore the effect of the signs and 
symptoms of the individual components on the composite endpoint. Since all ASAS components are continuous variables (eg, change from Baseline in PGADA), and analysis of 
covariance (ANCOVA) with treatment, region, and prior TNF inhibitor exposure as fixed 
effects and the Baseline values as covariate will be used for the analysis.
Additional sensitivity analyses to evaluate the assumptions related to the handling of missing 
data for the primary efficacy variable will be performed and are described in Section 15.7 .
15.3.2 Other efficacy analyses
[IP_ADDRESS] Analysis of the secondary efficacy variablesThe secondary efficacy variables will be analyzed for all subjects in the FAS.
All categorical variables (ie, ASAS20 response and ASAS5/6) will be analyzed for treatment 
effects using pairwise comparisons based on the same method as that for the primary efficacy 
variable.
All continuous variables (ie, ASDAS-CRP, ASDAS, BASDAI, and BASFI) will be analyzed for 
treatment effects using pairwise comparisons based on an analysis of covariance (ANCOVA) 
model with treatment, region, and biologic prior treatment as fixed effects and the Baseline value as covariate.
Pairwise testing of each bimekizumab dose versus placebo will account for multiplicity by [CONTACT_2329] 
a fixed sequence testing procedure with each bimekizumab dose being tested sequentially from the highest dose to the lowest dose as described in Section 15.3.1.
Dose and exposure response will be assessed using a nonlinear mixed effects modeling to 
characterize the relationship between dose, exposure and ASAS response. The model will be partitioned into structural and stochastic models. The structural model describes the main trends 
and dependencies in the data, for example how drug concentrations depend on dose and time, or 
how ASAS response depend on drug exposure. The stochastic part of the model is further divided into the interindividual variability (IIV) and the residual unexplained variability (RUV). 
The IIV describes how individual specific parameters differ from the typi[INVESTIGATOR_58926]. The 
RUV describes the differences between the observations and the predictions from the model. Further details will be given in a separate data analysis plan and reported in a separate document.REDACTEDlyzyzeded
spponson
ased oased oCOPY fficacficac
This documenthow ow 
dividivi
TTcannotoned ined i
dependepen
wAAbep
ze thee thusedto tho t
osureosureto tin
thethesupport h bimebim
ng prng pranyand band marketing o
S-CRP-CR
omparompa
biauthorizationcyyvavyy
d for alfor al
se ande and
n the theapplication d to td to 
re desc des
araandnalalysys
ththanyororexex
isiextensionsated fted f
igns angns a
all ASall A
DA),DA),or variations ine ne thereof. 
UCB [ADDRESS_64137] date when the response is achieved. 
Subjects who discontinue study treatment prior to achieving a response will be censored at the 
date of study treatment discontinuation. Subjects who reach the Week 12 visit without achieving a response will be censored at the date of the Week 12 visit. 
The median time to response including the 2-sided 95% confidence interval will be calculated for 
each treatment. Between group differences (each bimekizumab dose vs placebo will be analyzed with the log-rank statistic.
All other efficacy variables will be analyzed using observed cases as treated and imputed with 
NRI for binary variables and multiple imputation (MI) for continuous variables (see Section 15.7 ).
Subjects in the ESS who discontinue with bimekizumab treatment during the Dose-Blind Period 
will be treated as missing and categorical/continuous variables will be imputed.
15.4 Subgroup analyses
Subgroup analyses will be performed on the primary and secondary efficacy variables. The following variables for subgroup analyses will be defined: 
•Age
•Gender
•Region
•Anti-bimekizumab antibody status
•TNF inhibitor exposure
•Concomitant synthetic DMARDs vs no concomitant synthetic DMARDs
•BASDAI (<4 [mild disease]; ≥4 to ≤7 [moderate disease]; >7 to ≤10 [severe disease])
All subgroup analyses are based on imputed data and will be summarized using descriptive 
statistics only.
15.5 Planned safety and other analyses
15.5.1 Safety analyses
All safety variables will be analyzed for all subjects in the SS. In addition, safety analyses during 
the Dose-Blind Period will be conducted on all subjects in the DBS.mekizmeki
continucontin
ss
d ond onCOPYI) I) fof
zu
This documentll 
statisstatis
11cannotASDASDA
subgsubgbemitanmitaused orrexex
nttto mababsupport bbantanany marketingn the pn the p
alysyses wesauthorization umab mab 
nuous vuous application cases acases 
contincontianderer
vs plvs plany val wval wextensionsachiechie
ensorensore
withowithoorll bell bvariations d usinusinthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 97 of 143Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA®). Adverse events will be summarized descriptively by [CONTACT_1570], primary 
system organ class, high level term, and preferred term. Additional tables will summarize AEs 
by [CONTACT_58998], AEs leading to withdrawal from the study, SAEs, and deaths. 
Treatment-emergent AEs will be defined as events that have a start date on or following the first 
administration of study treatment through the final administration of study treatment +140 days (covering the 20-week SFU Period). 
Laboratory values, urinary values, ECGs, vital signs, and extent of exposure will be presented 
descriptively by [CONTACT_1570].
15.5.2 Other analyses
Pharmacokinetic variables will be analyzed for all subjects in the PK-PPS. Pharmacodynamic 
variables will be analyzed for all subjects in the PD-PPS.
Pharmacokinetic and PD analyses including the calculation of population estimates for total body 
clearance (CL/F) and volume of distribution (V/F) will be detailed in a separate data analysis 
plan and reported in a separate document. Plasma concentration-time data of bimekizumab and 
ASAS40 responder rates will be used as the PK and PD response. If data merits, a further PK/PD analysis on other PD variables may be performed.
Bimekizumab plasma concentrations will be summarized for each treatment at each scheduled 
visit.
Anti-bimekizumab antibody status will be summarized for each treatment at each scheduled 
visit.
The biomarker data including IL-17A, IL-17F, IL-6, and IL-23 concentrations will be 
summarized for each treatment at each scheduled visit.
In addition to the PD variables, whole blood will be stored to isolate deoxyribonucleic acid 
(DNA) which may be used to examine genetic and epi[INVESTIGATOR_14364]. Analysis will include, but not be limited to genotypi[INVESTIGATOR_58927] (HLA Cw6, HLAB27, etc).
15.[ADDRESS_64138], or on the primary efficacy, key safety, or PK/PD outcomes 
for an individual subject. The criteria for identifying important protocol deviations will be 
defined within the appropriate protocol-specific document. Important protocol deviations will be reviewed as part of the ongoing data cleaning process and all important deviations will be 
identified and documented prior to unblinding to confirm exclusion from analysis sets
15.[ADDRESS_64139] with missing data or who has discontinued double-blind study treatment prior to Week 12 will be counted as a nonresponder. Continuous secondary efficacy 
variables will be imputed using MI assuming that missingness is missing at random (MAR).mm
be sume sum
AACOPY D D
mmarmar
This document enen
15.15cannowithwith
wed awed a
ntifietifiebeviduvidu
hinhiusedcol dl d
mpact pact
uallto devdevsupportto o
ing ofng of
ling ing anywhowh
examexammarketing  ILIL--1717
ach schch sc
holeholauthorization rized ized
mmarmmarapplication d in d in 
onn--timetim
ponse. ponseandation ation 
aany extensions res
harmharmorsententvariations yys s thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 98 of 143Two sensitivity analyses will be performed for the primary dose response analysis and for the 
supportive analysis (3) ( Section [IP_ADDRESS]) :
1. An analysis will be performed in which all available data at Week [ADDRESS_64140] the primary outcome data for all subjects at Week 12, 
there may still be some subjects for whom Week 12 efficacy data cannot be obtained. In this 
case, the subjects will be assumed to be nonresponders. The estimand here is the difference in outcome improvement at the planned endpoint for all randomized participants 
(Mallinckrodt, 2012). This is an estimand of effectiveness to evaluate the de facto hypothesis. 
It should be noted that this measures something different from the primary analysis and could be confounded by [CONTACT_58999] [ADDRESS_64141] prematurely discontinued study treatment will be excluded from the analysis. The same procedure described for the primary efficacy analysis of dose response will be used.
Sensitivity analyses will also be performed for the pairwise comparisons of bimekizumab doses 
versus placebo based on ASAS40 response at Week 12. The following analyses will be conducted:
1. Missing data will be imputed using MI. In MI, the missing value is replaced by a set of 
plausible values, where each value is a Bayesian draw from the conditional distribution of the missing data given the observed data. Intermittent missing data will be imputed using the 
Markov-Chain Monte Carlo [MCMC] method, followed by [CONTACT_59000]. The ASAS components will be imputed individually and then the ASAS response 
will be calculated using the complete datasets. The multiply imputed data sets will be 
analyzed using a logistic regression model with fixed effects fixed effects for treatment, region, and prior TNF inhibitor exposure. Finally, the results will be combined into a single 
inference using Rubin’s rule (Carpenter and Kenward, 2013). This procedure assumes a 
MAR pattern of missingness and corresponds to an estimand of what has been called the difference in outcome improvement if all subjects tolerated or adhered to treatment 
(Mallinckrodt et al, 2012).
2. The logistic regression model will be applied where all available data at Week 12 will be 
considered, as described in sensitivity analysis (1) for the primary dose-response efficacy 
analysis.
3. The logistic regression model will be applied where only observed data for subjects still on 
the initially randomized treatment at Week 12 will be considered, as described in sensitivity 
analysis (2) for the primary dose-response efficacy analysis.REDACTEDor theor the
e at We at W
ing Ming MCOPYwill bwill b
analyanaly
This document2. TTcannotreencnc
MallinMallin
ThThbepattepatte
ncenceused rioior
using sing 
ernernto a lo
rrTTsupportompoompo
using thsing 
ogistogisany[M[M
evaluevalumarketingMI. InMI. In
ue is a Be is a 
ed datad dat
MCMMCauthorizationysis osis o
pairwpairw
WeekWeekapplication d data odata
ubjectsubject
e excluexcl
of dof dandresuesuanyy ony on
ults ultsextensionsdiffeiff
nts ts 
e factoe facto
ryyanaanyyor . In I
ervariations r 
k 12, k 12, 
ntntthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 99 of 143For the dose/exposure response model, missing data will not be imputed. If a subject drops out, 
this will be used as a covariate in the model.
Other binary efficacy variables will be imputed using NRI and other continuous efficacy 
variables will be imputed using MI as described above.
15.[ADDRESS_64142] completed the 12 weeks Double-Blind Period. 
The objectives of this interim analysis are (i) to analyze the dose:exposure response for the 
ASAS response criteria to determine the optimal therapeutic dose(s) for subsequent studies, and 
(ii) to perform a comprehensive evaluation of all double-blind data of the study. 
For the interim analysis, the database will be locked and the treatment codes will be made 
available to UCB personnel with exception of operational staff working on the study. An interim 
report will be written. The investigators and subjects will remain blind to the assigned bimekizumab dosing regimen until the subject completes the Dose-Blind Period at Week 48. 
Safety data will be provided to an independent DMC. The DMC will review those safety data 
periodically. It is not planned for the DMC to review efficacy data, and no formal stoppi[INVESTIGATOR_58928].
15.9 Determination of sample size
A total of 285 subjects (57 in each treatment group) are planned to be randomized in this study. 
The primary efficacy analysis will be based on the FAS. While some randomized subjects may 
not be in the FAS, it is expected that this number will not impact the following calculations.
The sample size is calculated based on the ASAS40 response data from the Phase 3 studies in 
subjects with AS treated with secukinumab (MEASURE 1 and 2; Baeten et al, 2015). The 
ASAS40 response rates at Week 12 were reported to be 40% in both studies for the secukinumab 150mg dose while placebo response rates were 18% (MEASURE 1) and 9% 
(MEASURE 2). 
Based on those ASAS40 response rates and preliminary information on the bimekizumab
dose-response profile, ASAS40 response rates of 40.0%, 36.0%, 20.0%, 15.0%, and 12.0% at the 
end of a 12-week Treatment Period for bimekizumab 320mg, bimekizumab 160mg, 
bimekizumab 64mg, bimekizumab 16mg, and placebo have been assumed, respectively. Since the loading dose regimen of MEASURE 1 (iv) was different from MEASURE 2 (sc), the 
assumption for placebo response was based primarily on MEASURE 2, but with a weighting 
towards the higher placebo response rate of MEASURE 1.
The sample size for the primary objective of evaluating the dose-response relationship was 
calculated using a 2-sided test for detecting a linear trend across proportions (Nam, 1987) at a 
2-sided significance level of 0.05. Assuming [ADDRESS_64143] for detecting the overall dose response based on ASAS40 response is powered at >99% for the 
subjects with diagnosis of AS (ie, 57 subjects per group).
The sample size calculations were performed using the software nQuery Advisor® 7.0.REDACTED t grout grou
ed oned on
his nuhis nu
on ton tCOPY izeize
This document he he
calcucalcu
22cannot onon
ds theds the
e samsambe dosdo
n forn forusedTT
64mg,4mg
ose rse rtoTreatreasupport 0 respo0 resp
, ASAASAanye plae plmarketing the AShe AS
numabnuma
12 wer2 we
acaauthorization up) arep) are
n the Fthe F
mber mberapplication C will rwill 
y data, y dataand toto
Blind lind anyn then th
 the the extensionsstudistudi
will bwill b
eor the he variations r all all thereof. 
UCB [ADDRESS_64144]’s informed consent must be obtained and documented in accordance with local 
regulations, ICH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by [CONTACT_737] (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with the Investigator.
Prior to participation in the study, the written Informed Consent Form should be signed and 
personally dated by [CONTACT_423], or his/her legal representative, and by [CONTACT_28490] (Investigator or designee). The subject or his/her legal 
representative must receive a copy of the signed and dated Informed Consent Form. As part of 
the consent process, each subject must consent to direct access to his/her medical records for study-related monitoring, auditing, IRB/IEC review, and regulatory inspection.
If the Informed Consent Form is amended during the study, the Investigator (or the Sponsor, if 
applicable) must follow all applicable regulatory requirements pertaining to the approval of the amended Informed Consent Form by [CONTACT_1201]/IEC and use of the amended form.
All studies conducted at centers in the [LOCATION_002] must include the use of a Health Insurance 
Portability and Accountability Act Authorization Form.
The subject may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the Informed Consent Form. An
eCRF must not be started, nor may any study specific procedure be performed for a given subject, without having obtained his/her written consent to participate in the study.
16.[ADDRESS_64145] with him/her at all times.
16.3 Institutional Review Boards and Independent Ethics 
Committees
The study will be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.
The Investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or applicable country-specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to initiation of the study, the Investigator/UCB will forward copi[INVESTIGATOR_18280], Informed
Consent Form, IB, Investigator’s curriculum vitae (if applicable), advertisement (if applicable), REDACTED StatSta
zationzation
ent toent to
when hwhen h
nynyCOPY uiremuir
and uand u
atestes
This document f HH
ThThcannotudydywwyy
-GCP-GCP
HelsHelbe used InstInst
CCtoto kto ksupportCoCo
rd in thd in t
on and n and
keekanyificifi
onseonsmarketinghe/se/s
y studystudyy
s/her w/her w
icatcaauthorization s
mustmust
FormForm
o partiparti
/shesheapplicationryyininyy
he e InveInv
ents pents p
e of te of tand/her mher m
inspnspany his/his
nsent sent Fextensions signesigne
son won w
s/he/heor wi wvariations of of 
(or or 
withitthereof. 
UCB [ADDRESS_64146]-related documents to be used for the study to the IRB/IEC for its review and 
approval.
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by [CONTACT_59001], it may be possible for the Investigator to obtain an expedited review by [CONTACT_1201]/IEC as 
allowed.
As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study completion.
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active investigators in accordance with applicable regulatory requirements. The appropriate IRB/IEC will also be informed by [CONTACT_29539], as specified 
by [CONTACT_59002]. Where applicable, 
investigators are to provide the Sponsor (or its representative) with evidence of such IRB/IEC notification.
16.[ADDRESS_64147] privacy
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this study, all data forwarded to UCB (or designee) will be identified only by [CONTACT_18427].
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospi[INVESTIGATOR_1684] a subject’s study participation, and autopsy reports for deaths 
occurring during the study).
16.[ADDRESS_64148] 
be approved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to being implemented.REDACTEDed bed by
[CONTACT_59003]
(or it(or itCOPYtyty info infoyy
ance wnce w
This documentProtoProto
stastacannot g dud
5be occocc
durindurinused mm
resultresult
ccurcurtont
medimedsupport  that rethat r
tativeativeanyCB (oCB (marketing m and m and
orauthorizationwith awith 
the the InI
ch conh con
ts reprs reprapplication k in
the IRhe IR
rmatiomati
apandB/IEC/IE
nvolnvoanystudstudieie
CCextensionsjectect
originorigi
by[CONTACT_59004] s,s,
CCthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 102 of [ZIP_CODE] FINANCE, INSURANCE, AND PUBLICATION
Insurance coverage will be handled according to local requirements.
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreements, as applicable.
18 REFERENCES
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an 
Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med. 2015;373:2534-48.
Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, et al. Clinical and imaging 
efficacy of infliximab in HLA–B27–Positive patients with magnetic resonance imaging–
determined early sacroiliitis. Arthritis Rheum. 2009;60:946-54.
Braun J. Axial spondyloarthritis: thoughts about nomenclature and treatment targets. Clin Exp 
Rheumatol. 2012;30:S132-5.
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379-90.Braun J, Baraliakos X. Imaging of axial spondyloarthritis including ankylosing spondylitis. Ann 
Rheum Dis. 2011;70(Suppl 1):i97-103.
Braun J, Baraliakos X, Golder W, Brandt J, Rudwaleit M, Listing J, et al. Magnetic resonance 
imaging examinations of the spi[INVESTIGATOR_58929], before and after 
successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 
2003;48:1126-36.
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 
2010 update of the ASAS/EULAR recommendations for the management of ankylosing 
spondylitis. Ann Rheum Dis. 2011;70:896-904.
Braun J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin 
Rheumatol. 2002;16:573-604.
Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, et al. Efficacy of 
sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis 
and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis. 
2006;65:1147-53.
Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to 
defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing 
Spondylitis Functional Index. J Rheumatol. 1994;2:2281-5.
Carpenter JR, Kenward MG. Multiple imputation and its application. Chichester: John Wiley & 
Sons Ltd; 2013.CPMP/EWP/556/95. Points to consider on the clinical investigation of medicinal 
products other than NSAIDS for the treatment of RA. June 2004.
CPMP/ICH/135/95. Note for guidance on good clinical practice. July 2002. 
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements 
in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous orpaused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol 
Venereol. 2009;23(12):1374-82.REDACTEDn of an of 
X, BoeX, Boe
ecomecomCOPY aleit Maleit M
th ankh an
This documentSonsons
proprocannotlitis tis 
pentepente
sLLbeunctiuncti
FFused ett S, ett S,to gsupport iakosako
s with iwith
spondpondany sXmarketingmmenmmen
0:8960:[ADDRESS_64149]
iand 0.0.any nt tnt extensionsand ind i
magingaging
targtaror imivariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 103 of 143Diderichsen PM, Cox E (Quantitative Solutions BV, Breda, NL). Comparative effectiveness 
modeling of treatment in ankylosing spondylitis. Final Report. UCB Celltech; [ADDRESS_64150] 
report No.: UCB-MBMA-AS-164.
Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of 
the ASQL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 
2003;62:20-6.
Food and Drug Administration. Guidance for Industry. Drug-induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to 
defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease 
Activity Index. J Rheumatol. 1994;21:2286-91.
Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of 
subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann 
Rheum Dis. 2007;66:419-21.
Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active 
ankylosing spondylitis. Ann Rheum Dis. 2005;64:124-6.
Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of 
adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial by [CONTACT_18428]-label extension up to week fifty-two. Arthritis Rheum. 2008;58:1981-91. 
Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes 
study sleep measure. Sleep Med. 2005;6:41-4.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh KC, et al. Estimates of the 
prevalence of arthritis and other rheumatic conditions in the [LOCATION_002]. Part I. Arthritis Rheum. 2008;58:15-25.
Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewé R, van der Tempel H, Mielants 
H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis. 2003;62:127-32.
International Menopause Society. Cornwall, [LOCATION_006]: Menopause Terminology; c2015. 
http://www.imsociety.org/menopause_terminology.php. Accessed [ADDRESS_64151] Microbe. 2008;4:337–49.
Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al. Ustekinumab 
significantly improves symptoms of anxiety, depression, and skin-related quality of life in 
patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-
controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457-65. 
Lukas C, Braun J, van der Heijde D, Hermann K-G A, Rudwaleit M, Ostergaard M, et al. 
Scoring inflammatory activity of the spi[INVESTIGATOR_58930]: a multireader experiment. J of Rheum. 2007;34:862-70. REDACTED arthart
mized, mized, 
o. ArthArt
itzer Kitzer K
05;605;6COPY 66
Wong RWong
thritthri
This documentLangang
signsign
pcannot ota dta d
ine. ne. CC
gleglebeFrutoFrut
dirdiusedsocietociet
tostostopaupausupportoorenborenb
f enthefe n t h
seany marketing KL
6:41-46:41-4
e RC, GRC, 
heumheumauthorization RLRL
tis witis wi
doubdoub
hritis hritis
LL. . PsPapplication bel triael tri
LL, Ku,Kandek opk opanyNo efNo ef
penextensions pproacproac
tis Diis Dor variations ting ng 
nd nd thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 104 of 143Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an 
ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann 
Rheum Dis. 2009;68:18-24.
Mantel N, Haenszel W. Statistical aspects of the Analysis of Data From Retrospective Studies of 
Disease. J Natl Cancer Inst. 1959; 22:719-48.
Maruish ME, editor. User’s manual for the SF-36v2 Health Survey. 3rd ed. Lincoln, RI: 
QualityMetric Incorporated; 2011.
Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG. Feasibility and 
Validation of a Computer-Automated Columbia-Suicide severity Rating Scale Using Interactive 
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224-8.
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of 
rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis 
Rheum. 2010;62:1576-82.
Nam, JM. A simple approximation for calculating sample sizes for detecting linear trend in 
proportions. Biometrics. 1987;43(3):701-5.
National Research Council Panel on Handling Missing Data in Clinical Trials. The prevention 
and treatment of missing data in clinical trials. Washington DC: National Academies Press. 
2010. Ogdie A, Weiss P. The Epi[INVESTIGATOR_58931]. Rheum Dis Clin North Am. 
2015;41(4):545-68.
Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the 
bath ankylosing spondylitis indices: a prospective study. J Rheumatol. 2005;32:80-5.
Pedersen SJ, Poddubmyy D, Sorensen IJ, Loft A-G, Hindrup JS, Thamsborg G, et al. Course of 
Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac 
Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter 
Study of Adalimumab in Spondyloarthritis, as Assessed by [CONTACT_59005]. Arthritis and Rheumatology. 2016;68:418-29. 
Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet 
Dis. 2013;5:45-54.
Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. Effect of 
non-steroidal anti-inflammatory drugs on radiographic spi[INVESTIGATOR_58932]: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 2012;71:1616-22.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266-77.
Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondyloarthritis in the [LOCATION_002]: 
estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012;64:905-10.
Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral 
spondyloarthritis. Curr Opin Rheumatol. 2010;22:375-80.REDACTED of theof the
rospecrospe
en Ien IJ,J,COPYingting
oriaticoriat
This documentol
ThreThre
RRcannot 166
er K, Br K, B
umbumbbe hri
6166162sedntii--inin
itis: itis:towalwalsupportndydyloaloa
eianyda Mda Mmarketing  LofLof
d d InflaInfl
d, Doud, Do
oarthoarthauthorization c AA
e minimini
ctive stive s
ftftapplication in Clinin Clin
n DC: n DC
ArthrArthanddetectietectany extensionsInteInte
incidencide
20072007or yyaa
eraervariations andandthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 105 of 143Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, et al. The early 
disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception 
Cohort. Arthritis Rheum. 2009a;60:717-27.
Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The 
Assessment of SpondyloArthritis International Society classification criteria for peripheral 
spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25-31.
Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development
of Assessment of SpondyloArthritis international Society classification criteria for axial 
spondyloarthritis (part I): classification of paper patients by [CONTACT_18430][INVESTIGATOR_18287]. Ann Rheum Dis. 2009b;68:770-6.
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment 
of SpondyloArthritis International Society (ASAS) handbook: a guide to assess 
spondyloarthritis. Ann Rheum Dis. 2009;68(Supple 2):ii1-44.
Snaith RP, Zigmond AS. The hospi[INVESTIGATOR_56105], with the irritability-
depression-anxiety scale and the Leeds situational anxiety scale manual. 1994.
Woodworth T, Furst DE, Alten R, Bingham C, Yocum D, Sloan V, et al. Standardizing 
assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology 
Common Toxicity Criteria v.2.0. J Rheumatol. 2007;34:1401-14.
van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, et al. 
Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of 
America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis 
Rheum. 2005;52:386-94.
van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adalimumab 
effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: 
long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68:922-9.
van Tubergen A, Black PM, Coteur G. Are patient-reported outcome instruments for ankylosing 
spondylitis fit-for-purpose for the axial spondyloarthritis patient? A Qualitative and 
Psychometric Analysis. Rheum. 2015;54:1842-51.
van Tubergen A, Debats I, Ryser L, Londoño J, Burgos-Vargas R, Cardiel MH, et al. Use of a 
numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. 
Arthritis Rheum. 2002a;47:242-8.
van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment 
of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 
2002b;47:8-16.
Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary scales: a user’s 
manual; 1994.
Wells G, Li T, Maxwell L, MacLean R, Tugwell P. Determining the minimal clinically 
important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J 
Rheumatol. 2007;34:280-9.REDACTED mama
nationnation
g cling clin
rJ ,rJ ,COPYatoto
7;34:17;34:
an Man M
This documentWareWare
mmcannotrgg
gue inue in
2bb;47;47be gen Agen used scasca
um. 20m. 2toebaeba
alealesupportforfortt
RheumRheu
ats IatsanyCoteurCoteu
thethmarketing KivitzKivitz
kylylosinosi
S trial.S triaauthorization MH, MMH, M
nal Wal W
nical trical tapplication an
an V, en V, 
yy clinic clinyy
401401-1andwith tith 
nual.ualany thethextensions unc
l. The The
ess ss orcertcertvariations mentmentthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 106 of [ZIP_CODE] APPENDICES
19.1 Modified [LOCATION_001] (mNY) Classification Criteria for AS
Table 19 ‒1: Modified [LOCATION_001] (mNY) Classification Criteria for AS
Diagnosis
Clinical criteria:
a.Low back pain and stiffness for more than [ADDRESS_64152] expansion relative to normal values corrected for age and sex.
Radiologic criterion:
Sacroiliitis grade ≥[ADDRESS_64153] 1 clinical 
criterion
AS=ankylosing spondylitis; mNY=modified [LOCATION_001] Criteria
Note: A second grading of “probable ankylosing spondylitis” is part of the modified NY criteria, but it is not
applicable for this study. k
pondylondyCOCriteCriteCOPY n in 
CO
This document cannot be used to support any marketing authorization eriaria
itis” is itis” is nnapplication sociateociatetioand aany extensions nd sexnd sex
extor variations is is atithereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 107 of [ZIP_CODE].2 Markedly abnormal laboratory values
Table 19 ‒2: Definitions of markedly abnormal hematology values
Parameter (RCTC units)Markedly Abnormal Definition
Low High
Hemoglobin (g/dL) <LLN 
AND 
>2.0 decrease from baselineN/A
Hemoglobin (g/dL) <8.0 N/A
Leukocytes (total x 1000) <2.0 N/A
Lymphocytes (x 1000) <0.5 N/A
Neutrophils (x 1000) <1.0 N/A
Platelets (x 1000) <50 N/A
LLN=lower limit of normal; N/A = Not Applicable; RCTC=Rheumatology Common Toxicity Criteria
Data source: modified from Appendix Rheumatology Common Toxicity Criteria v.2.0 presented in 
Woodworth et al, 2007
aWithdrawal criteria for neutrophils is <0.5 ( Section 6.3 ).
Table 19 ‒3: Definitions of markedly abnormal biochemistry values
Parameter (RCTC units)Markedly Abnormal Definition
Low High
Alkaline Phosphatase N/A >[ADDRESS_64154]
ALT N/A >[ADDRESS_64155] N/A >[ADDRESS_64156]
Calcium (mg/dL) <7.0 >12.5
Creatinine (mg/dL) N/A >1.[ADDRESS_64157]
Glucose (mg/dL) <40 >250
Potassium (mmol/L) <3.0 >6.4
Sodium (mmol/L) <125 N/A
Total bilirubin N/A ≥[ADDRESS_64158]
Uric acid N/A ≥[ADDRESS_64159]
ALT=alanine aminotransferase; AST=aspartate aminotransferase; N/A=Not applicable; RCTC=Rheumatology 
Common Toxicity Criteria; ULN=upper limit of normalREDACTED abnoabno
AC
EDCOPY 
This document t
mmmeAAcannotSodSodn
cbeassiussi
ddbeusedse (me (m
iumiumseto mg/mgtosupport L)L)ort
g/dL)g/dLupany nymarketing eti
amamamamaauthorization ormarma
ho
aapplication nnnn CommoCommo
Criteria Criteriaand dany ny extensions AAs
N/AN/Asio
xteor ovariations nnnonthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 108 of [ZIP_CODE].3 Protocol Amendment 1
Rationale for the amendment
The purpose of this protocol amendment is the following:
•The SAE reporting fax number for the US and Canada was updated.
•The extra-articular manifestations variable was removed from the other efficacy variables, as 
these will be assessed as AEs. In addition, the other objective regarding extra-articular 
manifestations was updated to be specific to enthesitis. 
•The number of subjects to be included in the imaging evaluation was increased from 
[ADDRESS_64160] can not be demonstrated for subjects who 
are MRI-negative at Baseline. Thus, MRI-negative subjects are excluded from the substudy.
•A clarification that MRI assessments will occur at the Baseline Visit was added to all 
relevant sections.
•Criteria for the definition of AE intensity were added in response to a regulatory agency 
request. 
•All study variables have been rearranged for clarification reasons. 
In addition, minor typographical errors were corrected.
Modifications and changes
Global change #[ADDRESS_64161] been adjusted as needed.
Global change #2
The following global change was made for all visits from Week 4 (Section 8.3.3) through 
Week 44 (Section 8.4.8).
•Collect pulse and BP once after dosing (any time).
Has been changed to:
•Collect pulse and BP once after dosing (any time).REDACTEDyy were weryy
rrangerange
orsorCOPYat theat th
This document HaHacannot4 (S4 (S
ColleCollebewing wing usednge #ge #toin thin tsupport angng
thetheany gesgemarketing ed
swwereerauthorization e addeadde
d for forapplicationdemodemo
cts are ects are
BaselBaseandd thth
at Baat Baany eaturatu
hat rhatextensions om m 
performerfor
CriteCrite
and sand sor variations as as thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 109 of 143Global change #[ADDRESS_64162] been removed from the 
protocol.
•Section 19.3: PGADA (NRS)
•Section 19.4: Total spi[INVESTIGATOR_18230]
•Section 19.5: Bath Ankylosing Spondylitis Functional Index (BASFI)
•Section 19.6: Bath Ankylosing Disease Activity Index (BASDAI)
•Section 19.7: Lateral spi[INVESTIGATOR_18205]
•Section 19.8: BASMI – linear function
•Section 19.9: ShortForm (SF36) Questionnaire
•Section 19.10: MOS Sleep Scale Questionnaire
•Section 19.11: ASQoL
•Section 19.12: Tuberculosis Questionnaire
Specific changes
Change #1
Original text: 
Serious adverse event reporting
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: [PHONE_1064]
[LOCATION_003]: +[PHONE_299]
or +[PHONE_300]
Canada: +[PHONE_1063]
Email Global: [EMAIL_311]
Has been changed to:
Serious adverse event reporting (24h)
Fax Europe and Rest of the World: [PHONE_1064]
[LOCATION_003] and Canada: +[PHONE_299] or +[PHONE_300]
Email Global: [EMAIL_1108] COPY 
This document cannot tbeenbeen
aacabe mama
bused d
ailailseto CCtsupport e a
A:A:+1 +1
or +or +any and Rand Rymarketing ous advus adke
mauthorization application and any extensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 110 of 143Change #2
Section 1 Summary
Original text:
The secondary objectives of the study are to assess the efficacy of the individual dose regimens 
of bimekizumab compared to placebo, safety and tolerability, PK, PD, immunogenicity, and the 
exposure:response relationship of bimekizumab as it relates to efficacy and safety. The 
secondary efficacy variables include: Change from Baseline in Ankylosing Spondylitis Disease Activity Score  C reactive protein (ASDAS-CRP), Assessment in Axial SpondyloArthritis 
International Society 20% response criteria (ASAS20) response, Assessment in Axial 
SpondyloArthritis International Society 5 out of 6 response criteria (ASAS5/6) response, Change from Baseline in BASDAI, and Change from Baseline in BASFI, all at Week 12. Safety 
variables include incidence of adverse events (AEs) and serious adverse events (SAEs), 
withdrawal due to AEs, change from Baseline in vital signs, body weight, physical examination, ECG, and clinical laboratory variables.
Other objectives are to assess the impact on patient-reported quality of life (fatigue, sleep, and 
pain), extra-articular disease manifestations (uveitis, inflammatory bowel disease [IBD], and psoriasis), the impact of administration of bimekizumab on biological pathways relating to 
disease biology and response to therapy via candidate biomarker analysis and to enable genomic 
and proteomic analysis of subject samples and evaluation of the potential for subject stratification approaches, and to assess the impact of bimekizumab on inflammatory changes in 
the spi[INVESTIGATOR_58886] (SI) joint using magnetic resonance imaging (MRI) in a subset of 
subjects (approximately 10 subjects per treatment arm). 
Has been changed to: 
The secondary objectives of the study are to assess the efficacy of the individual dose regimens 
of bimekizumab compared to placebo, safety and tolerability, PK, PD, immunogenicity, and the exposure:response relationship of bimekizumab as it relates to efficacy and safety. The 
secondary efficacy variables include: Change from Baseline in Ankylosing Spondylitis Disease 
Activity Score C-reactive protein (ASDAS-CRP), Assessment in Axial SpondyloArthritis International Society 20% response criteria (ASAS20) response, Assessment in Axial 
SpondyloArthritis International Society 5 out of 6 response criteria (ASAS5/6) response, Change 
from Baseline in BASDAI, and Change from Baseline in BASFI, all at Week 12. Safety variables include incidence of adverse events (AEs), serious adverse events (SAEs), and 
withdrawal due to AEs as secondary safety variables and change from Baseline in vital signs, 
body weight, physical examination, ECG, and clinical laboratory variables as other safety 
variables.pactpact
gnetic gnetic 
treatmreatmCOPYte biote bi
aluatioaluat
ct ofto
This document cannotightgh
bles.les.be duedu
ht, pht pused BABA
ude incde inc
ue toettonte
ASDASDsupportproteprote
0% res% re
ernaternatany of bf 
ncludnclud
einimarketing yy are to are tyy
ebo, sabo, sa
fb i mbimauthorizationion oon 
f bimef bime
resonreson
ment arent aapplication tyy oyy
oryryboboyy
biologibiolog
markermarke
of tofand of liof lanyphyphyextensions ponseponse
2. Saf. Saf
nts (SAts (SA
sor s s variations ease ase thereof. 
UCB [ADDRESS_64163] on patient-reported quality of life (fatigue, sleep, and 
pain), extra articular disease manifestations (uveitis, inflammatory bowel disease [IBD], and 
psoriasis), the impact of administration of bimekizumab on biological pathways relating to 
disease biology and response to therapy via candidate biomarker analysis, and to enable genomic and proteomic analysis of subject samples and evaluation of the potential for subject 
stratification approaches, and to assess the impact of bimekizumab on inflammatory changes in 
the spi[INVESTIGATOR_58886] (SI) joint using magnetic resonance imaging (MRI) in a subset of subjects (approximately 10 subjects per treatment arm at Baseline). 
Change #3 
Section 2.1.1 Clinical studiesOriginal text: 
Three clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque psoriasis, RA0124 in 30 healthy volunteers, and PA0007 in 53 subjects with PsA.
Has been changed to: 
Four clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque psoriasis, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, 
and UP0031 in 12 healthy volunteers.
Change #4
Section 2.1.1 Clinical studies
The following text has been added: 
UP0031 was a Phase 1, open-label, parallel-group, randomized, single-dose study to evaluate the 
BA, PK, and tolerability of 2 different formulations of bimekizumab in healthy subjects. There 
were no treatment-emergent adverse events (TEAEs) leading to discontinuation, and no SAEs or 
fatalities were reported. 
Change #5
Section 2.1.1 Clinical studies
Original text: 
Two additional studies of bimekizumab are ongoing. RA0123 is a Phase 2a, double-blind, 
randomized, placebo-controlled, multiple dose study to evaluate the safety, PK, PD, and efficacy 
of multiple doses of bimekizumab administered as add-on therapy to stable certolizumab pegol (CZP; Cimzia
®) therapy in subjects with moderate to severe RA. UP0031 is an open-label, 
parallel-group, single-dose study designed to evaluate the relative bioavailability and tolerability
of 2 dose levels of UCB4940 (bimekizumab) given as 2 x80mg or 1x 160mg given via sc injection in healthy subjects.REDACTED ddCOPYmpletple
voluntvolunt
This documentof mof m
(C(Ccannot additiodditi
domidomibetexttextused 1 Clin Clinto support t adaanyifferffer
dverdvemarketing ded: ded: 
l, paral, par
renreauthorization teapplication d: UP0d: UP
eers, Pers, Pand0007007any39 su39 su
7i n7iextensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 112 of 143Has been changed to: 
One additional stud yof bimekizumab isongoing. RA0123 is a Phase 2a, double-blind, 
randomized, placebo-controlled, multiple dose study to evaluate the safety, PK, PD, and efficacy 
of multiple doses of bimekizumab administered as add-on therapy to stable certolizumab pegol (CZP; Cimzia
®) therapy in subjects with moderate to severe RA. UP0031 is an open label, 
parallel group, single dose study designed to evaluate the relative bioavailability and tolerability
of 2 dose levels of UCB4940 (bimekizumab) given as 2 x80mg or 1x 160mg given via sc 
injection in healthy subjects.
Change #6
Section 3.3 Other objectivesOriginal text: 
To assess extra-articular disease manifestations (enthesitis, uveitis, inflammatory bowel disease, 
and psoriasis)
Has been changed to: 
To assess the impact on extra articular disease manifestations (enthesitis, uveitis, inflammatory 
bowel disease, and psoriasis) enthesitis
Change #7
Section 4 Study Variables
Original text: 
4 STUDY VARIABLES
4.1 Efficacy variable(s)
4.1.1 Primary efficacy variable
The primary efficacy variable for this study is as follows:
•ASAS40 response at Week 12 
4.1.2 Secondary efficacy variables
The secondary efficacy variables for this study are as follows:
•Change from Baseline in ASDAS-CRP at Week 12
•ASAS20 response at Week 12
•ASAS5/6 response at Week 12
•Change from Baseline in BASDAI at Week 12 
•Change from Baseline in BASFI at Week 12REDACTED COPY 
This document•AA
•cannotnge ge 
ASASASASbe ary
ef ref rusedryy eeyy
yyeffeffyyto effeffsupportiable fable f
e at Wat Wanyiableiablemarketing authorization application ons (entns (enicaand any mmatommatextensions or variations ythereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 113 of 1434.1.3 Other efficacy variables
Other efficacy variables will be assessed as specified in Table 5‒1(analyses at all time points not 
specified in Section 4.1.1 or Section 4.2.1 are exploratory):
•ASAS40 response
•Time to ASAS40 response
•Change from Baseline in ASDAS-CRP
•ASDAS status (eg, inactive disease, moderate, high and very high disease activity)
•ASAS20 response 
•Time to ASAS20 response
•ASAS5/6 response
•Ankylosing Spondylitis Disease Activity Score major improvement (ASDAS-MI) 
•ASAS partial remission 
•Change from Baseline in BASDAI 
•Change from Baseline in BASFI 
•Change from Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
•Occurrence of extra-articular manifestations
−Uveitis flares (as determined by [CONTACT_59006], as 
appropriate)
−Inflammatory bowel disease flares (as determined by a gastroenterologist, as appropriate)
−Psoriasis disease activity
•Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index
•Physician’s Global Assessment of Disease Activity (PhGADA)
•Change from Baseline in Patient’s Global Assessment of Disease Activity (PGADA)
•Change from Baseline in total and nocturnal spi[INVESTIGATOR_18172] (NRS)
•Change from Baseline in the average of Questions 5 and 6 of the BASDAI  
•Change from Baseline in Physical Component Summary (PCS) and Mental Component 
Summary (MCS) of the SF-36 (Short-Form 36-Item Health Survey) 
•Change from Baseline in Sleep quality (Medical Outcomes Study [MOS]-12 item scale)
•Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL)REDACTED ionsons
an opan op
llCOPY pondypond
This document ••cannotChanghang
SumSumot befrofro
be usedm BaBa
om omto se
asesupport Assessmssess
eline line any he Mhe Mmarketing lares (alares (authorizationylitisylitis
phthalhthalapplication Mand t (A(any ASDASextensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 114 of 143•Change from Baseline in: 
−Spondyloarthritis Research Consortium of Canada (SPARCC) MRI index for Assessment 
of Spi[INVESTIGATOR_58892], and 
−Ankylosing Spondylitis spi[INVESTIGATOR_25342]- activity (ASspi[CONTACT_9268]-a) in the Berlin modification 
score 
•Change from Baseline in Hospi[INVESTIGATOR_5620] - Anxiety (HADS-A) and 
Hospi[INVESTIGATOR_5620] - Depression (HADS-D) scores 
•Percentage of subjects with scores below 8 in HADS-A and HADS-D (subjects with normal 
scores)
4.2 PK and PD variables
4.2.1 PK variables
The PK variables are plasma concentrations of bimekizumab, total body clearance (CL/F), and 
volume of distribution (V/F)
4.2.2 PD variables
The PD variables are concentrations of cytokines of relevance to the IL-17A/F signaling pathway 
and AS biology, and include but are not limited to IL-17A, IL-17F, IL-23, IL-6, and TNF α 
4.3 Pharmacogenomic variables
4.3.1 Genomic, proteomic, and metabolite variables
Where local regulations permit, additional blood samples will be collected from consenting 
subjects at specific time points and stored at -80°C for up to 20 years to allow for potential, exploratory analyses of genomic, genetic, proteomic, and metabolomic biomarkers relevant to 
disease biology and progression, response to therapy, and the inflammatory and immune 
response processes. 
4.4 Immunological variables
Immunological variables allow evaluation of immunogenicity as well as immunological biomarkers. 
•Anti-bimekizumab antibody detection prior to and following study treatment
•Serum complement concentrations.
•Flow cytometry analysis of key immune cell populations, including but not limited to CD3, 
CD19, CD4, CD8, and CD69 (using fluorescence activated cell sorting). 
•Cytokines and other exploratory markers  REDACTED abolitbolit
onal bonal b
storedstoredCOPY lel
L-L-17A17
This documentCCcannotwcycy
CD19,D19
CyCbe om
totousedzumum
mplempleto mabmasupport riaia
es allows alloany ableablemarketing d at d at -
etic, prtic, p
esponseponsauthorization te vare var
blood lood 
88application ce to tce to 
A, ILA, ILand dyyccyyany clearcleextensions ith ornornovariations nd thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 115 of 1434.5 Safety variables
Safety variables to be assessed as specified in Table 5‒1are as follows: 
•Incidence of AEs and SAEs
•Withdrawal due to AEs
•Change from Baseline in vital signs (blood pressure, pulse rate) and body weight 
•Standard 12-lead electrocardiogram (ECG) intervals (RR, PR, QRS, QT, and QT intervals 
corrected for heart rate using Bazett’s and Fridericia’s formulas [QTcB and QTcF]), 
including changes from Baseline Electrocardiogram (ECG) variables 
•Change from Baseline in clinical laboratory variables (hematology, biochemistry, and 
urinalysis)
Has been changed to:
4 STUDY VARIABLES
4.1 Primary variable(s)
4.1.1 Primary efficacy variable
The primary efficacy variable for this study is as follows:
•ASAS40 response at Week 12 
4.2 Secondary variables
4.2.1 Secondary efficacy variables
The secondary efficacy variables for this study are as follows:
•Change from Baseline in ASDAS-CRP at Week 12
•ASAS20 response at Week 12
•ASAS5/6 response at Week 12
•Change from Baseline in BASDAI at Week 12 
•Change from Baseline in BASFI at Week 12REDACTED eses
r thirt h iCOPY llowslows
This document cannot be used BaBtoaselasesupportWeekWeek
eline inine in
iany 1212
kk1marketing is studs stud
ASS--CRCRauthorization application and any extensions istrystryor variations vals als thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 116 of 1434.2.2 Secondary safety variables
Assessment time points for safety variables are specified in Table 5‒1. Variables are as follows: 
•Incidence of AEs and SAEs
•Withdrawal due to AEs
4.3 Other variables
4.3.1 Other efficacy variables
Assessment time points for the other efficacy variables are specified in Table 5‒1(analyses at 
all time points not specified in Section 4.1.1 or Section 4.2.1 are exploratory). Variables are as 
follows:
•ASAS40 response
•Time to ASAS40 response
•Change from Baseline in ASDAS-CRP
•ASDAS status (eg, inactive disease, moderate, high and very high disease activity)
•ASAS20 response 
•Time to ASAS20 response
•ASAS5/6 response
•Ankylosing Spondylitis Disease Activity Score major improvement (ASDAS-MI) 
•ASAS partial remission 
•Change from Baseline in BASDAI 
•Change from Baseline in BASFI 
•Change from Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI)
•Occurrence of extra articular manifestations
Uveitis flares (as determined by [CONTACT_59006], as 
appropriate)
−Inflammatory bowel disease flares (as determined by a gastroenterologist, as appropriate)
Psoriasis disease activity
•Change from Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index
•Physician’s Global Assessment of Disease Activity (PhGADA)
•Change from Baseline in Patient’s Global Assessment of Disease Activity (PGADA)
•Change from Baseline in total and nocturnal spi[INVESTIGATOR_18172] (NRS)
•Change from Baseline in the average of Questions 5 and 6 of the BASDAI  REDACTED vityvityScSyy
AIAICOPY 
This documentPP
••cannot soro
Changhang
PhPhbe oriasoriasbused e)e)
mmatomatoseto ))ts(as das upport rticularticulor
(as deas dsuanyBBath Aath marketing I 
SFI FI authorization core mcore mapplication yy high highyyand any extensionsables blesorysyseevariations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 117 of 143•Change from Baseline in Physical Component Summary (PCS) and Mental Component 
Summary (MCS) of the SF-36 (Short-Form 36-Item Health Survey) 
•Change from Baseline in Sleep quality (Medical Outcomes Study [MOS]-12 item scale)
•Change from Baseline in Ankylosing Spondylitis Quality of Life (ASQoL)
•Change from Baseline in: 
−Spondyloarthritis Research Consortium of Canada (SPARCC) MRI index for Assessment 
of Spi[INVESTIGATOR_58892], and 
−Ankylosing Spondylitis spi[INVESTIGATOR_25342]- activity (ASspi[CONTACT_9268]-a) in the Berlin modification 
score 
•Change from Baseline in Hospi[INVESTIGATOR_5620] - Anxiety (HADS-A) and 
Hospi[INVESTIGATOR_5620] - Depression (HADS-D) scores 
•Percentage of subjects with scores below 8 in HADS-A and HADS-D (subjects with normal 
scores)
4.3.2 Other safety variables
Assessment time points for other safety variables are specified in Table 5‒1. Variables are as 
follows: 
•Change from Baseline in vital signs (blood pressure, pulse rate) and body weight 
•Standard 12-lead electrocardiogram (ECG) intervals (RR, PR, QRS, QT, and QT intervals 
corrected for heart rate using Bazett’s and Fridericia’s formulas [QTcB and QTcF]), 
including changes from Baseline Electrocardiogram (ECG) variables 
•Change from Baseline in clinical laboratory variables (hematology, biochemistry, and 
urinalysis)
4.3.3 Other PK and PD variables
•The PK variables are plasma concentrations of bimekizumab, total body clearance (CL/F), 
and volume of distribution (V/F).
•The PD variables are concentrations of cytokines of relevance to the IL-17A/F signaling 
pathway and AS biology, and include but are not limited to IL-17A, IL-17F, IL-23, IL-6, and 
TNFα. 
4.3.4 Other immunological variables
Immunological variables allow evaluation of immunogenicity as well as immunological 
biomarkers. 
•Anti-bimekizumab antibody detection prior to and following study treatment
•Serum complement concentrations.
•Flow cytometry analysis of key immune cell populations, including but not limited to CD3, 
CD19, CD4, CD8, and CD69 (using fluorescence activated cell sorting). 
•Cytokines and other exploratory markers  REDACTEDd prepr
ECG) iCG) i
t’s andt’s and
e Electe ElectCOPY spsp
ressres
This document omom
••cannot hehe
unolounolo
markmarbe ereriiusedd ASAStoes aes a
bbsupportplasmlasm
ributionbutiopp
areareany ablab
mamarketingtrocroc
laboratlabora
esauthorization sure, pure, p
intervnterv
d FridFrid
ocarcarapplication ified infied iand --DDany D (suD( sextensionsificafica
yy(HA(HAyyor atitivariations ment ment thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 118 of 1434.3.5 Other pharmacogenomic, proteomic, and metabolite variables
Where local regulations permit, additional blood samples will be collected from consenting 
subjects at specific time points and stored at -80°C for up to 20 years to allow for potential, 
exploratory analyses of genomic, genetic, proteomic, and metabolomic biomarkers relevant to disease biology and progression, response to therapy, and the inflammatory and immune 
response processes. 
Change #8
Section 5.1.2 Double-Blind Period
Original text: 
At Baseline/Day 1, subjects will be randomized 1:1:1:1:1 (stratified by [CONTACT_59007]) to receive the following blinded IMP treatment regimens at the clinical site. 
The enrollment of TNF inhibitor-experienced subjects will be limited to approximately 30% of 
the total study population. Therefore, each arm will have approximately 18 TNF inhibitor experienced subjects in a total of 57 subjects per arm.
Has been changed to:
At Baseline/Day 1, subjects will be randomized 1:1:1:1:1 (stratified by [CONTACT_59007]) to receive the following blinded IMP treatment regimens at the clinical site. 
The enrollment of TNF inhibitor-experienced subjects will be limited to approximately 30% of 
the total study population. Therefore, each arm will have approximately 18 TNF inhibitor 
experienced subjects in a total of 57 subjects per arm.
Change #9
Section 5.1.7 Radiographic evaluationOriginal text: 
5.1.7 Radiographic evaluation
In a subpopulation of AS0008, MRIs of the spi[INVESTIGATOR_58894] 10 subjects per treatment arm at Baseline, Week 12, and Week 48. Analyses will 
be exploratory in nature and will be performed at selected sites.
Has been changed to:
5.1.7 Imaging evaluation
In a subpopulation of AS0008, MRIs of the spi[INVESTIGATOR_58894] 20subjects per treatment arm at Baseline. Magnetic resonance imaging at
Week 12 and Week 48 will be performed only for subjects who are MRI-positive at Baseline
based on an ASAS-Outcome Measures in Rheumatology Clinical Trials (OMERACT) 
assessment. The Baseline MRI should be performed after confirmation of eligibility for the study based on screening assessments and before the first bimekizumab injection. Magnetic 
resonance imaging at Week 12 and Week 48 should be performed as close to the 
Week 12/Week 48 Visit as possible. Further details are provided in Section 9.15. Analyses 
will be exploratory in nature and will be performed at selected sites.REDACTEDsubjsub
arm warm wTEjects pects ACCOPY:1:1:11:1:
ded Ided I MM
bjecbje
This documentapproppr
WeeWe
bbcannotmagag
subposubp
roxroxbe ch
ginginsedn natna
hanghantoubjeubj
atuatusupportaluatlua
AS000AS00
jectectany atiotimarketing valuataluaauthorizationMP trMP t
cts wits w
will haill harizper armer arthoapplication  (strati(strat
treatreaandtelyely11yyanyns ans 
approappro
8extensions n and pand p
at tat tor variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 119 of 143Change #10
Section 5.2 Table 5-1, footnote d
Original text: 
dAt Baseline/Day [ADDRESS_64164] pulse and BP prior to drug administration and once after dosing (any time). All other procedures are done prior to dosing. 
Has been changed to:
dAt Baseline/Day [ADDRESS_64165] pulse and BP prior to drug administration and once after dosing (any 
time). All other procedures are done prior to dosing. 
Change #11
Section 5.2 Table 5-1, footnote n and p
Original text: 
nAn MRI of the spi[INVESTIGATOR_58897] a subpopulation of approximately 10 subjects per 
treatment arm for exploratory purposes at Screening, Week 12, and Week 48. The MRI will be read centrally. 
pThe minimum time between doses during the Double-Blind Period should be no less than 26 days and no more 
than 30 days and during the Dose-Blind Period should be no less than 24 days and no more than 32 days.
Has been changed to:
nAn MRI of the spi[INVESTIGATOR_58897] a substudy with approximately 20 subjects per treatment arm at Screening Baseline . A central reader will assess Baseline MRIs to identify MRI-positive 
subjects as per the ASAS-Outcome Measures in Rheumatology Clinical Trials (OMERACT) criteria. An 
MRI at Week [ADDRESS_64166] bimekizumab injection. Magnetic resonance imaging at Week 12 and Week 48 
should be performed as close to the Week 12/Week 48 Visit as possible. For logistical reasons, it may not be possible to schedule the MRIs at the actual visit date and an additional visit for the MRI may be required.
pThe minimum time between doses during the Double-Blind Period should be no less than 25days and no more 
than 31days and during the Dose-Blind Period should be no less than 24 days and no more than 32 days.REDACTED ll be pell be p
entral entral 
asurasuCOPYPeriodPerio
e no lese no le
This document cannot be used to ngsupport s ata
een dosen do
g the Dthe Danyhe Whe W
t thett hmarketing rearea
res in Rres in R
erformerform
fter coner c
mmab inab authorizationss thath
erformform
adeadeapplicationation oftion o
ek48. T48. 
shouldshoul
han 2an 2and any extensionsdosindosiores anes a
ingngvariations nddthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 120 of 143Change #12
Section 6.2 Inclusion criterion 11
Original text: 
11. Subjects taking sulfasalazine (up to 3mg/day)  or hydroxych loroquine (up to 400mg per day 
total) are allowed to continue their medication if started at least [ADDRESS_64167] 8 weeks before randomization. Dose and dosing schedule 
should remain stable up to Week 16.  
Has been changed to: 
11. Subjects taking sulfasalazine (up to 3m g/day) or hydroxychl oroquine (up to 400mg per day
total) are allowed to continue their medication if started at least [ADDRESS_64168] 8 weeks before randomization. Dose and dosing schedule 
should remain stable up to Week 16
Change #13
Section 6.2, Inclusion criterion 12
Original text: 
12. Subjects may be TNF inhibitor-naïve or may have received [ADDRESS_64169]: 
−experienced an inadequate response to previous treatment given for at least 3 months 
−been intolerant to administration (eg, had a side effect/AE that led to discontinuation) 
−lost access to TNF inhibitor for other reasons
Has been changed to: 
12. Subjects may be TNF inhibitor-naïve or may have received [ADDRESS_64170]: 
−experienced an inadequate response to previous treatment given for at least 3 months
12 weeks
−been intolerant to administration (eg, had a side effect/AE that led to discontinuation) 
−lost access to TNF inhibitor for other reasons
Change #14
Section 6.2 Exclusion criterion 3
Original text: 
3. Subjects participating in another study of a medication or a medical device under 
investigation within the last [ADDRESS_64171] 5 half-lives whichever is greater.REDACTED slysly
e to pe to p
on (egon (e
forforCOPY have rhave 
mum
This document Secec
OrOrcannot nge #ge #
ctioctiobe acccusedoleralera
cesscessto ansupport F iF i
inadeqnadeqanytortor
inhibnhmarketing g
other rother 
nauthorizationreceece
ust hast ha
previoueviou
, hadhadapplication ceiveeivand any extensions 0mg p0mg p
rior to or to
osing ssing or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 121 of 143Has been changed to:
3. Subjects participating in another study of a medication or a medical device under 
investigation within the last [ADDRESS_64172] 5 half-lives whichever is greater.
Change #15
Section 6.2 Exclusion criterion 10
Original text: 
10. Subjects with known history of or current clinically active infection with Histoplasma, 
Coccidiodes, Paracoccidioides, Pneumocystis, nontuberculous mycobacteria (NTMB), 
Blastomyces, or Aspergillus or current active Candidiasis (local or systemic).
Has been changed to:
12. Subjects with known history of or current clinically active infection with Histoplasma, 
Coccidio ides, Paracoccidioides, Pneumocystis, nontuberculous mycobacteria (NTMB), 
Blastomyces, or Aspergillus or current active Candidiasis (local or systemic).
Change #16
Section 6.3 Withdrawal criterion 8
Original text: 
8. Subject develops laboratory abnormalities (with or without clinical symptoms) of ALT or 
AST as defined in Section 6.3.1 ; neutropenia <0.5x109/mL; lymphopenia <0.5x109/mL. Any 
laboratory value or change judged to be clinically significant by [CONTACT_737], and/or any lab values meeting the Rheumatology Common Toxicity Criteria (RCTC) Grade 4 criteria 
(with the exception of neutrophils which will be permitted with the above withdrawal 
criterion [neutropenia <0.5x10
9/mL]; Table 19‒2and Table 19‒3) must be discussed with the 
medical monitor before the subject is dosed again. (Refer to Section 6.3.1 for withdrawal 
criteria in relation to potential drug-induced liver injury [PDILI].)
Has been changed to: 
8. Subject develops laboratory abnormalities (with or without clinical symptoms) of ALT or 
AST as defined in S ection 6.3.1; neutropenia <0.5x109/mL; lymphopenia <0.5x109/mL. Any
laboratory value or change judged to be clinically significant by [CONTACT_59008]. For clarification, 
laboratory values that are markedly abnormal as per Table 19-2 and Table 19 ‒3 will be 
flagged to the Investigator and to the medical monitor but do not trigger mandatory withdrawal unless listed above and/or any lab values meeting the Rheumatology Common 
Toxicity Criteria (RCTC) Grade 4 criteria (with the exception of neutrophils, which will be 
permitted with the above withdraw criterion [neutropenia <0.5x109/mL]; Table 19 2 and 
Table 19 3) must be discussed with the medical monitor before the subject is dosed again
(Refer to Section 6.3.1 for withdrawal criteria in relation to potential drug induced liver 
injury [PDILI].)lities (ties (
eutropeutrop
ed to bed to b
llCOPY 
This documentwwcannotmptp
boratoorato
flaggeflagg
wiibe ryyy
t cot cosedpp
fined ined i
yvaluvalytops laps lasupportotenttent
to: to: 
abbanye subje sub
tiatimarketing be clbe c
ogyogy CoCyy
hils whils wh
0099/mL/mauthorization (with (with 
penia <enia 
cliliapplicationcal al andmymycoco
lo rorany with Hwith
babextensions asm
NTMBNTMB
c)..or ma, ma,variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 122 of 143Change #17
Section 7.3 Packaging
The following text has been added: 
Bimekizumab and placebo will be packaged and labeled according to Good Manufacturing 
Practice (GMP) guidelines and applicable laws or regulations. They will be suitably 
packaged in such a way as to protect the product from deterioration during transport and 
storage. Further information regarding storage and transport conditions are provided in the IMP Handling Manual.
Change #18
Section 7.8.2 Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014]), 
Table 7-1
Original text: 
Drug class Dose Exclusion criteria
Analgesics, including opi[INVESTIGATOR_2467] 
(acetaminophen/paracetamol, etc)Any dose Any ad hoc use in the 24 hours prior to any 
study visit. 
Stable doses of analgesics permitted.
NSAIDs/COX-2 inhibitors Any dose regimen Any change in dose/dose regimen in the 
14 days prior to the Baseline Visit
Oral corticosteroids Any dose regimen Any change in dose/dose regimen in the 
28 days prior to the Baseline Visit
Intramuscular (im)/intravenous (iv)/intra-articular (ia) corticosteroids/bursal corticosteroids Any dose Use in the 28 days prior to the Baseline 
Visit. 
Intra-articular hyaluronic acid Any dose Any use in the 6 months prior to the 
Baseline Visit. 
DMARDs:-azathioprine
-cyclosporine,-cyclophosphamide,-mycophenolic acid,-mycophenylate mofetil
-any other small molecule DMARDs 
(eg tofacitinib, apremilast)Any dose Use within 12 weeks prior to the Baseline 
Visit.
MTX Any dose regimen Use within 12 weeks prior to the Baseline 
Visit unless Inclusion Criterion # 10is met
SSZ Any dose Use within 12 weeks prior to the Baseline 
Visit unless Inclusion Criterion # 11is met
HCQ Any dose Use within 12 weeks prior to the Baseline 
Visit unless Inclusion Criterion # 11is metREDACTEDegimeegim
Any dosny dosDACOPY C
This document MTXMTXt
umuuucannotenylanyla
ther smher sm
tofacitofacicbelic aclic ac
ateateused ide,de,to support upany yanmarketing se
Any dAnyke
mauthorization n
nion
e regimregiuthapplication on cn c
y ad hocad ho
study viudy v
StaSio
aand crcranany extensions d thed theor variations nd d 
d in in thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 123 of 143Drug class Dose Exclusion criteria
DMARDs:-leflunomide Any dose Use in the 6 months prior to the Baseline 
Visit unless a cholestyramine washout has 
been performed; in which case, use up to 
28 days prior to the Baseline Visit is acceptable. 
TNF inhibitors-infliximab (IFX)-adalimumab (ADA)-etanercept (ETN)-golimumab (GOL)
-certolizumab pegol (CZP)Any dose For IFX, ADA, GOL, and CZP, any use 
within the 3 months prior to the Baseline Visit
For ETN, use within the 28 days prior to 
the Baseline Visit.
This applies to biosimilar versions of any 
TNF inhibitors.
Has been changed to: 
Drug class Dose Exclusion criteria
Analgesics, including opi[INVESTIGATOR_2467] (acetaminophen/paracetamol, etc)Any dose Any ad hoc use in the 24 hours prior to any 
study visit. 
Stable doses of analgesics permitted.
NSAIDs/COX-2 inhibitors Any dose regimen Any change in dose/dose regimen in the 
14 days prior to the Baseline Visit
Oral corticosteroids Any dose regimen Any change in dose/dose regimen in the 28
14days prior to the Baseline Visit
Intramuscular (im)/intravenous (iv)/
intra-articular (ia) corticosteroids/bursal corticosteroids Any dose Use in the 28 days prior to the Baseline 
Visit. 
Intra-articular hyaluronic acid Any dose Any use in the 6 months prior to the 
Baseline Visit. 
DMARDs:-azathioprine
-cyclosporine,
-cyclophosphamide,-mycophenolic acid,-mycophenylate mofetil-any other small molecule DMARDs 
(eg tofacitinib, apremilast)Any dose Use within 12 weeks prior to the Baseline 
Visit.
MTX Any dose regimen Use within 12 weeks prior to the Baseline 
Visit unless Inclusion Criterion # 10is met
SSZ Any dose Use within 12 weeks prior to the Baseline 
Visit unless Inclusion Criterion # 11is metREDACTED ose regse reTE
AnyAnRECOPY 
This document ny y
(eg toeg to
mMMmmeumcannot phaph
henolicenolic
ophenphen
othothbe ,
hamihamiused to tosupport cid id poany ursal rsal ymarketing y dose rdose rg
mAmmmamauthorization n
gimengimenizapplication clusionusioion
Any adAny 
studstulic
aand any yextensionss priopri
lar verar veror orvariations e atithereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 124 of 143Drug class Dose Exclusion criteria
HCQ Any dose Use within 12 weeks prior to the Baseline 
Visit unless Inclusion Criterion # 11is met
DMARDs:
-leflunomide Any dose Use in the 6 months prior to the Baseline 
Visit unless a cholestyramine washout has been performed; in which case, use up to 28 days prior to the Baseline Visit is acceptable. 
TNF inhibitors-infliximab (IFX)
-adalimumab (ADA)
-etanercept (ETN)-golimumab (GOL)-certolizumab pegol (CZP)Any dose For IFX, ADA, GOL, and CZP, any use 
within the 3 months 12 weeks prior to the 
Baseline Visit
For ETN, use within the 28 days prior to 
the Baseline Visit.
This applies to biosimilar versions of any 
TNF inhibitors.
Change #19
Section 8.1 Screening (Visit 1)
The following paragraphs have been added: 
Subjects who initially fail to meet selected eligibility criteria (including but not limited to 
documented completion of LTBI prophylactic therapy) or for whom eligibility assessments 
could not be completed as planned may be rescreened once after discussion with the 
Medical Monitor.
The MRI (done at selected sites) can be performed prior to the Baseline (Day 1, first dose of 
IMP, Visit 2) if eligibility is confirmed based on screening assessments, and before the first 
dose of IMP.
Change #20
Section 8.2 Baseline (Day 1, first dose of IMP) (Visit 2)
Original text:
•Obtain MRI of spi[INVESTIGATOR_58904]. 
Has been changed to: 
•Obtain MRI of spi[INVESTIGATOR_58904]. The 
Baseline MRI should be performed after confirmation of eligibility based on screening 
assessments for the study and before the first bimekizumab injection.REDACTED addeadde
ected ected 
prophyproph
dmdmCOPY 
This document ••cannottain Main M
s bes bebeextextusedBaselase
t:t:to isupport any s) )
confirconfimarketing ylayla
may be ay be
) cancaauthorization ed: d: 
eligibeligib
actiactiapplication and b
ors.s.
anany iosimiosimiextensions rior or 
e 28 da28 daor useus
rt otovariations ati
sesearthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 125 of 143Change #21
Section 8.3.5 Week 12 (+/-3 days) (Visit 7)
Original text: 
The following procedures of assessments will be completed prior to administration of IMP:
…
•Obtain MRI of spi[INVESTIGATOR_58933]. 
…
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing (any time).
Has been changed to: 
The following procedures of assessments will be completed prior to administration of IMP:
…
•Obtain MRI of spi[INVESTIGATOR_58905]-positive at Baseline. Magnetic resonance imaging at Week 12 
should be performed as close to the Week 12 Visit as possible.
…
The following procedures of assessments will be completed following administration of IMP:
•Collect pulse and BP once after dosing (any time pulse and BP to be collected 30 minutes 
and 1 hour after dosing).
Change #22
Section 8.4.9 Week 48 (+/-4 days) (Visit 16)Original text: 
•Obtain MRI of spi[INVESTIGATOR_58933]. REDACTED nts wilnts wil
dosindosinCOPY e su s
agnetiagnet
12 V12 V
This document cannot be used tospi[INVESTIGATOR_58934](+/-4+/-
neany -44dmarketing ng (ng (anagauthorizationc
Visit aVisit a
ll be c be capplication ect is pct is 
c resoresoand admiadmiany extensions ration tionor variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 126 of 143Has been changed to: 
•Obtain MRI of spi[INVESTIGATOR_58905]-positive at Baseline. Magnetic resonance imaging at Week 48 
should be performed as close to the Week 48 Visit as possible.
Change #23
Section 9.1 ASAS20, 40, ASAS 5/6 response, and ASAS partial remissionOriginal text: 
The ASAS 5/[ADDRESS_64173] 20% improvement in 5 of 6 domains, including 
spi[INVESTIGATOR_18171] (lateral spi[INVESTIGATOR_18205]) and CRP as more objective measures (Brandt et al, 2004).
Has been changed to: 
The ASAS 5/[ADDRESS_64174] 20% improvement in 5 of 6 domains, including 
spi[INVESTIGATOR_18171] (lateral spi[INVESTIGATOR_18205]) and hs-CRP as more objective measures (Brandt et al, 
2004).
Change #24
Section 9.7 Spi[INVESTIGATOR_58935]: 
Lateral spi[INVESTIGATOR_58936]’s heels and back resting against the wall with 
no flexion in the knees and no bending forward. The subject lets the arm hang normally with the palm of the hand resting against the outer thigh and the fingers extended. A mark is drawn on the 
thigh at the tip of the middle finger. The subject is then asked to bend sideways without bending 
the knees or lifting the heels, while sliding the hand down the thigh. At the point of furthest reach, another mark is drawn at the tip of the middle finger. The distance between the first and 
second mark is measured to the nearest 0.1cm. An alternative method is to measure the distances 
to the [ADDRESS_64175] the difference. The better of 2 tries is recorded for left and right separately. The mean of the left and right is reported for lateral spi[INVESTIGATOR_18191] (in cm to 
the nearest 0.1cm) (Sieper et al, 2009) (Appendix Section 19.7).
Has been deleted. 
Change #25
Original text: 
Section 9.10 BASFI
The BASFI is described in Section 9.4 above.
Has been deleted. REDACTED he subjhe subj
g forwg forw
outerouter
ThThCOPY 
This document ecec
ThThcannot #
nal tnal t
ctioctiobe #2#255usedtededto S
ddsupport r andan
he meae mea
ieper eper any h
e neae ne
drdmarketing r thigthig
he subjhe sub
slidingslidin
he tip e tipauthorization ject’s ject’s
ward. Tard. T
ghhapplication ande meameaany  domdomextensions incluinclu
andt endt eor variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 127 of 143Change #26
Section 9.12 Extra-articular manifestations
Original sections and text:
Information regarding uveitis, enthesitis, inflammatory bowel disease, and psoriasis disease 
activity will be captured. Enthesitis is assessed via MASES.
Section 9.13 MASES
The MASES is an index that measures the severity (ie, intensity and extent) of enthesitis through 
the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac 
spi[INVESTIGATOR_050], posterior iliac spi[INVESTIGATOR_050], iliac crest and proximal insertion of the Achilles tendon sites, and the 
fifth lumbar vertebral body spi[INVESTIGATOR_18239]) (Heuft-Dorenbosch et al, 2003) each scored as [ADDRESS_64176] been merged and changed to: 
Section 9.12 Extra artucilar manifestations
Information regarding uveitis, enthesitis, inflammatory bowel disease, and psoriasis disease 
activity will be captured. Enthesitis is assessed via MASES.
Section 9.10 MASES
Enthesitis is assessed with MASES. The MASES is an index that measures the severity (ie, 
intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral 
costochondral 1, costochondral 7, anterior superior iliac spi[INVESTIGATOR_050], posterior iliac spi[INVESTIGATOR_050], iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spi[INVESTIGATOR_58937]) (Heuft-Dorenbosch et al, 2003) each scored as 0 or 1 and then summed for a possible 
score of 0 to 13.
Change #27
Section 9.12 PhGADA
Original text: 9.[ADDRESS_64177] to their AS signs and 
symptoms and functional capacity (considering both joint and skin components) using an NRS in which 0=very good, asymptomatic and no limitations of normal activities and 100=very poor, 
very severe symptoms which are intolerable and inability to carry out normal activities.REDACTEDe assee asse
r supersuper
tendonendon
003) e003) eCOPY ES is ES is
This document cannot vev
evereverebe nd
eryerygyysedor wilr wil
d fund funto support any marketingeachachauthorizationan inan in
ssmenssmen
rior rior ilil
n sitesn sites
hshsapplicationseaseseaseon
dand any extensions perieri
n sitessites
ch scoh scoor thth
ioriorvariations hrouhrouthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 128 of 143Has been changed to: 
9.[ADDRESS_64178] to their AS signs and 
symptoms and functional capacity (considering both joint and skin components) using an NRS in which 0=very good, asymptomatic and no limitations of normal activities and 100 10=very poor, 
very severe symptoms which are intolerable and inability to carry out normal activities.
Change #28
Original text: 
Section 9.15 Total and nocturnal spi[INVESTIGATOR_58938] 9.3.
Has been deleted. 
Change #29
Section 9.15 MRI Assessment (SPARCC and ASspi[CONTACT_9268]), paragraph 2Original text: 
9.19 MRI Assessment (SPARCC and ASspi[CONTACT_9268])
An MRI of the spi[INVESTIGATOR_58897] a substudy with approximately 
10 subjects per treatment arm at Screening, Week 12, and Week 48. Additional details for 
standardized performance and processing of MRIs will be provided in an MRI manual. The 
MRIs will be read centrally by [CONTACT_59009] a charter for independent imaging assessment.  
Has been changed to:
9.15 MRI Assessment (SPARCC and ASspi[CONTACT_9268])
An MRI of the spi[INVESTIGATOR_58897] a substudy with approximately 
20 subjects per treatment arm at Screening Baseline. A central reader will assess Baseline 
MRIs to identify MRI-positive subjects as per the ASAS-Outcome Measures in 
Rheumatology Clinical Trials (OMERACT) criteria. An MRI at Week [ADDRESS_64179] bimekizumab injection. Magnetic resonance imaging at 
Week 12 and Week 48 should be performed as close to the Week 12/Week [ADDRESS_64180] fortoMRIMRsupport SP
d sacrosacr
ment arent ar
IIpany PAPARCRCmarketingof
who arwho a
ordirding ngauthorization RI)RI)
e perfoperfo
Week 1eek 1
f MRMRapplication MRI), pMRI), and any extensions n 9.3.9.3or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 129 of 143Change #30
Section 12.1.5 Description of adverse events
Original text:
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Any discrepancies between the subject’s own words 
on his/her own records (eg, diary card) and the corresponding medical terminology should be clarified in the source documentation.
Details for completion of the Adverse Event eCRF (including judgment of relationship to IMP) 
are described in the eCRF Completion Guidelines.
Has been changed to:
When recording an AE, the Investigator should use the overall diagnosis or syndrome using standard medical terminology, rather than recording individual symptoms or signs. The eCRF and source documents should be consistent. Any discrepancies between the subject’s own words 
on his/her own records (eg, diary card) and the corresponding medical terminology should be 
clarified in the source documentation.
When recording the intensity of an AE in the eCRF (ie, mild, moderate, or severe), the 
Investigator should use the following criteria:
•Mild: the subject is aware of the sign or symptom (syndrome), but it does not interfere 
with his/her usual activities and/or is of no clinical consequence
•Moderate: the AE interferes with the usual activities of the subject or it is of some 
clinical consequence
•Severe: the subject is unable to work normally or to carry out his/her usual activities, or 
the AE is of definite clinical consequency
Details for completion of the Adverse Event eCRF (including judgment of intensity and
relationship to IMP) are described in the eCRF Completion Guidelines.REDACTED or symor sym
is of nis of 
ith theith thCOPYCRF (iCRF (
This document cannot be used to support e Ae A
describescriany l c
AdveAdvemarketing e ue u
to woro wo
consconauthorization mptommptom
no clino cli
usuusuapplication we
medicaledica
e, mile, miandomsoms
een een anyor syor sy ny
so roextensionship tohip toor variations rds ds 
be e thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 130 of 143Change #31
Section 12.5 Laboratory measurements, Table 12-2
Original text:
Hematology Chemistry Urinalysis
Basophils Calcium Albumin
Eosinophils Chloride Bacteria
Lymphocytes Magnesium Crystals
Atypi[INVESTIGATOR_58939]-CRPb
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; CRP=C-reactive protein; GGT=gamma glutamyltransferase; hs-CRP=high sensitivity C-reactive protein; 
LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; RBC=red blood cell; SFU=Safety Follow-up; WBC=white blood cell
Has been changed to:
Hematology Chemistry Urinalysis
Basophils Calcium Albumin
Eosinophils Chloride Bacteria
Lymphocytes Magnesium Crystals
Atypi[INVESTIGATOR_58940] Y
CO
This document ymm
AtyAtynt
mmmumcannot ophilsphilsot
mphophoanbe eused angng
setogedgesupportMCHMCH
n corpuscorpuanynine nine
; GGTGGT
Hmarks-CRPCRbketing regnaegn
ing
rke
amamauthorization n
at
erolrolho
nannanauapplication n 
ca
ppppppand stickic
ndany k fokf onyextensions on
ns
exor orvariations ontioo
arthereof. 
UCB [ADDRESS_64181]
MCHC ALT
MCV ALP
Platelet count GGT
RBC count Total bilirubin
WBC count LDH
Uric acid
Total cholesterol
Serum pregnancy testinga
CRPb
hs-CRPb
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; CRP=C-reactive protein; GGT=gamma glutamyltransferase; hs-CRP=high sensitivity C-reactive protein; 
LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular hemoglobin 
concentration; MCV=mean corpuscular volume; RBC=red blood cell; SFU=Safety Follow-up; WBC=white blood cell
Change #32
Section 12.6.1 Vital signs
Original text:
The Investigator or designee should measure all vital signs (systolic and diastolic BP, 
temperature [oral, axillary, or otic], pulse rate) after the subject has been sitting for at least 
[ADDRESS_64182] should remain seated during the measurements. Body temperature 
should be obtained prior to dosing with IMP at study visits when IMP is administered. At Baseline/Day [ADDRESS_64183] pulse and BP prior to drug 
administration and once after dosing (any time).
Has been changed to:
The Investigator or designee should measure all vital signs (systolic and diastolic BP, temperature [oral, axillary, or otic], pulse rate) after the subject has been sitting for at least 
[ADDRESS_64184] should remain seated during the measurements. Body temperature 
should be obtained prior to dosing with IMP at study visits when IMP is administered. At Baseline/Day [ADDRESS_64185] pulse and BP prior to drug 
administration and once after dosing (any time).REDACTED meameaCOPY 
This documents
30 m30 m
adadcannotes, as, a
d be od be o
elineelinebee [or[o
andanused tor or or or 
oraloratogedgesupporter doser do
ce afterafte
dtdanyng ng
collecollec
imarketingasure asure 
ulse raulse r
remainemai
g witwiauthorization application P=h
C=meanC=mea
FU=SafFU=Saandtransfransf
highhighdany yaextensions s
sio
xteor rvariations onononon
riavthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 132 of 143Change #33
Section 12.6.5 Tuberculosis and TB risk factor assessment and management, 
Exclusion criteria at Screening
Original text:
Exclusion Criteria at Screening
Subjects with known TB infection, at high risk of acquiring TB infection, with LTBI*, or current 
or history of NTMB infection.
*Subjects with LTBI may enter the study only after they have completed at least 8 weeks of 
appropriate prophylactic therapy and thereafter, will continue and complete the entire regimen. 
Has been changed to:
Exclusion Criteria at Screening
Subjects with known TB infection, at high risk of acquiring TB infection, with LTBI*, or current 
or history of NTMB infection.
*Subjects with LTBI may enter the study only after they have completed at least [ADDRESS_64186] 8 weeks of LTBI prophylactic therapy.
Change #34
Section 15.1 Definition of analysis setsOriginal text:
The PK-PPS will consist of all randomized subjects who took at least [ADDRESS_64187] 1 PD measurement postdose that is without important protocol deviation affecting that 
time point.
The Dose-Blind Set (DBS) consists of all subjects starting the Dose-Blind Period and who 
received at least [ADDRESS_64188] Set (ESS) consists of all subjects starting the Dose-Blind Period and who 
received at least [ADDRESS_64189] 10% reduction from Baseline in PGADA and total and nocturnal spi[INVESTIGATOR_58941] 16, Week 24, or Week 36.
The Dose-Blind Responder Set (DBRS) consists of all subjects starting the Dose-Blind Period 
and who received at least [ADDRESS_64190] 10% reduction from Baseline in PGADA and total and nocturnal spi[INVESTIGATOR_58942] 16, Week 24, and Week 36. Subjects who are eligible for the ESS, but do not receive 
rescue medication, remain in the DBRS.REDACTED is seis sCOPYr, subr, su
ctic thctic th
This document Weee
TheThecannotat lat l
ast 10%st 10%
ek 1ek 1bee Sue Su
leleusedSete
st 1 dot 1 do
ubjbjtot (Dt (Dsupport allal
nt postnt pos
Bany ncnc
l ranl ranmarketing domizeomiz
centrcentrauthorizationherahera
tssapplication compleompl
ue and e and
jects mects
apyapandion,on,any ,w iwextensions eekseks
tire regire regor sosovariations rrent rent thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 133 of 143Has been changed to:
The Pharmacokinetic Per Protocol Set (PK-PPS) is a subset of the FAS, consisting of those 
subjects who had no important protocol deviations affecting the pharmacokinetic 
variables, as confirmed during ongoing data cleaning meetings prior to database lock. 
The Pharmacodynamic Per Protocol Set ( PD-PPS) will consist of all randomized subjects who 
took at least [ADDRESS_64191] 1 PD measurement postdose that is without 
important protocol deviation affecting that time point.
The Dose-Blind Set (DBS) consists of all subjects starting the Dose-Blind Period and who 
received at least [ADDRESS_64192] Set (ESS) consists of all subjects starting the Dose-Blind Period and who 
received at least [ADDRESS_64193] 10% reduction from Baseline in PGADA and total and nocturnal spi[INVESTIGATOR_58924] 16, Week 24, or Week 36.
The Dose-Blind Responder Set (DBRS) consists of all subjects starting the Dose-Blind Period 
and who received at least [ADDRESS_64194] 10% reduction from Baseline in PGADA and total and nocturnal spi[INVESTIGATOR_58925] 16, Week 24, and Week 36. Subjects who are eligible for the ESS, but do not receive 
rescue medication, remain in the DBRS.
Change #35
Section 15.4 Subgroup analyses
Original text:
•BASDAI ( ≥4 to ≤7 [moderate disease]; >7 to ≤10 [severe disease])
Has been changed to:
•BASDAI (<4 [mild disease]; ≥4 to ≤7 [moderate disease]; >7 to ≤10 [severe disease])
Change #36
Section 15.5.1 Safety analysesThe following paragraph has been added:
Treatment-emergent AEs will be defined as events that have a start date on or following 
the first administration of study treatment through the final administration of study treatment +140 days (covering the 20 week SFU Period).REDACTED ssCOPY PGAG
are elare ePY
This documenttreatreatcannot mentment
first first 
ttbewingwinused 5.[ADDRESS_64195] nve nor o o variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 134 of 143Change #37
Section 15.5.2 Other analyses
Original text:
Pharmacokinetic and PD analyses will be detailed in a separate data analysis plan and reported in 
a separate document. Plasma concentration-time data of bimekizumab and ASAS40 responder 
rates will be used as the PK and PD response. If data merits, a further PK/PD analysis on other 
PD variables may be performed.
Has been changed to:
Pharmacokinetic and PD analyses including the calculation of population estimates for total 
body clearance (CL/F) and volume of distribution (V/F) will be detailed in a separate data 
analysis plan and reported in a separate document. Plasma concentration-time data of 
bimekizumab and ASAS40 responder rates will be used as the PK and PD response. If data 
merits, a further PK/PD analysis on other PD variables may be performed.
Change #38
Table 19-1 Table footnote
Original text:
Note: A second grading of “probably ankylosing spondylitis” is part of the modified NY criteria, but it is not 
applicable for this study. It is included here for completeness. The grading will be probable ankylosing spondylitis if 
3 clinical criteria are present and the radiologic criterion is present without any signs or symptoms satisfying the clinical criteria (other causes of sacroiliitis should be considered).
Has been changed to:
AS=ankylosing spondylitis; mNY=modified [LOCATION_001] CriteriaNote: A second grading of “probable ankylosing spondylitis” is part of the modified NY criteria, but it is not applicable for this study. It is included here for completeness. The grading will be probable ankylosing spondylitis if 
3 clinical criteria are present and the radiologic criterion is present without any signs or symptoms satisfying the 
clinical criteria (other causes of sacroiliitis should be considered).REDACTED ndylitindyliti
mpletemplete
critericriteri
hould bhould COPY 
This document cannot be used to supportthe the tof sacrof sacrpoanynkk
ed hered henye radraamarketing be 
fied Newed Ne
kylosikyloauthorization s” is pa” is p
ness. Tness. T
on is pn is p
 conconapplication andPD
ormedrmedany meme
D resD resextensions matesmate
n a sepa se
ededor variations r thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 135 of [ZIP_CODE].4 Protocol Amendment 2
Rationale for the amendment
The purpose of this substantial protocol amendment is the following:
•To update the study contact [CONTACT_59010].
•To revise the withdrawal criteria section to provide instructions for the management of 
subjects with newly diagnosed IBD or with IBD flares during the study.
•Amend the time window between doses during the Double-Blind Period of the study.
•To revise and clarify the SAE criteria for pregnancy for consistency.
•Amend the table for identification/exclusion of alternative etiology to include ALT and AST.
Modifications and changes
Global changes
No global changes have been made. Specific changes are listed below.
Specific changes
Change #[ADDRESS_64196] OF ABBREVIATIONS
The following abbreviation and definition was added: 
RCTC Rheumatology Common Toxicity Criteria
Change #[ADDRESS_64197] INFORMATIONOriginal text:
Sponsor Study Physician
Name: , MD
Address: UCB BIOSCIENCES Inc.
[ADDRESS_64198]
Raleigh, NC [ZIP_CODE]
UNITED STATES
Phone:
Has been changed to: REDACTED on wasn was
gygy CoCoyyCOPY 
This document cannot dd
anbe dresdreseused:d 
utoPhyPhysupport RR
siany MAMATTmarketing ommmmauthorization s addeadde
momoapplication d belowbeloand any ccextensions studytudy
cludeludeor variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 136 of 143Name: , MD, MSc, PhD , MD
Address: UCB Pharma Ltd. UCB BIOSCIENCES Inc.
[ADDRESS_64199]
Slough, SL1 3WE Raleigh, NC [ZIP_CODE]
UNITED KINGDOM UNITED STATES
Phone:
Change #[ADDRESS_64200] INFORMATION
Original text: 
Clinical Trial Biostatistician
Name: [INVESTIGATOR_124]. , Senior Biostatistician
Address: UCB BIOSCIENCES GmbH
Alfred-Nobel-Str.10
[ZIP_CODE] Monheim am RheinGERMANY
Phone:
Has been changed to: 
Clinical Trial Biostatistician
Name: , MS Dr. , Senior 
Biostatistician
Address: UCB BIOSCIENCES Inc. GmbH
[ADDRESS_64201] Alfred Nobel Str.10
Raleigh, NC [ZIP_CODE] [ZIP_CODE] Monheim am Rhein
UNITED STATES GERMANY 
Phone:
Change #4
Section 6.3 Withdrawal Criteria
The following was added to the withdrawal criteria:
11. Subjects with newly diagnosed IBD or with IBD flares during the study must:REDACTEDRheinRhein
AC
REREDACOPY HY
This document ChChcannot PhoPhoot
anananbe used to supportBiostBiosppuUuuupsuport any nn
anamarketing gauthorization thapplication nior Bionior Bitio
pliand any extensions or variations vvvthereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 137 of 143−Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist
−Discontinue IMP and be followed-up until resolution of active IBD symptoms
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgment in deciding whether the subject should continue in the study and contact [CONTACT_58950]'s suitability for continued 
participation in the study .
Change #5
Section 7.2 Treatments to be administered, paragraph 2Original text: 
The IMP (bimekizumab and placebo) will be administered at the times indicated in Table 5 ‒1. 
The minimum time between doses during the Double-Blind Period should be no less than 26 days and no more than 30 days and during the Dose-Blind Period should be no less than 24 days 
and no more than 32 days.
Has been changed to: 
The IMP (bimekizumab and placebo) will be administered at the times indicated in Table 5 ‒1. 
The minimum time between doses during the Double-Blind Period should be no less than 2 56
days and no more than 3 10 days and during the Dose-Blind Period should be no less than 24 
days and no more than 32 days.
Change #6
Section 7.3 Packaging
Original text: 
Bimekizumab and placebo will be packaged and labeled according to Good Manufacturing 
Practice (GMP) guidelines and applicable laws or regulations. They will be suitably packaged in 
such a way as to protect the product from deterioration during transport and storage. Further 
information regarding storage and transport conditions are provided in the IMP Handling Manual.
Has been changed to: 
Bimekizumab and placebo will be manufactured, packaged and labeled according to Good 
Manufacturing Practice (GMP) guidelines and applicable laws or regulations. They will be 
suitably packaged in such a way as to protect the product from deterioration during transport and 
storage. Further information regarding storage and transport conditions are provided in the IMP Handling Manual.REDACTED dmdm
he Dohe Do
ing thng thCOPY minmin
This documentBimeBime
MMcannot beenbeenbe usedo propro
egardgardtoideldel
otetsupport cebo webo w
linelinany marketing authorization isterestere
oubleuble
he Dose Dosapplication d shoushoandinin
houldould
ouloulany ndicatdicaextensions or variations thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 138 of 143Change #7
Section 12.1.8 Pregnancy, paragraph 5
A pregnancy becomes an SAE in the following circumstances: miscarriage, abortion (elective for 
a medical condition or spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormonal contraceptive was correctly used), ectopic pregnancy, fetal demise, or any 
congenital anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report Form.
Has been changed to: 
A pregnancy becomes an SAE in the following circumstances: miscarriage, elective 
abortion when medically indicated (e.g. when pregnancy is endangering life or health of woman or when fetus will be born with severe abnormalities), unintended pregnancy after 
hormonal contraceptive failure (if the hormonal contraceptive was correctly used), ectopic 
pregnancy, fetal demise, or any congenital anomaly/birth defect of the baby. Those SAEs must be additionally reported using the Investigator SAE Report form.
Change #8
Section [IP_ADDRESS] Testing: identification/exclusion of alternative etiology, Table 
12-4 
Original table: 
Virology-
relatedHepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)
Immunology Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology Eosinophil count
Urinalysis Toxicology screena
Chemistry Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubinbodybodyDA
RECOPY /excluexcl
This document HHen
umuuucannot lobe ogyogyusedEpstpst
hetehetuuuuuto steisteiosupportC C RNRNt
megalomegaloppsany amarketing ng
antibodntibodke
mauthorizationusiousio
thapplication ononand thth
t formt formanyrrecrre
he bahe baextensions ectivective
e or hor h
ed pred pre
ctlctor variations he he thereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 139 of 143Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation
Additional Prothrombin time/INRb
Serum pregnancy test
PK sample
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb-IgM=hepatitis B core antibody-IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; LDH=lactate 
dehydrogenase; PDILI=potential drug-induced liver injury; PK=pharmacokinetic; RNA=ribonucleic acid; 
ULN=upper limit of normal
aFor detecting substances (ie, amphetamines, benzodiazepi[INVESTIGATOR_1651], opi[INVESTIGATOR_2438], marijuana, cocaine, phencyclidine, and tricyclic antidepressants), additional tests may be performed based on the Investigator’s medical judgment and patient’s history.
bMeasured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative cause).
Has been changed to: 
Virology-
relatedHepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)
Immunology Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology Eosinophil count
Urinalysis Toxicology screena
Chemistry Amylase
ALT, AST
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevationREDACTED D
CT
EDCOPY OP
This document mmumcannotalysislysis
hemiheminnbe gyy
beusedTyTyppyy
EEseutoto s
tosupport clear anlear art
smoomooppany al al
ntibodtibodmarketing gM antiM aneti
lcapcamaauthorization at
ho
aapplication lic
aand (w(wanyr quadr qua
withouithoextensions yclidinyclidin
al judgl judg
ms of hs of h
dor d; d; variations tioon
lactateactatethereof. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 140 of 143Additional Prothrombin time/INRb
Serum pregnancy test
PK sample
ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; HBcAb-
IgM=hepatitis B core antibody-IgM; HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; 
INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential drug-induced liver injury; PK=pharmacokinetic; RNA=ribonucleic acid; ULN=upper limit of normal
aFor detecting substances (ie, amphetamines, benzodiazepi[INVESTIGATOR_1651], opi[INVESTIGATOR_2438], marijuana, cocaine, phencyclidine, and tricyclic antidepressants), additional tests may be performed based on the Investigator’s medical judgment and 
patient’s history.
bMeasured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative cause).
Change #9
Section 17.1 Markedly abnormal laboratory values, Tables 17-1 (Definitions of markedly 
abnormal hematology values) and 17-2 (Definitions of markedly abnormal biochemistry values)
Amended units in both table headers: 
Parameter (SI units)Markedly Abnormal Definition
Low High
Has been changed to:
Parameter (SI RCTC units)Markedly Abnormal Definition
Low High
Change #10
Section 17.1 Markedly abnormal laboratory values, Table 17-1 (Definitions of markedly 
abnormal hematology values), abbreviations in table footer:
LLN=lower limit of normal; N/A = Not Applicable; SI = standard international
Has been changed to:
LLN=lower limit of normal; N/A = Not Applicable; SI = standard international RCTC= 
Rheumatology Common Toxicity Criteria
Change #11
Section 17.1 Markedly abnormal laboratory values, Table 17-2 (Definitions of markedly 
abnormal biochemistry values), abbreviations in table footer:REDACTED ED
AC
RCOPY CO
This document hecannot enn
=lowelowe
eumumbe n chan chused logo
mit omit otoogy vgy support edldly ayaany marketing ng
rke
mmammauthorization MarkMaron
LowLowza
thoapplication 7-1 (D-1 (D
edledly aby [CONTACT_59011]. 
UCB 09 Mar 2018
Clinical Study Protocol Bimekizumab AS0008
Confidential Page 141 of 143ALT=alanine aminotransferase; AST=aspartate aminotransferase; N/A=Not applicable; 
SI=standard international; ULN=upper limit of normal
Has been changed to:
LLN=lower limit of normal; N/A = Not Applicable; SI=standard international RCTC=
Rheumatology Common Toxicity Criteria
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB [ADDRESS_64202].
Investigator:
Printed name [CONTACT_1782]/Signature
[CONTACT_59012]/Sate/app/SigSigpplication ppand any extensionsbe 
ation ation
ents wnts wortreatrevariations thereof. 
UCB [ADDRESS_64203] this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 